AUTHOR INDEX

Aamdal S, *see* Semb KA
Abbas F, *see* Leibman BD
Abbruzzese JL, *see* Ayoub J-P
— *see* Pisters PWT
Abbruzzese MC, *see* Ayoub J-P
Abeloff MD, *see* Fetting JH
Abler SL, *see* Tetreault S
Ablin A, *see* Matthay K
Abner A, *see* Gage I
— *see* Nixon AJ
Aboulafia D, *see* Stewart S
Abourachid H, *see* Tourani J-M
Abrams JR, *see* Syrjala KL
Abramson SJ, *see* Boulad F
Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma, 859
Abu-Zahra H, *see* Levine M
Aceñero MJF, González JF, Gallego MG, Ballesteros PA. Vascular enumeration as a significant prognosticator for invasive breast carcinoma, 1684
Achalhorn A, *see* Wendt TG
Ackland S, *see* Gurney HP
Adachi I, *see* Yamamoto N
Adachi K, *see* Asou N
Adachi M, Taki T, Huang C-I, Higashiyama M, Doi O, Tsuji T, Miyake M. Reduced integrin a3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung, 1060
—, Taki T, Konishi T, Huang C-l, Higashiyama M, Miyake M. Novel staging protocol for non-small-cell lung cancers according to *MRP-1/CD9* and *KA11/cd82* gene expression, 1397
Adak S, *see* Colevas AD
— *see* Mehta MP
Adams G, *see* Al-Sarraf M
Adamson PC, *see* Berg SL
Adde MA, *see* Haddy TB
Adkins DR, Brown RA, DiPersio JF. Patient selection in high-dose trials of breast cancer (letter), 1238
— Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor (letter), 812
Aghajanian C, Fennelly D, Shapiro F, Walzman R, Almadrones L, O'Flaherty C, O'Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs D. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer, 1852
Agnello A, *see* Mercadante S
Agosti JM, *see* Meropol NJ
A'Hern R, *see* Gore M
Ahles TA, Silberfarb PM, Herndon J II, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group B, 1954
Ahmann FR, *see* Serafini AN
Ahrens S, *see* Paulussen M
Aihara T, *see* Yamamoto K
Aisner J, *see* Ahles TA
Ajani J, *see* Ilson DH
— *see* Takiuchi H
Akabani G, *see* Bigner DD
Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L. Phase I trial of weekly paclitaxel in advanced lung cancer, 153
— *see* Choy H
— *see* Glantz MJ
Akiyama F, *see* Shimizu Y
Akiyama H, *see* Asou N
Akiyoshi T, *see* Mori M
Alani RM, Münger K. Human papillomaviruses and associated malignancies, 330
Albain KS, *see* Lau DH
— *see* Wozniak AJ
Albanel J, *see* Seidman AD
Albanese P, *see* Saltz LB
Albers P, *see* Leibovitch I
Alberti D, *see* Berlin J
Albertini P, *see* Zinzani PL
Albiol S, *see* Grau JJ
Alcobendas F, *see* Grau JJ
Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver, 1479
Alexopoulos CG, *see* Sculier J-P
Alhava EM, *see* Karjalainen JM
Alhström H, *see* Örlefors H
Ali V, *see* Schimmer AD
Al-Katib AM, *see* Varterasian ML
Allasia C, *see* Charpin C
Alleaume C, *see* Gamelin É
Allen J, *see* Mason WP
Allen JC, *see* Dunkel IJ
Allman D, *see* Mackean M
Almadrones L, *see* Aghajanian C
Alpen B, *see* Thiede C
Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy *versus* radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099, 1310
Alsina M, *see* Kraut EH
Alt C, *see* Clarke K
Altendorf-Hofmann A, *see* Köckerling F
Alterini R, *see* Messori A
Alvarado C, *see* Katzenstein HM
Alvord WG, *see* Curti BD
Amatruda JF, Tran K, Mantel M, Singer S, Demetri G. Askin Tumor, 1997
Ambros RA, *see* Kallakury BV
Ambus U, *see* Andrulis IL
American Federation of Clinical Oncologic Societies. Access to quality cancer care: Consensus statement, 1628
American Society of Clinical Oncology. Training resource document for curriculum development in medical oncology, 372
— Cancer care during the last phase of life, 1986
— 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer, 793
Ames MM, *see* Nicholson HS
Amin K, *see* Popat U
Amylon M, *see* Laver J
Amy R, *see* Westeel V

AUTHOR INDEX

Aamdal S, *see* Semb KA
Abbas F, *see* Leibman BD
Abbruzzese JL, *see* Ayoub J-P
— *see* Pisters PWT
Abbruzzese MC, *see* Ayoub J-P
Abeloff MD, *see* Fetting JH
Abler SL, *see* Tetreault S
Ablin A, *see* Matthay K
Abner A, *see* Gage I
— *see* Nixon AJ
Aboulafia D, *see* Stewart S
Abourachid H, *see* Tourani J-M
Abrams JR, *see* Syrjala KL
Abramson SJ, *see* Boulad F
Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma, 859
Abu-Zahra H, *see* Levine M
Aceñero MJF, González JF, Gallego MG, Ballesteros PA. Vascular enumeration as a significant prognosticator for invasive breast carcinoma, 1684
Achalhorn A, *see* Wendt TG
Ackland S, *see* Gurney HP
Adachi I, *see* Yamamoto N
Adachi K, *see* Asou N
Adachi M, Taki T, Huang C-I, Higashiyama M, Doi O, Tsuji T, Miyake M. Reduced integrin a3 expression as a factor of poor prognosis of patients with adenocarcinoma of the lung, 1060
—, Taki T, Konishi T, Huang C-l, Higashiyama M, Miyake M. Novel staging protocol for non-small-cell lung cancers according to *MRP-1/CD9* and *KA11/cd82* gene expression, 1397
Adak S, *see* Colevas AD
— *see* Mehta MP
Adams G, *see* Al-Sarraf M
Adamson PC, *see* Berg SL
Adde MA, *see* Haddy TB
Adkins DR, Brown RA, DiPersio JF. Patient selection in high-dose trials of breast cancer (letter), 1238
— Anaphylactoid reaction in a normal donor given granulocyte colony-stimulating factor (letter), 812
Aghajanian C, Fennelly D, Shapiro F, Walzman R, Almadrones L, O'Flaherty C, O'Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs D. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer, 1852
Agnello A, *see* Mercadante S
Agosti JM, *see* Meropol NJ
A'Hern R, *see* Gore M
Ahles TA, Silberfarb PM, Herndon J II, Maurer LH, Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski LL, Green MR, Holland JC. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: A study by the Cancer and Leukemia Group B, 1954
Ahmann FR, *see* Serafini AN
Ahrens S, *see* Paulussen M
Aihara T, *see* Yamamoto K
Aisner J, *see* Ahles TA
Ajani J, *see* Ilson DH
— *see* Takiuchi H
Akabani G, *see* Bigner DD
Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L. Phase I trial of weekly paclitaxel in advanced lung cancer, 153
— *see* Choy H
— *see* Glantz MJ
Akiyama F, *see* Shimizu Y
Akiyama H, *see* Asou N
Akiyoshi T, *see* Mori M
Alani RM, Münger K. Human papillomaviruses and associated malignancies, 330
Albain KS, *see* Lau DH
— *see* Wozniak AJ
Albanel J, *see* Seidman AD
Albanese P, *see* Saltz LB
Albers P, *see* Leibovitch I
Alberti D, *see* Berlin J
Albertini P, *see* Zinzani PL
Albiol S, *see* Grau JJ
Alcobendas F, *see* Grau JJ
Alexander HR Jr, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver, 1479
Alexopoulos CG, *see* Sculier J-P
Alhava EM, *see* Karjalainen JM
Alhström H, *see* Örlefors H
Ali V, *see* Schimmer AD
Al-Katib AM, *see* Varterasian ML
Allasia C, *see* Charpin C
Alleaume C, *see* Gamelin É
Allen J, *see* Mason WP
Allen JC, *see* Dunkel IJ
Allman D, *see* Mackean M
Almadrones L, *see* Aghajanian C
Alpen B, *see* Thiede C
Al-Sarraf M, LeBlanc M, Giri PGS, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy *versus* radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099, 1310
Alsina M, *see* Kraut EH
Alt C, *see* Clarke K
Altendorf-Hofmann A, *see* Köckerling F
Alterini R, *see* Messori A
Alvarado C, *see* Katzenstein HM
Alvord WG, *see* Curti BD
Amatruda JF, Tran K, Mantel M, Singer S, Demetri G. Askin Tumor, 1997
Ambros RA, *see* Kallakury BV
Ambus U, *see* Andrulis IL
American Federation of Clinical Oncologic Societies. Access to quality cancer care: Consensus statement, 1628
American Society of Clinical Oncology. Training resource document for curriculum development in medical oncology, 372
— Cancer care during the last phase of life, 1986
— 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer, 793
Ames MM, *see* Nicholson HS
Amin K, *see* Popat U
Amylon M, *see* Laver J
Amy R, *see* Westeel V

Anasetti C, *see* Lee SJ
Anastasi J, *see* Dann AJ
Anderlini P, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Andersen MK, *see* Pedersen-Bjergaard J
Andersen N, *see* Freedman AS
Anderson GT, *see* Miller DR
Anderson KC, *see* Freedman AS
Andersson B, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Ando M, *see* Yamamoto N
Andrac L, *see* Charpin C
Andreesen R, *see* Köhne C-H
André F, *see* Fizazi K
Andreu G, *see* Fouillard L
Andrieu J-M, Colonna P. Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages? (letter), 2283
— *see* Tourani J-M
Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D. *neu/erbB-2* Amplification identifies a poor-prognosis group of women with node-negative breast cancer, 1340
— *see* de Alava E
Angert A, *see* Lundin J
Ang K-K, *see* Shin DM
Angstwurm M, *see* Pantel K
Annino L, *see* Cheson BD
Ansari R, *see* Fleming GF
Anthony LB, *see* Goren MP
Antin JH, *see* Lee SJ
Antman K. In reply (letter), 801
— *see* Ayash LJ
— *see* Frank TS
— *see* Grann VR
— *see* Hesdorffer C
Antonescu CR, *see* de Alava E
Anttila M, Kosma V-M, Ji H, Wei-Ling X, Puolakka J, Juhola M, Saarikoski S, Syrjänen K. Clinical significance of a-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer, 2591
Aoudjhane M, *see* Fouillard L
Appelbaum FR, *see* Liu SY
Arasteh K, *see* Stewart S
Arbuck SG, *see* Senderowicz AM
Arceci RJ, *see* Bradshaw DM
Archimbaud E, *see* Löwenberg B
Argani P, *see* de Alava E
Ariyoshi Y, *see* Furuse K
— *see* Kudoh S
Armand JP, *see* De Crevoisier R
Armitage JO. Presidential address-American Society of Clinical Oncology: Where have we been? Where are we going?, 380
—, Weisenburger DD for the Non-Hodgkin's Lymphoma Classification Project. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes, 2780
— *see* Vose JM
Armstead B, *see* Vaughn DJ
Armstrong FD, *see* Mulhern RK
Arndt C, *see* Berg SL
Arnold A, *see* Levine M
Aro AR, *see* Joensuu H
Arranz R, García-Alfonso P, Sobrino P, Zamora P, Carrión R, García-Laraña J, Pérez G, López J, Lavilla E, Lozano M, Rayón C, Colomer R, Barón MG, Flores E, Pérez-Manga G, Fernández-Rañada JM. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization, 1538
Arthur DC, *see* Heerema NA
— *see* Uckun FM
Arvay C, *see* Schrijvers D
Arzoomanian RZ, *see* Berlin J
Asai O, *see* Usui N
Ascani S, *see* Zinzani PL
Ashley DM, *see* Friedman HS
Ashley S, *see* Eisen T
— *see* Ellis P
Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R for the Japan Adult Leukemia Study Group. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-*trans* retinoic acid and chemotherapy, 78
Assouline D, *see* Loeffler M
Aster J, *see* Freedman AS
Athanasiadis I, *see* Kies MS
Atkins CD. Ethics of off-label treatment (letter), 1637
— Adjuvant chemotherapy with CEF *versus* CMF for node-positive breast cancer (letter), 3916
Atkins MB, *see* Falkson CI
Atkinson EN, *see* Kudelka AP
— *see* Morris M
Atkinson JB, *see* Matthay K
Auböck J, *see* Pehamberger H
Auchter RM. Early *versus* late irradiation in small-cell lung cancer (letter), 1235
Audhuy B, *see* Ravaud A
Audisio E, *see* Pich A
Audouin J, *see* Davi F
Audrain H, Rimer B, Cella D, Garber J, Peshkin BN, Ellis J, Schildkraut J, Stefanek M, Vogel V, Lerman C. Genetic counseling and testing for breast-ovarian cancer susceptibility: What do women want?, 133
Avril M-F, *see* Keilholz U
Ayala A, *see* Harris MB
Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, Lynch C, Warren D, Shapiro C, Richardson P, Hurd D, Schnipper L, Frei E III, Antman K. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma, 1000
Aydin H, *see* Wendt TG
Ayello J, *see* Hesdorffer C
Aylesworth C, *see* Rowinsky E
— *see* Villalona-Calero MA

Ayoub J-P, Hess KR, Abbruzzese MC, Lenzi R, Raber MN, Abbruzzese JL. Unknown primary tumors metastatic to liver, 2105
Ayres M, *see* Gandhi V
Azagury M, *see* Tourani J-M

Babul N, *see* Bruera E
Bacchini P, *see* Bacci G
Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M, Bacchini P, del Prever AB, Tienghi A, Comandone A, Campanacci M. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin, 658
— In reply (letter), 2291
Bade J, *see* Köhne C-H
Baglan RJ. Combined modality therapy for lung cancer (letter), 807
Baida M, *see* Andrulis IL
Bailey AJ, Parmar MKB, Stephens RJ. Patient-reported short-term and long-term physical and psychologic symptoms: Results of the continuous hyperfractionated acclerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer, 3082
Bailey NP, *see* Rafi I
Bainbridge T, *see* Lawlor ER
Bajorin DF, Mazumdar M, Meyers M, Motzer RJ, Vlamis V, Lin P, Bosl GJ. Metastatic germ cell tumors: modeling for response to chemotherapy, 707
—, McCaffrey JA, Hilton S, Mazumdar M, Kelly WK, Scher HI, Spicer J, Herr H, Higgins G. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial, 2722
— *see* Herr HW
— *see* Kushner BH
Baker AR, *see* Yang JC
Baker LH, *see* Sugawara Y
— *see* Wozniak AJ
Baker SD, *see* Villalona-Calero MA
Balcerzak SP, *see* Press OW
— *see* Salmon SE
— *see* Wozniak AJ
Balch CM, *see* Eton O
— *see* Gershenwald JE
Baldi A, *see* Susini T
Baldi F, *see* Susini T
Balducci L, *see* Broeckel JA
— *see* Extermann M
Balis FM, *see* Berg SL
Ballatori E, Del Favero A, Roila F. Clinical benefit as a primary efficacy endpoint (letter), 803
Ballester O, *see* Berenson JR
Ballesteros PA, *see* Aceñero MJF
Balmaceda C, *see* Hesdorffer C
Baltzer L, *see* Nolte MJ
Baly D, *see* Pegram MD
Banerjee D, *see* Gorlick R
Bangerter M, *see* Moog F
Banik DM, *see* Daugherty CK
Bank A, *see* Hesdorffer C
Barakat R, *see* Aghajanian C
Baranda J, *see* Metzger R
Baranzelli MC, *see* Pein F
Bar-Chama N, *see* Herr HW
Bargolis B, *see* Desikan KR
Barnard GF, *see* Mori M
Barón AE, *see* Cagnoni PJ
Barón MG, *see* Arranz R
Barresi L, *see* Mercadante S
Barrett JA, *see* Cheson BD
Barr FG, *see* de Alava E
Bartelink H, Dewitt L, In reply (letter), 802
— *see* Recht A
Barter C, *see* Zalcberg J
Bartlett DL, *see* Alexander HR Jr
Bartlett J, *see* Clarke K
Bartl R, *see* Body JJ
Bartolucci AA, *see* Loeffler M
Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, Fidler P, Stella PJ, Swan DK, Vaught NL, Novotny P. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors, 495
Barton JJ, *see* Colevas AD
Bartsch H-H, *see* Willenbacher W
Barza M, *see* Engels EA
Baselga J, *see* Pegram MD
— *see* Seidman AD
Basser RL, To LB, Begley CG, Maher D, Juttner C, Cebon J, Mansfield R, Olver I, Duggan G, Szer J, Collins J, Schwartz B, Marty J, Menchaca D, Sheridan WP, Fox RM, Green MD. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor, 1899
— *see* Clarke K
Bassinet L, *see* Chouaid C
Bastian G, *see* Saliba F
Batist G, *see* Lilenbaum RC
— *see* Venook AP
Baughman SA, *see* Pegram MD
Baumann M, Herrmann T, Thames HD. Combined modality in advanced Hodgkin's disease (letter), 2893
Baumelou E, *see* Blay J-Y
Baumgart J, *see* Christodoulou CV
Baum M, *see* Ellis P
Baum R, *see* Serafini AN
Bauters F, *see* Fouillard L
Bayerdörffer E, *see* Thiede C
Bayer L, *see* Mason WP
Bayle C, *see* Davi F
— *see* Decuadin D
Beard CJ, *see* D'Amico AV
— *see* Talcott JA
Bearden JD, *see* Taylor CW
Beare S, *see* Hoskins P
Bear HD, *see* Fisher B
Bearman SI, *see* Cagnoni PJ
— *see* Jaeckle KA
Beaulieu R, *see* Shepherd F
Bechard K, *see* Wu C
Beck T, *see* Glick JH
Beckwith JB, *see* Green DM
Bécouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz J-F, Nasca S, Nguyen TD, Paillot B, Raoul J-L, Duffour J, Fandi A, Dupont-André G, Rougier P for the Digestive Group of French Federation of Cancer Centers. Phase II trial of oxalipla-

tin as first-line chemotherapy in metastic colorectal cancer patients, 2739
Bedikian A, *see* Eton O
— *see* Legha SS
Begley CG, *see* Basser RL
Begovic M, *see* Fisher B
Behm FG, *see* Consolini R
— *see* Harris MB
— *see* Pui C-H
Behr J, *see* Budman DR
Beitler JJ. XRT for stage IV Hodgkin's disease? Less chaff please (letter), 2893
Belani C, *see* Treat J
Belanich M, *see* Jaeckle KA
Belinson J, *see* Markman M
Belkacemi Y, *see* Fouillard L
Bell B, *see* Saylors RL III
Bellmunt J, *see* Dombernowsky P
Bell R, *see* Berenson JR
Belzile M, *see* Bruera E
Bence-Bruckler I, *see* McLaughlin P
Bendahmane B, *see* Decuadin D
Bendandi M, *see* Zinzani PL
Benedetti J, *see* Green S
Benesch M, Urban C. Influence of surgical resection on adjuvvant therapy and outcome (letter), 389
Benevolo M, Mottolese M, Cosimelli M, Tedesco M, Giannarelli D, Vasselli S, Carlini M, Garofalo A, Natali PG. Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer, 3406
Benhammouda A, *see* Keilholz U
— *see* Tourani J-M
Benhattar J, Perey L, Peters R, Leyvraz S. Reverse transciptase-polymerase chain reaction and islet cell carcinoma: Not antagonist, but complementary tools (letter), 806
Beniket AJ, *see* Watts MJ
Benjamin RS, *see* Eton O
Bennaceur A, *see* Decuadin D
Benner SE, *see* Sulkes A
Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T, Seday MA, Sartor O. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer, 3101
Ben-Othman T, *see* Leblond V
Benraad TJ, *see* Berns EMJJ
Benson AB III, *see* Hoffman JP
— *see* Wadler S
Bentzen SM, Nielsen OS, Work E. In reply (letter), 1236
— *see* Work E
Benz C, *see* Eppenberger U
Beran M, *see* Sacchi S
Berchier MC, *see* Sculier J-P
Berdah J-F, *see* Tourani J-M
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events, 593
—, Major P, Hortobagyi G. Relevant clinical end points in biphosphonate trials (letter), 3204
— In reply (letter), 2572
Beretta F, *see* Colleoni M
Berger F, *see* Davi F
Berger MS, *see* Chang SM
Bergeron C, *see* Pein F
Bergh J, *see* Sjögren S
Berghorn E, *see* Budman DR
Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers, 181
Bergström M, *see* Örlefors H
Berille J, *see* Zalcberg J
Berkery R, *see* Nolte MJ
Berkey B, *see* Minsky BD
Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G. Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy, 1142
Bernard S, *see* Lilenbaum RC
— *see* Choi NC
Bernath AM, *see* O'Connell MJ
Berneman ZN, *see* Löwenberg B
Bernhardt B, *see* Frank TS
— *see* Geller G
Bernoux A, *see* Fagnou C
Berns EMJJ, Klijn JGM, van Putten WLJ, de Witte HH, Look MP, Meijer-van Gelder ME, Willman K, Portengen H, Benraad TJ, Foekens JA. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer, 121
Bernstein ID, *see* Liu SY
Bernstein M, *see* Langevin A-M
— *see* Smith M
Beron PJ, *see* Silverstein MJ
Berry D, *see* Laughlin MJ
Bertheault-Cvitkovic F, *see* Bécouarn Y
Bertino JR, *see* Gorlick R
Bertoni F, *see* Bacci G
Bertrand A, *see* Serafini AN
Betticher DC, von Rohr A, Ratschiller D, Schmitz S-FH, Egger T, Sonderegger T, Herrmann R, Kroner T, Zulian GB, Cavalli F, Fey MF, Cerny T. Fewer infections, but maintained antitumor activity with lower-dose *versus* standard-dose Cladribine in pretreated low-grade non-Hodgkin's lymphoma, 850
Beyer J, *see* Kollmannsberger C
Bezwoda W, *see* Dombernowsky P
Bhalla K, *see* Ilson DH
Bhatia S, Meadows AT, Robison LL. Second cancers after pediatric Hodgkin's disease (letter), 2570
Bhatnagar A, *see* Trunet PF
Bhattacharyya M, Sarin R. Is concomitant radiotherapy and chemotherapy superior to optimal radiotherapy alone in anal cancer? (letter), 802
Bianco AR, *see* Gridelli C
Bierman PJ, *see* Vose JM
Biesma B, *see* Tjan-Heijnen VCG
Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao X-G, Pegram CN, Wikstrand CJ, Herndon JE II, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment

of patients with recurrent malignant gliomas: Phase I trial results, 2202
— *see* Friedman HS
Bigner SH, *see* Bigner DD
— *see* Friedman HS
Binder M, *see* Pehamberger H
Binet J-L, *see* Leblond V
Bird JM, *see* Marks DI
Birnbaum EH, *see* Ogunbiyi OA
Biron P, *see* Blay J-Y
— *see* Kollmannsberger C
Bischoff H, *see* Diehl V
Bishop J, *see* Zalcberg J
Bishop JF, *see* Toner GC
Bitker M-O, *see* Leblond V
Bitran JD, *see* Fleming GF
Bjordal K, *see* Hjermstad MJ
Bjurling P, *see* Orlefors H
Black CT, *see* Matthay K
Blacklock H, *see* Berenson JR
Blackstein ME, *see* Andrulis IL
Blackwood MA, Weber BL. *BRCA1* and *BRCA2:* From molecular genetics to clinical medicine, 1969
Blake P, *see* Gore M
Blanco R, *see* Kwiatkowski DJ
Blaney S, *see* Langevin A-M
Blaney SM, *see* Berg SL
Blanks D, *see* Shapiro C
Blatt J, *see* Berg SL
Blay J-Y, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, Bouabdallah R, Coiffier B, Wagner J-P, Le Mevel A, Dramais-Marcel D, Baumelou E, Chauvin F, Biron P. High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series, 864
— *see* Fizazi K
Blayney D, *see* Hortobagyi GN
Bleiberg H, Sahmoud T, Di Leo A, Cunningham D, Rougier P. Adequate number of patients are needed to evaluate adjuvant treatment in gastric cancer (letter), 3714
— *see* Grimaldi C
Blessing JA, *see* Rose PG
Bleyer WA. A flat dose for all adult [*sic*] patients (letter), 3715
— *see* Smith M
Bloddy AV, *see* Rafi I
Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review, 1218
—, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: Based on a Canadian randomized trial with palliative end points, 2272
— In reply (letter), 3205
Blume KG, *see* Stiff PJ
Blumenstein B, *see* Green S
Blum RH, *see* Falkson CI
Bodrogi I, *see* Fosså SD
— *see* Kaye SB
Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AHG, Rubens RD for the International Bone and Cancer Study Group. Current use of biophosphonates in oncology, 3890
Bogaert J, *see* Vansteenkiste JF
Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M. Salivary gland protection by amifostine in high-dose radioiodine treatment: Results of a double-blind placebo-controlled study, 3542
Boisdron-Celle M, *see* Gamelin É
Bokemeyer C, *see* Kollmannsberger C
Bolis G, *see* Bookman MA
Bolton JS, *see* O'Connell MJ
Bombí J, *see* Grau JJ
Bonadona V, *see* Lasset C
Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute, 93
Bonichon F, *see* Ravaud A
Bonilla F, *see* Garcia-Patiño E
Bonilla MA, *see* Cheung N-KV
Bonistalli L, *see* Messori A
Bonnay M, *see* Saliba F
Bonnier P, *see* Charpin C
Bookman MA, Malmström H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after priority chemotherapy that contained cisplatin or carboplatin and paclitaxel, 3345
Booser DJ, *see* Valero V
Borbas C, *see* Guadagnoli E
Bordas J, *see* Grau JJ
Bordoni R, *see* Berenson JR
Bordow SB, Norris MD, Haber PS, Marshall GM, Haber M. Prognostic factors significance of *MYCN* oncogene expression in childhood neuroblastoma, 3286
Borel C, *see* Bécouarn Y
Borg Å, *see* Jóhannsson OT
Borgen P, *see* Robson M
Bornstein B, *see* Chabner E
— *see* Nixon AJ
Borowitz MJ, *see* Harris MB
— *see* Shuster JJ
Borsi JD, *see* Smith M
Bosch F, *see* Terol M-J
Bosl GJ, *see* Bajorin DF
Bosl GL. Germ cell tumors: There is still plenty to learn (editorial), 1244
Bosq J, *see* Decuadin D
Bostick PJ, Chatterjee S, Chi DD, Huynh KT, Giuliano AE, Cote R, Hoon DSB. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients, 2632
Bostrom BC, *see* Dunkel IJ
Boswell W, *see* Tulpule A
Botti G, *see* Ciarmiello A
Bottiglieri T, *see* Quinn CT
Bouabdallah R, *see* Blay J-Y
— *see* Solal-Céligny P
Boucher J, *see* Savarese D
Bougon N, *see* Zalcberg J

Boulad F, Kernan NA, LaQuaglia MP, Heller G, Lindsley KL, Rosenfield NS, Abramson SJ, Gerald W, Small TN, Gillio AP, Gulati SC, O'Reilly RJ, Ghavimi F. High-dose induction chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseous Ewing's sarcoma, and undifferentiated sarcoma, 1697
Bourhis J, *see* De Crevoisier R
Boutard P, *see* Pein F
Bowman D, *see* Levine M
Bowman LC, *see* Katzenstein HM
Boyd C, *see* Paszat LF
Boyett JM, *see* Dunkel IJ
— *see* Gururangan S
— *see* Walter AW
Bozik ME, *see* Chang SM
Bracy D, *see* Desikan KR
Brader KR, Morris M, Levenback C, Levy L, Lucas KR, Gershenson DM. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design, 1879
— *see* Morris M
Brade WP, *see* Goren MP
Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance, 3674
Brady MF, *see* Markman M
Brady MS, *see* Kavolius JP
Brambilla C, *see* Bonadonna G
Bramwell V, *see* Levine M
Brancaccio L, *see* Gridelli C
Brener D, *see* Frank TS
Brenner W, *see* Bohuslavizki KH
Breslow N, *see* Diller L
Breslow NE, *see* Green DM
Bretscher ME, *see* Sloan JA
Brewer Y, *see* Tourani J-M
Brice P, *see* Solal-Céligny P
Bridge JA, *see* Lawlor ER
Brisson J, *see* Dorval M
Brittinger G, *see* Lundin J
Brochstein JA, *see* Pecora AL
Bröcker EB, *see* Keilholz U
Brockstein B, Haraf DJ, Stenson K, Fasanmade A, Stupp R, Glisson B, Lippman SM, Ratain MJ, Sulzen L, Klepsch A, Weichselbaum RR, Vokes EE. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil amd hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck, 735
Broder S, *see* Welles L
Brodeur GM, *see* Katzenstein HM
— *see* Matthay K
Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer, 1689
Bron D, *see* Guglielmi C
— *see* Tirelli U
Brosteanu D, *see* Loeffler M
Brosteanu O, *see* Loeffler M
Brousse N, *see* Solal-Céligny P
Brouwers P, *see* Sandor V
Browman G, Newman TE, Mohide EA, Graham ID, Levine M, Pritchard KI, Evans WK, Maroun JA, Hodson DI, Carey MS, Cowan DH. Progress of clinical oncology guidelines development using the practice guidelines development cycle: The role of practitioner feedback, 1226
— *see* Zee B
Brown A, *see* Fisher B
Brown C, *see* Aghajanian C
Brown E, *see* Murray N
Brown MT, *see* Bigner DD
Brown RA, *see* Adkins DR
Brown TD, *see* Venook AP
Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain, 3222
Brugger S, *see* Laczika K
Brunelli C, *see* Ripamonti C
Brunet J-S, *see* Foulkes WD
Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, Kaye SB, Verweij J, Fossella FV, Valero V, Rigas JR, Seidman AD, Chevallier B, Fumoleau P, Burris HA, Ravdin PM, Sheiner LB. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer, 187
Bruso P, *see* Clayman GL
Bryant J, *see* Fisher B
Bryon PA, *see* Davi F
Bryson P, *see* Hoskins P
Buchanan GR, *see* Oeffinger KC
Buckley BJ, *see* Kaplan R
Buckley J, *see* Ozkaynak MF
Buckner JC, *see* Galanis E
— *see* Taylor BV
Budach V, *see* Eberhardt W
Budd GT, *see* Taylor CW
Budman D, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine, 1795
— *see* Venook AP
Buffa R, *see* Pignataro L
Buggisch P, *see* Riethmüller G
Bui N, *see* Fizazi K
— *see* Ravaud A
Bull SB, *see* Andrulis IL
Burch P, *see* Galanis E
— *see* O'Connell MJ
Burckhardt P, *see* Body JJ
Bureau G, *see* Sculier J-P
Burgess AM, *see* Eton O
Burke TW, *see* Morris M
Burkitt's Lymphoma Study Group, *see* Davi F
Burman C, *see* Zelefsky MJ
Burnell M, *see* Levine M
Burris HA III, *see* Bruno R
— *see* Hainsworth JD
— *see* Schilsky RL
— *see* Valero V
Burrow GN, *see* Tallini G
Burtin P, *see* Gamelin E
Burt ME, *see* Kavolius JP
Busch M, *see* Hiddemann W

Busch MA, *see* Christie JM
Buset M, *see* Grimaldi C
Bush DA, *see* Goren MP
Bushnell W, *see* Gralla RJ
— *see* Perez EA
Bush SA, *see* Liu SY
Busse PM, *see* Colevas AD
Buys S, *see* Frank TS
Buzaid AC, *see* Eton O
— *see* Legha SS
Buzdar A, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: Comparison of safety and efficacy, 348
— In reply (letter), 2000
— *see* Chang S
— *see* Rahman Z
Buzzi M, *see* Zinzani PL
Byrd JC, Weiss RB. In reply (letter), 3210
— *see* Weiss RB
Caballero MD, *see* Ciudad J
Cabanillas F, *see* Khouri IF
— *see* McLaughlin P
— *see* Popat U
Cabriales S, *see* Tulpule A
Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Barón AE, Ross M, Matthes S, Dunbar SE, Jones RB. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer, 1661
— *see* Nieto Y
Cahn J-Y, *see* Guglielmi C
Cailleux PE, *see* Gamelin É
Cairncross JG. Cognition in survivors of high-grade glioma (letter), 3210
Cairo M, *see* Ozkaynak MF
Calabresi P, *see* Glantz MJ
Calderone L, *see* Mercadante S
Callander NS, *see* Ravdin PM
Callender DL, *see* Shin DM
Calvert AH, *see* Rafi I
Calvete JA, *see* Rafi I
Calvo F, *see* Degiuli M
Camitta B, *see* Mahoney DH Jr
— *see* Shuster JJ
Campanacci M, *see* Bacci G
Campana D, *see* Consolini R
Campbell E, *see* Rowinsky E
Campo E, *see* Terol M-J
Cancer and Leukemia Group B 9264, *see* Venook AP
Canellos GP. New publisher for the *Journal of Oncology* (editorial), 3719
Canete A, *see* Cheung N-KV
Cannetta RM, *see* Sulkes A
Cannistra SA, *see* Tai Y-T
Cantor SB, Hudson DV Jr, Lichtiger B, Rubenstein EB. Costs of blood transfusion: A process-flow analysis, 2364
Cantwell S, *see* Pecora AL
Cany L, *see* Ravaud A
Capaccio P, *see* Pignataro L
Capstick V, *see* Hoskins P
Caraceni A, De Conno F. Analgesic effects of chemotherapy? (letter), 803
Carboni N, *see* Pignataro L
Carde P, *see* Decuadin D
— *see* Hagenbeek A
Carey MS, *see* Browman GP
Carey RW, *see* Choi NC
Carlini M, *see* Benevolo M
Carracedo C, *see* Gómez H
Carriero MV, *see* Ciarmiello A
Carrión R, *see* Arranz R
Carroll AJ, *see* Harris MB
— *see* Shuster JJ
Casanova L, *see* Gómez H
Cascino TL, *see* Taylor BV
Caspard H, *see* Leblond V
Casper E, *see* Meyers P
Cassileth PA, *see* Loeffler M
Castiglione-Gertsch M, *see* Goldhirsch A
Castleberry RP, *see* Katzenstein HM
Casto DT, *see* Langevin A-M
Casuccio A, *see* Mercadante S
Catalano PJ, *see* Nichols CR
Catalano R, *see* Wadler S
Catton C, *see* Warde P
Caty A, *see* Ravaud A
Cavalli F, *see* Betticher DC
Cebon J, *see* Basser RL
— *see* Clarke K
Cella D, *see* Audrain J
— *see* Demetri G
— *see* Fetting JH
Centurioni R, *see* Santini G
Cerny T, *see* Betticher DC
Cervantes A, *see* Grimaldi C
Cesana BM, *see* Pignataro L
Chabner E, Nixon A, Gelman R, Hetelekidis S, Recht A, Bornstein B, Connolly J, Schnitt S, Silver B, Manola J, Harris J, Garber J. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer, 2045
Chacon I, *see* Sanchez E
Champlin R, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Chang AE, *see* Yang JC
Chang J, *see* Weaver A
ChangLai S-P, *see* Kao C-H
Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body mass index, 3731
Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold SC Jr, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados MD. Phase I study of paclitaxel in patients with recurrent malignant glioma: A North American Brain Tumor Consortium report, 2188
Chan JKC, *see* Cheung MMC
Chan PTM, *see* Cheung MMC
Chan WC, *see* Vose JM
Chao NJ, *see* Laughlin MJ
Chapko MK, *see* Syrjala KL
Chapman RA, *see* Press OW
Chappell R, Miranpuri SS, Mehta MP. Dimension in defining tumor response (letter), 1234

Charlotte F, *see* Leblond V
Charnsangavej C, *see* Pisters PWT
Charpin C, Garcia S, Bonnier P, Martini F, Andrac L, Horschowski N, Lavaut M-N, Allasia C. bcl-2 automated and quantitative immunocytochemical assays in breast carcinomas: Correlation with 10-year follow-up, 2025
Chastang C, *see* Tourani J-M
Chatterjee S, *see* Bostick PJ
Chaturvedi P, *see* Rowinsky E
Chaudri HA, *see* Dombernowsky P
— *see* Trunet PF
Chauvenet AR, *see* Marcus RB
Chauvin F, *see* Blay J-Y
— *see* Guglielmi C
— *see* Ladenstein R
— *see* Lasset C
Chawla S, *see* Perez EA
Chen BDM, *see* Varterasian ML
Chen CC, *see* Gibril F
Chen J, Swerdlow SH, Jacobs SA. Mantle-cell lymphoma, 2568
Chen JK, *see* Yang C-T
Cherlow JM, *see* Nachman J
Cheron N, *see* Fouillard L
Cheson BD, Frame JN, Vena D, Quashu N, Sorensen JM. Tumor lysis syndrome: An uncommon complication of fludarabine therapy of chronic lymphocytic leukemia, 2313
—, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, Tallman M, Annino L, Connors J, Coiffier B, Lauria F. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: A Report of 979 patients, 3007
— *see* Wilson WH
Chetanneau A, *see* Serafini AN
Cheung IY, *see* Cheung N-KV
Cheung MMC, Chan JKC, Lau WH, Foo W, Chan PTM, Ng CS, Ngan RKC. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: Clinical features, tumor immunophenotype, and treatment outcome in 113 patients, 70
Cheung N-KV, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM. Anti-GD2 Antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age, 3053
— *see* Kushner BH
Cheung TW, *see* Dezube BJ
Chevallier B, *see* Bruno R
Chevreau C, *see* Blay J-Y
— *see* Ravaud A
Chi DD, *see* Bostick PJ
Chieng P-U, *see* Kao C-H
Children's Cancer Group, *see* Dunkel IJ
Chiodo TA, *see* Wojtowicz-Praga S
Chisesi T, *see* Santini G
Chiusa L, *see* Pich A
Choi NC, Herndon JE II, Rosenman J, Carey RW, Chung CT, Bernard S, Leone L, Seagren S, Green M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractioned-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer, 3528
Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: An analysis using a Markov model, 2700
Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T. Multiinstitutional phase II trial of paclitaxel, carboplatin, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer, 3316
— *see* Akerley W
Chretien Y, *see* Tourani J-M
Christie JM, Simmonds M, Patt R, Coluzzi P, Busch MA, Nordbrock E, Portenoy RK. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain, 3238
Christodoulou CV, Ferry DR, Fyfe DW, Young A, Doran J, Sheehan TMT, Eliopoulos A, Hale K, Baumgart J, Sass G, Kerr DJ. Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer, 2761
Chung C, *see* Choi NC
— *see* Choy H
Ciarmiello A, Del Vecchio S, Silvestro P, Potena MI, Carriero MV, Thomas R, Botti G, D'Aiuto G, Salvatore M. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer, 1677
Cid M-C, *see* Terol M-J
Cigolari S, *see* Gridelli C
Cimerman N, *see* Foekens JA
Cioffi R, *see* Gridelli C
Cipolla G, *see* Colleoni M
Cirera L, *see* Grimaldi C
Cirrincione C, *see* Laughlin MJ
Citron ML, *see* Fetting JH
— *see* Kaplan R
Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernández J, Moro MJ, Mateos MV, Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia, 3774
Clahsen PC, van de Velde CJH, Duval C, Pallud C, Mandard A-M, Delobelle-Deroide A, van den Broek L, Sahmoud TM, van de Vijver MJ. p53 Protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer, 470
Clancy L, *see* Steward WP
Clarke K, Basser RL, Maher D, Morgan DJ, Cebon J, Fox RM, Hill JS, Alt C, Bartlett J, Geldard H, Kaye AH, Green MD. Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer, 2181
Clarke MJ, *see* Specht L
Clark GM, *see* Diab SG
— *see* Levesque MA
Clark JA, *see* Talcott JA
Clark S, *see* Frank TS
Clausen M, *see* Bohuslavizki KH
Clauvel J-P, *see* Leblond V
Claxton D, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu T-J, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H. Adenovirus-

mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma, 2221
— *see* Shin DM
Cleary KR, *see* Pisters PWT
Cleary SF, *see* Wolden SL
Clelland J, *see* Surtees R
Clemm C, *see* Steyerberg EW
Clendenin N, *see* Rafi I
Clough K, *see* Lombard I
Coates AS, *see* Ellis PM
— *see* Falkson CI
— *see* Goldhirsch A
Cocconi G, Cunningham D, Van Custem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM. Open, randomized, multicenter trial of raltitrexed *versus* fouorouracil plus high-dose leucovrin in patients with advanced colorectal cancer, 2943
Cockburn J, Redman S, Kricker A. Should women take part in clinical trials in breast cancer? Issues and some solutions, 354
Cohen H, *see* Metzger R
Cohn SL, *see* Katzenstein HM
Coia L, *see* Minsky BD
Coiffier B. Which treatment for mantle-cell lymphoma patients in 1998? (editorial), 3
— *see* Blay J-Y
— *see* Cheson BD
— *see* Solal-Céligny P
Cokgor I, *see* Bigner DD
— *see* Friedman HS
Colan SD, *see* Nysom K
Coldman A, *see* Murray N
— *see* Ragaz J
Cole BF, Gelber RD, Kirkwood JM. Survival benefit in melanoma (letter), 388
—, Gelber RD, Goldhirsch A. In reply (letter), 3718
—, Solal-Céligny P, Gelber RD, Lepage E, Gisselbrecht C, Reyes F, Sebban C, Sugano D, Tendler C, Goldhirsch A. Quality-of-life-adjusted survival analysis of interferon alfa-2b treatment for advanced follicular lymphoma: An aid to clinical decision making, 2339
— *see* Choy H
— *see* Glantz MJ
— *see* Zee B
Coleman RE, *see* Bigner DD
— *see* Lowe VJ
Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, Fabian RL, Fitzgerald TJ, Dreyfuss A, Peters ES, Adak S, Costello R, Barton JJ, Posner MR. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: A phase I/II trial, 1331
Colleoni M, Martinelli G, Beretta F, Marone C, Gallino A, Fontana M, Graffeo R, Zampino G, De Pas T, Cipolla G, Martinoni C, Goldhirsch A. Intracavity chemotherapy with thiotepa in malignant pericardial effusions: An active and well-tolerated regimen, 2371
— *see* Goldhirsch A
Collette L, *see* Fossâ SD
— *see* Kaye SB
Collier BD, *see* Serafini AN
Collins CD, *see* Weaver A
Collins J, *see* Basser RL
Collins RD, *see* Hutchinson RJ
Colome MI, *see* Gershenwald JE
Colomer R, *see* Arranz R
— *see* Garcia-Carbonero R
— *see* Gómez H
Colonna P, *see* Andrieu J-M
Colon-Otero G, *see* O'Connell MJ
Coluzzi P, *see* Christie JM
Colvin OM, *see* Friedman HS
Comandone A, *see* Bacci G
Come S, *see* Gage I
Confalonieri C, *see* Fossati R
Congiu AM, *see* Santini G
Conlon KC, *see* Mann GB
Connolly J, *see* Chabner E
Connolly JL, *see* Gage I
Connors J, *see* Cheson BD
Conradt C, *see* Keilholz U
Conroy T, *see* Blay J-Y
Consolini R, Pui C-H, Behm FG, Raimondi SC, Campana D. In vitro cytotoxicity of docetaxel in childhood acute leukemias, 907
Constine LS. Should MOPP-ABVD alone be standard for childhood Hodgkin's? (letter), 1235
Conti F, *see* Lopez M
Contu A, *see* Santini G
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: Differing metabolic activity in osteoblastic and osteolytic lesions, 3375
Cook J, *see* Herscher LL
Cooley TP, *see* Dezube BJ
Cooper BW, Moss TJ, Ross AA, Ybanez J, Lazarus HM. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer, 3509
Cooper DL, Salloum E. Late solid tumors after treatment for Hodgkin's disease (letter), 2287
Cooper J, *see* Al-Sarraf M
Cooper MR, *see* Mansour EG
Coppin C, *see* Murray N
Corey B, *see* Savarese D
Cornish JM, *see* Marks DI
Cortés-Funes H, *see* Garcia-Carbonero R
— *see* Gómez H
Cortes J, Talpaz M, O'Brien S, Rios MB, Majlis A, Keating M, Freireich EJ, Kantarjian H. Suppression of cytogenic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia, 3279
— *see* Rodriguez J
Cosimelli M, *see* Benevolo M
Costa J, *see* Tallini G
Costantini M, *see* Messori A
Costantino J, *see* Fisher B
Costello R, *see* Colevas AD
Cote C, *see* Saliba F
Cote R, *see* Bostick PJ
Cotterill S, *see* Craft A
Cottler-Fox M, *see* Egorin MJ
Cowan DH, *see* Browman GP
Cox A, *see* Tjan-Heijnen VCG
Coze C, *see* Ladenstein R

Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, Imeson J, Lewis I. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study, 3628
Craig PH, *see* Silverstein MJ
Crawford ED, *see* Nichols CR
Creaven PJ, *see* Budman DR
Crews JR, *see* Laughlin MJ
Crist WM, *see* Hudson MM
Crookes P, *see* Metzger R
Crowley J, *see* Green S
Crowley JJ, *see* Kraut EH
— *see* Lau DH
— *see* Salmon SE
— *see* Wozniak AJ
Crowther D, *see* Loeffler M
— *see* Weaver A
Crowther H, *see* Lundin J
Crump M, Gluck S, Pritchard K, Shepherd L, Pater J. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America (letter), 800
— *see* Hofstra LS
— *see* Schimmer AD
Cruz AB Jr, *see* Fisher B
Cruz MA, *see* Sanchez E
Cuatrecasas M, *see* Gerald W
Culine S, *see* Fizazi K
Cullen M, *see* Fosså SD
— *see* Kaye SB
Cummings S, *see* Frank TS
Cunningham D, *see* Bleiberg H
— *see* Cocconi G
Curcio C, *see* Gridelli C
Curran AC, *see* Toner GC
Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience, 145
— *see* Giaccone G
Currie V, *see* Seidman AD
Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment, and recurrence from melanoma, 1760
Curti BD, Ochoa AC, Powers GC, Kopp WC, Alvord WG, Janik JE, Gause BL, Dunn B, Kopreski MS, Fenton R, Zea A, Dansky-Ullmann C, Strobl S, Harvey L, Nelson E, Sznol M, Longo DL. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer, 2752
Curtin J, *see* Aghajanian C
Cutuli B. Radiation-induced breast cancer after treatment for Hodgkin's disease (letter), 2285
Cuzick J, *see* Holli K
Cvitkovic E. Bleomycin in nonseminomatous germ-cell tumors: cure rate *versus* morbidity (letter), 799
— *see* Saliba F
— *see* Schrijvers D
Czaykowski PM, *see* Siu LL
Czeijka M, *see* Rosen HR
Czuczman MS, *see* McLaughlin P
Dacamara P, *see* Andrulis IL
Dahlberg S, *see* Stiff PJ
Dahl GV, *see* Skapek SX
D'Aiuto G, *see* Ciarmiello A
Dallaire BK, *see* McLaughlin P
Dalton VMK, Gelber RD, Li F, Donnelly MJ, Tarbell NJ, Sallan SE. Second malignancies in patients treated for childhood acute lymphoblastic leukemia, 2848
—, Gelber R, Tarbell NJ, Sallan SE. In reply (letter), 3918
Dalton WS, *see* Taylor CW
Damasio E, *see* Cheson BD
— *see* Santini G
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy, 3094
Danenberg KD, *see* Gorlick R
— *see* Metzger R
Danenberg PV, *see* Gorlick R
— *see* Metzger R
Danese F, *see* Degiuli M
Danforth DN, *see* Yang JC
D'Angio GJ, *see* Green DM
Dan MD, *see* Varterasian ML
Dann AJ, Anastasi J, Larson RA. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase, 1498
Danquechin-Dorval E, *see* Gamelin É
Dansky-Ullmann C, *see* Curti BD
D'Aprile M, *see* Gridelli C
Dapunt O, *see* Zeimet AG
Darke A, *see* Bruera E
Daryanani S. Dermatomyositis and breast cancer, 2890
Das Gupta TK, *see* Mehta RR
Datiles M III, *see* Haddy TB
Daugherty CK, Ratain MJ, Minami H, Banik DM, Vogelzang NJ, Stadler WM, Siegler M. Study of cohort-specific consent and patient control in phase I clinical cancer trials, 2305
Davidson NE, *see* Hahm HA
Davi F, Delecluse HJ, Guiet P, Gabarre J, Fayon A, Gentilhomme O, Felman P, Bayle C, Berger F, Audouin J, Bryon PA, Diebold J, The Burkitt's Lymphoma Study Group, Raphaël M. Burkitt-like lymphomas in AIDS patients: Characterization within a series of 103 human immunodeficiency virus–associated non-Hodgkin's lymphomas, 3788
— *see* Leblond V
Davis BJ, *see* Merchant TE
Davis PC, *see* Hutchinson RJ
Davis TC, *see* Bennett CL
Dawson NA. Apples and oranges: Building a consensus for standardized eligibility criteria and endpoints in prostate cancer clinical trials, 3398
Daxenbichler G, *see* Zeimet AG
— *see* Zeimet AG
de Alava E, Kawai A, Healey JH, Fligman I, Meyers P, Huvos AG, Gerlad WL, Jhanwar SC, Argani P, Antonescu CR, Pardo-Mindan FJ, Ginsberg J, Womer R, Lawlor ER, Wunder J, Andrulis I, Sorensen PHB, Barr FG, Ladanyi M. *EWS-FLI1*

fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma, 1248
— *see* Gerald W
DeAngelis LM, *see* Abrey LE
De Bock R, *see* Hagenbeek A
Debruyne C, *see* Giaccone G
Debus J, *see* Pirzkall A
de Cataldo R, *see* Löwenberg B
DeCillis A, *see* Fisher B
Deconinck E, *see* Leblond V
De Conno F, *see* Caraceni A
— *see* Ripamonti C
De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A, Mamelle G, Janot F, Julieron M, Leridant AM, Marandas P, Armand JP, Schwaab G, Luboinski B, Eschwege F. Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients, 3556
Decuadin D, Bosq J, Tertian G, Nedellec G, Bennaceur A, Venuat A-M, Bayle C, Carde P, Bendahmane B, Hayat M, Munck J-N. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas, 579
Defusco P, *see* Laughlin MJ
Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian Gastric Cancer Study Gropu prospective multicenter surgical study, 1490
Degos L, *see* Demetri G
De Greve J, *see* Grimaldi C
de Jong S, *see* Wisman GBA
Dekker AW, *see* Löwenberg B
DeLaney T, *see* Yang JC
de la Rochefordière A, *see* Lombard I
Delatre O, *see* Fagnou C
Delbeke D, *see* Lowe VJ
Delecluse HJ, *see* Davi F
Delepine N, *see* Bacci G
De Leyn PR, *see* Vansteenkiste JF
Del Favero A, *see* Ballatori E
Delgado MA, *see* Leblond V
de Lima M, *see* Popat U
Delmas PD, *see* Body JJ
Delmer A, *see* Leblond V
Delobelle-Deroide A, *see* Clahsen PC
del Prever AB, *see* Bacci G
Delva R, *see* Gamelin É
Del Vecchio S, *see* Ciarmiello A
DeMario MD, Ratain MJ. Oral chemotherapy: Rational and future directions, 2557
Demedts MG, *see* Vansteenkiste JF
Demers R, *see* Ramalingam S
Demetri G, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a Prospective Community Oncology study, 3412
— *see* Amatruda JF
de Moor C, *see* Diab SG
deMulder P, *see* Kaye SB
De Mulder PHM, *see* Fossâ SD
DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, McGahan JP, Salako Q, Shen S, Lewis JP. Maximum-tolerated dose, toxicity, and efficacy of 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma, 3246
DeNardo SJ, *see* DeNardo GL
Deneffe GJ, *see* Vansteenkiste JF
De Pas T, *see* Colleoni M
DePiro P, *see* Wu C
De Placido S, *see* Gridelli C
De Prijck L, *see* Kaye SB
de Prijck L, *see* Fossâ SD
Derzko C, *see* Schimmer AD
Desai S, *see* Laver J
DeSantes K, *see* Matthay K
Desch CE, *see* Hillner BE
Deschênes L, *see* Dorval M
Desiderio F, *see* Tassinari D
Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma, 1547
deSmet M, *see* Sandor V
Desmond K, *see* Ganz PA
De Souza C, *see* Santini G
Deutsch M, *see* Fisher B
Devereux S, *see* Watts MJ
Devin J, *see* Treat J
de Vries EGE, Meijs PJM, Rodenhuis S. Third-party payers and breast cancer study (letter), 809
— *see* Hofstra LS
— *see* Wisman GBA
de Wit R, *see* Fossâ SD
— *see* Kaye SB
— *see* Steward WP
— *see* Steyerberg EW
de Witte HH, *see* Berns EMJJ
Dewitt L, *see* Bartelink H
De Wolf-Peeters C, *see* Hagenbeek A
de Wynter E, *see* Weaver A
Dexter TM, *see* Weaver A
Dezube BJ, Von Roenn JH, Holden-Wiltse J, Cheung TW, Remick SC, Cooley TP, Moore J, Sommadossi J-P, Shriver SL, Suckow CW, Gill PS. Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS clinical trial group study, 1444
— *see* Northfelt DW
— *see* Stewart S
Dhaliwal H, *see* Latreille J
Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy, 1655
Diamandis EP, *see* Levesque MA
Diasia R, *see* Schilsky RL
DiBernardo C, *see* Hahm HA
Dickson R, *see* Wojtowicz-Praga S
Diebold J, *see* Davi F
Diehl LF, *see* Weiss RB
Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer J-U, Sextro M, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G,

Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M for the German Hodgkin's Lymphoma Study Group. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group, 3810
— *see* Loeffler M
Diel IJ, *see* Body JJ
Di Filippo F, *see* Koops HS
Digestive Group of French Federation of Cancer Centers, *see* Bécouarn Y
Dignam J, *see* Fisher B
Di Lauro L, *see* Lopez M
Di Leo A, *see* Bleiberg H
Diller L, Ghahremani M, Morgan J, Grundy P, Reeves C, Breslow N, Green D, Neuberg D, Pelletier J, Li FP. Constitutional *WT1* mutations in Wilms' tumor patients, 3634
Dilliolugil O, *see* Leibman BD
Dimich AB, *see* Tallini G
Dimitrov N, *see* Fisher B
Dimopoulos MA, Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder, 1601
— *see* Berenson JR
Dinapoli RP, *see* Galanis E
— *see* Taylor BV
Di Palma M, *see* Tourani J-M
DiPaola RS, *see* Silber JH
DiPersio JF, *see* Adkins DR
Dissing M, Le Beau MM, Pedersen-Bjergaard J. Inversion of chromosome 16 and uncommon rearrangements of the *CBFB* and *MYH11* genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?, 1890
Dobashi N, *see* Usui N
Doggett RS, *see* Shipley WU
Dohollou N, *see* Fizazi K
— *see* Ravaud A
Doi O, *see* Adachi M
Doksum T, *see* Geller G
Dolan ME, Roy SK, Fasanmade AA, Paras PR, Schilsky RL, Ratain MJ. O6-benzylguanine in humans: Metabolic, pharmacokinetic and pharmacodynamic findings, 1803
— *see* Friedman HS
Domanski MJ, *see* Haddy TB
Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hofmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effet and improved efficacy and tolerability compared with megestrol acetate, 453
— *see* Ryberg M
Dombret H, *see* Lundin J
Domenge C, *see* De Crevoisier R
Donaldson SS, Lamborn KR. Radiation in pediatric Hodgkin's disease (letter), 391
— *see* Wolden SL
Donato M, *see* Khouri IF
— *see* Popat U
Donegan J, *see* Ilson DH
Dong Q, *see* Eton O
Donnelly BJ, *see* Shipley WU
Donnelly MJ, *see* Dalton VMK
Donohue JH, *see* O'Connell MJ
Donohue JP, *see* Leibovitch I
Doppman JL, *see* Gibril F
Doran J, *see* Christodoulou CV
Dorent R, *see* Leblond V
Doria L, *see* Pecora AL
Dörken B, *see* Köhne C-H
— *see* Reichardt P
Dorval M, Maunsell E, Deschênes L, Brisson J, Mâsse B. Long-term quality of life after breast cancer: Comparison of 8-year survivors with population controls, 487
Dorval T, *see* Keilholz U
Douay L, *see* Fouillard L
Dougherty E, *see* Mann GB
Douillard J-Y, *see* Ravaud A
Downing JR, *see* Pui C-H
Doyen C, *see* Solal-Céligny P
Dramais-Marcel D, *see* Blay J-Y
Dranoff G. Cancer gene therapy: Connecting basic research with clinical inquiry, 2548
Drengler R, *see* Rowinsky E
Drevon M, *see* Ravaud A
Dreyfuss A, *see* Colevas AD
Drinkard LC, *see* Masters GA
Drobins P, *see* Treat J
Drouin P, *see* Hoskins P
Droz J-P, *see* Fizazi K
— *see* Kollmannsberger C
Duboisset P, *see* Leblond V
Dubowy R, *see* Langevin A-M
Ducreux M, *see* Bécouarn Y
Duehmke E, *see* Diehl V
Duez N, *see* Grimaldi C
Duffour J, *see* Bécouarn Y
Dugan M, *see* Friedman HS
Dugan W, *see* Passik SD
Duggan G, *see* Basser RL
Du M, *see* Gandhi V
Dumas M, *see* Stadler WM
Dumesic DA, *see* Loprinzi CL
Dumesnil Y, *see* Gamelin É
Dummer R, *see* Keilholz U
Du Mond C, *see* Northfelt DW
Dunbar SE, *see* Cagnoni PJ
Dunkel IJ, Boyett JM, Yates A, Rosenblum M, Garvin JH Jr, Bostrom BC, Goldman S, Sender LS, Gardner SL, Li H, Allen JC, Finlay JL for the Children's Cancer Group. High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma, 222
— *see* Gururangan S
— *see* Mason WP
Dunn B, *see* Curti BD
Dunn RL, *see* Smith DC
Dunst J, *see* Paulussen M
Dupont-André G, *see* Bécouarn Y
Dupont PJ, *see* Vansteenkiste JF
Durack LD, *see* Liu SY
Durant J. Alternative medicine: An attractive nuisance (editorial), 1
— In reply (letter), 3203

Durham C, *see* Lerman C
Duval C, *see* Clahsen PC
Du W, *see* Redman BG
Dworak O, *see* Köckerling F

Earhart RH, *see* Valero V
Eary JF, *see* Liu SY
Eastern Cooperative Oncology Group 4593, *see* Mehta MP
Eaton WL, *see* Ahles TA
— *see* Perry MC
Ebbs S, *see* Ellis P
Eberhardt W, Wilke H, Stamatis G, Stuschke M, Harstrick A, Menker H, Krause B, Müeller MR, Stahl M, Flasshove M, Budach V, Greschuchna D, Konietzko N, Sack H, Seeber S. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial, 622
Eckhardt SG, *see* Rowinsky E
— *see* Villalona-Calero MA
Edgerton S, *see* Passik SD
Edwards MJ, Gamel JW, Feuer EJ. Improvement in the prognosis of breast cancer from 1965 to 1984, 1030
—, Gamel JW, Vaughan WP, Wrightson WR. Infiltrating ductal carcinoma of the breast: The survival impact of race, 2693
Efremidis A, *see* Sculier J-P
Eggermont AMM, *see* Keilholz U
— *see* Koops HS
Egger T, *see* Betticher DC
Eghbali H, *see* Blay J-Y
— *see* Ravaud A
Egner JR, *see* Barton DL
Egorin MJ, Rosen DM, Sridhara R, Sensenbrenner L, Cottler-Fox M. Plasma concentrations and pharmacokinetics of dimethylsulfoxide and its metabolites in patients undergoing peripheral-blood stem-cell transplants, 610
— *see* Glantz MJ
— *see* Lilenbaum RC
— *see* Venook AP
Ehninger G, *see* Thiede C
Eijkenboom WM, *see* Levendag PC
Eilender DS, *see* Varterasian ML
Einhorn LH, *see* Gralla RJ
— *see* Loehrer PJ Sr
— *see* Nichols CR
— *see* Saxman SB
— *see* Zon RT
Eisenhauer E, *see* Hoskins P
— *see* Siu LL
Eisen T, Smith IE, Johnston S, Ellis PA, Prendville J, Seymour MT, Walsh G, Ashley S. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide *versus* infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer, 1350
Eisinger E, Julian-Reynier C, Stoppa-Lyonnet D, Vennin P, Lasset C, Noguès C, Sobol H. Breast and ovarian cancer prone women and prophylactic surgery temptation (letter), 2573
Elashoff R, *see* Hoon DSB
Elfring GL, *see* Saltz LB
Elias A, *see* Ayash LJ
Eliopoulos A, *see* Christodoulou CV
Elledge RM, *see* Diab SG
Ellis J, *see* Audrain J
Ellis P, Smith I, Ashley S, Walsh G, Ebbs S, Baum M, Sacks N, McKinna J. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer, 107
— *see* Eisen T
Ellis PM, Coates AS. Effects of randomized clinical trials (letter), 2570
Ell PJ, *see* Serafini AN
El-Naggar AK, *see* Clayman GL
Elwood P, *see* Wilson WH
Emanuel EJ, Patterson WB. Ethics of randomized clinical trials, 365
—, Patterson WB. Scientific misconduct in cancer clinical trials, 3433
Emanuel J, *see* Tallini G
Emi N, *see* Asou N
Emi T, *see* Gambhir SS
Endrizzi L, *see* Santini G
Engelholm SA, *see* Sangelov
Engelking C, *see* Wadler S
Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis, 1179
Engenhart-Cabillic R, *see* Pirzkall A
Eng M, *see* Saltz LB
Ensley JF, *see* Al-Sarraf M
Ensminger WD, *see* McGinn CJ
Entezam S, *see* Leblond V
Epenetos A, *see* Lundin J
Eppenberger-Castori S, *see* Eppenberger U
Eppenberger U, Keung W, Schlaeppi J-M, Roesel JL, Benz C, Nueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foesens JA, Eppenberger-Castori S. Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients, 3129
Erban JK, *see* Valero V
Erder MH, *see* Silber JH
Eriksson B, *see* Örlefors H
Erland JB, *see* Hainsworth JD
Erlichman C, *see* O'Connell MJ
Ernst S, *see* Bloomfield DJ
— *see* Latreille J
Errante D, *see* Tirelli U
Eschwege F, *see* De Crevoisier R
Escudier B, *see* Ravaud A
Eshelman DA, *see* Oeffinger KC
Eskelinen MJ, *see* Karjalainen JM
España P, *see* Garcia-Patiño E
Esparza-Guerra L, *see* Valero V
Espina BM, *see* Tulpule A
Estapé J, *see* Grau JJ
Estrov Z, *see* Kurzrock R
Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS. Prognostic factors for survival of patients treated systemically for disseminated melanoma, 1103
— *see* Legha SS
Ettinger AG, *see* Nicholson HS
Ettinger D, *see* Gralla RJ
European Organization for Research and Treament of Cancer Lung Cancer Cooperative Group, *see* Giaccone G
European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group, *see* Hagenbeek A

Evans DB, *see* Pisters PWT
Evans PAS, Short MA, Owen RG, Jack AS, Forsyth PD, Shiach CR, Kinsey S, Morgan GJ. Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia, 3616
Evans WE, *see* Pui C-H
Evans WK. In reply (letter), 808
— *see* Browman GP
Even-Shoshan O., *see* Silber JH
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients, 1582
Eyre HJ, *see* Jaeckle KA

Fabian RL, *see* Colevas AD
Fagnou C, Michon J, Peter M, Bernoux A, Oberlin O, Zucker J-M, Magdelenat H, Delatre O, Société Française d'Oncologie Pédiatrique. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor, 1707
Fainsinger R, *see* Bruera E
Fairclough DL, *see* Fetting JH
Fajardo MT, *see* Welles L
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Phase III trial of dacarbazine *versus* dacarbazine with interferon a-2b *versus* dacarbazine with tamoxifen *versus* dacarbazine with interferon a-2b and tamoxifen in patients with metastic malignant melanoma: An Eastern Cooperative Oncology Group study, 1743
Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Commings FJ, Sledge GW, Abeloff MD. Eastern Cooperative Oncology Group randomized trials of observation *versus* maintenance therapy for patients with metastatic breast cancer in conplete remission following induction treatment, 1669
— *see* Dombernowsky P
— *see* Mansour EG
Fallowfield L, Lipkin M, Hall A. Teaching senior oncologists commmunication skills: results from phase I of a comprehensive longitudinal program in the United Kingdom, 1961
Fandi A, *see* Bécouarn Y
Farrell G, *see* Gurney HP
Fasanmade AA, *see* Brockstein B
— *see* Dolan ME
— *see* Fleming GF
Fassas A, *see* Desikan KR
Favre M, *see* Lombard I
Fayers PM, *see* Hjermstad MJ
Fayon A, *see* Davi F
Feierabend C, *see* Berlin J
Feigal E, *see* Welles L
Feig S, *see* Ozkaynak MF
— *see* Sievers EL
Fein DA, *see* Siegelmann-Daniel N
Feld R, *see* Siu LL
Felman P, *see* Davi F
Fenaux P, *see* Fouillard L
Fennelly D, *see* Aghajanian C
Fennelly J, *see* Steward WP
Fenton R, *see* Curti BD
Ferguson MK, *see* Masters GA
Ferguson WS, *see* Harris MB
— *see* Skapek SX
Fernandez CV, Stutzer CA, MacWilliam L, Fryer C. Alternative and complementary therapy use in pediatric oncology patients in British Columbia: Prevalence and reasons for use and nonuse, 1279
Fernández-Rañada JM, *see* Arranz R
Ferraironi A, *see* Lopez M
Ferrari L, *see* Bonadonna G
Ferrari S, *see* Bacci G
Ferreira MR, *see* Bennett CL
Ferrero J-M, *see* Ravaud A
Ferry DR, *see* Christodoulou CV
Festen J, *see* Tjan-Heijnen VCG
Fetell M, *see* Hesdorffer C
Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD. Sixteen-week multidrug regimen *versus* cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study, 2382
Fety R, *see* Gamelin É
Feuer EJ, *see* Edwards MJ
Feuerstein I, *see* Welles L
Fey MF, *see* Betticher DC
Fidler P, *see* Barton DL
Field M, *see* Wadler S
Fields SZ, *see* Bookman MA
Figg WD, *see* Senderowicz AM
— *see* Welles L
Figueredo A, *see* O'Connell MJ
Fillet G, *see* Löwenberg B
Finch D, *see* Saxman SB
Findlay B, *see* Latreille J
— *see* Levine M
Finklestein JZ, *see* Green DM
Finlay JL, *see* Dunkel IJ
— *see* Gururangan S
— *see* Mason WP
Finn R, *see* Cheung N-KV
Firby PS, *see* Siu LL
Fischer DS. Need randomized clinical trials, not litigation (letter), 1237
Fischkoff S, *see* Villalona-Calero MA
Fischl MA, *see* Northfelt DW
Fischman AJ, *see* Serafini AN
Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: finding from National Surgical Adjuvant Breast and Bowel Project B-17, 441
—, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer, 2672
Fisher DC, *see* Freedman AS
Fisher DR, *see* Liu SY
Fisher ER, *see* Fisher B
Fisher HA, *see* Kallakury BV
Fisher RI, *see* Glick JH
— *see* Loeffler M

— *see* Press OW
— *see* Stiff PJ
Fisher SJ, *see* Sugawara Y
Fitzgerald TJ, *see* Colevas AD
Fitzgibbins RJ, *see* O'Connell MJ
Fizazi K, Culine S, Droz J-P, Kramar A, Théodore C, Ruffié P, Le Chevalier T. Primary mediastinal nonseminomatous germ cell tumors: Results of modern therapy including cisplatin-based chemotherapy, 725
—, Dohollou N, Blay J-Y, Guérin S, Le Cesne A, André F, Pouillart P, Tursz T, Bui NB. Ewing's family of tumors in adults: Multivariate analysis of survival and long-term results of multimodality therapy in 182 patients, 3736
Flaherty L, *see* Margolin KA
— *see* Redman BG
Flasshove M, *see* Eberhardt W
Fléchon A, *see* Kollmannsberger C
Fleisch H, *see* Body JJ
Fleming GF, Kugler JW, Hoffman PC, Ansari R, Bitran JD, Klepsch A, Malone D, Fasanmade AA, Ratain MJ, Vokes EE. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer, 2032
Fleshman JW, *see* Ogunbiyi OA
Fletcher JA. Ewing's sarcoma oncogene structure: A novel prognostic factor? (editorial), 1241
Fletcher JW, *see* Lowe VJ
Fletcher WS, *see* Lau DH
— *see* Margolin KA
Fligman I, *see* de Alava E
Flores E, *see* Arranz R
Fluellen L, *see* Markman M
— *see* Rose PG
Fode K, *see* Work E
Foekens JA, Kos J, Peters HA, Krašovec M, Look MP, Cimerman N, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WLJ, Klijn JGM. Prognostic significance of cathepsins B and L in primary human breast cancer, 1013
— *see* Berns EMJJ
— *see* Eppenberger U
Fogelman I, *see* Cook GJ
Foley KM, Houde RW. Methadone in cancer pain management: Individualize dose and titrate to effect (editorial), 3213
Fonseca R, *see* Loprinzi CL
Fontana M, *see* Colleoni M
Foo W, *see* Cheung MMC
Forastiere A, *see* Al-Sarraf M
— *see* Ilson DH
Ford I, *see* Bruera E
Forman SJ, *see* Stiff PJ
Fornasiero A, *see* Dombernowsky P
Forsyth PD, *see* Evans PAS
Fort N, *see* Leblond V
Foshag LJ, *see* Hoon DSB
Fosså S, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, van Groeningen CJ, de Mulder PHM, Stenning S, Lallemand E, de Prijck L, Collette L. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy, 716
— *see* Kaye SB
— *see* Steyerberg EW
Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A. Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women, 3439
Fossella FV, *see* Bruno R
Foster RS, *see* Leibovitch I
Fouillard L, Laporte JP, Labopin M, Lesage S, Isnard F, Douay L, Lopez M, Aoudjhane M, Zunic P, Cheron N, Stachowiak J, Lemonnier MP, Andreu G, Belkacemi Y, Noël-Walter MP, Morel P, Fenaux P, Jouet JP, Bauters F, Najman A, Gorin NC. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: The role of graft purging and radiotherapy posttransplantation-Results of a retrospective analysis on 120 patients autografted in a single institution, 2803
Foulkes WD, Wong N, Brunet J-S, Narod SA. *BRCA* mutations and survival in breast cancer (letter), 3206
Fourquet A, *see* Recht A
Fowble B, *see* Recht A
Fowler JF, *see* Mehta MP
Fox K, *see* Vaughn DJ
— *see* Silber JH
Fox RM, *see* Basser RL
— *see* Clarke K
Fraker DL, *see* Alexander HR Jr
Frame JN, *see* Cheson BD
Fram R, *see* Villalona-Calero MA
Francois E, *see* Cocconi G
Frangoul HA, Patterson K. Congenital acute myelogenous leukemia with cutaneous involvement, 3199
Franklin J, *see* Diehl V
Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Rieger P, McClure M, Ward BE, Shattuck-Eidens D, Oliphant A, Skolnick MH, Thomas A. Sequence Analysis of *BRCA1* and *BRCA2*: Correlation of mutations with family history and ovarian cancer risk, 2417
Frappaz D, *see* Ladenstein R
— *see* Pein F
Frazier MW, *see* Goren MP
Frederick M, *see* Clayman GL
Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission, 13
Freedman RS, *see* Kudelka AP
Frei E III, *see* Ayash LJ
— *see* Hryniuk W
Freiman J, *see* Weiss RB
Freireich EJ, *see* Cortes J
Freund M, *see* Hiddemann W
Frickhofen N, *see* Moog F
Fridman M, *see* Silber JH
Friedlander M, *see* Zalcberg J
Fried M, *see* Colevas AD
Friedman AH, *see* Bigner DD
— *see* Friedman HS
Friedman C, *see* Gralla RJ
— *see* Perez EA

Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, Schold SC Jr. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma, 3570

—, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to temodal in newly diagnosed malignant glioma, 3851

— *see* Bigner DD

— *see* Mulhern RK

Friedman-Kien A, *see* Northfelt DW

Frisch J, *see* Steward WP

Fritsch P, *see* Pehamberger H

Frölich B, *see* Paulussen M

Fryer C, *see* Fernandez CV

Fryer JH, *see* Hutchinson RJ

Fuchs D, *see* Zeimet AG

Fuhrman C, *see* Chouaid C

Fu J, *see* Gorlick R

Fujiwara Y, *see* Kudoh S

Fu KK, *see* Al-Sarraf M

Fuks Z, *see* Zelefsky MJ

Fukuda H, *see* Yamamoto N

Fukuoka M, *see* Furuse K

— *see* Kudoh S

— *see* Masuda N

Fulton D, *see* Chang SM

Fumoleau P, *see* Bruno R

Funakoshi S, *see* Usui N

Funke I, Schraut W. Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated, 557

— *see* Riethmüller G

Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N for the Japan Clinical Oncology Group. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor *versus* standard chemotherapy in extensive-disease small-cell lung cancer, 2126

— *see* Kudoh S

Fusco N, *see* Markman M

— *see* Rose PG

Fuss M, *see* Pirzkall A

Fuster J, *see* Grau JJ

Fyfe DW, *see* Christodoulou CV

Gabarre J, *see* Davi F

— *see* Solal-Céligny P

Gadgeel S, *see* Ramalingam S

Gadner H, *see* Ladenstein R

Gage I, Schnitt SJ, Recht A, Abner A, Come S, Shulman LN, Monson JM, Silver B, Harris JR, Connolly JL. Skin recurrences after breast-conserving therapy for early-stage breast cancer, 480

Gagliardi G, *see* Ogunbiyi OA

Gagnet S, *see* Press OW

Gail M, Rimer B. Risk-based recommendations for mammographic screening for women in their forties, 3105

Gajewski J, *see* Khouri IF

— *see* Popat U

— *see* Ueno NT

Galanis E, Kvols LK, Rubin J. Carcinoid sydrome, 797

—, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, Scheithauer BW, Rowland KM, Vukov AM, Mailliard JA, Morton RF. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results, 2953

Gallego MG, *see* Aceñero MJF

Galleshaw J, *see* Stewart S

Gallino A, *see* Colleoni M

Gallo C, *see* Gridelli C

Gamagami P, *see* Silverstein MJ

Gambhir SS, Shepherd JE, Shah BD, Hart E, Hoh CK, Valk PE, Emi T, Phelps ME. Analytical decision model for the cost-effective management of solitary pulmonary nodules, 2113

Gamelin É, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin-Dorval E, Larra F, Robert J. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovrin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients, 1470

Gamel JW, *see* Edwards MJ

— *see* Edwards MJ

Gammon G, *see* Hoon DSB

Gandara DR, *see* Lau DH

— *see* Wozniak AJ

Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia, 2321

—, Plunkett W, Rodriguez CO Jr, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response, 3607

Gandjbakhch I, *see* Leblond V

Gan J, *see* Sievers EL

Ganyon PS, *see* Nachman J

Ganz PA, Rowland JH, Desmond K, Meyerowitz BE, Wyatt GE. Life after breast cancer: understanding women's health-related quality of life and sexual functioning, 501

Garaventa A, *see* Ladenstein R

Garber J. Inherited breast cancer: Increasingly familiar territory (editorial), 1639

— *see* Audrain J

— *see* Chabner E

— *see* Frank TS

Garcia AA, Keren-Rosenberg S, Parimoo D, Rogers M, Jeffers S, Koda R, Muggia FM. Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors, 2959

García-Alfonso P, *see* Arranz R

Garcia-Carbonero R, Pas-Ares L, Colomer R, Cortés-Funes H. In reply (letter), 810

Garcia JF, *see* Sanchez E

Garcia JM, *see* Garcia-Patiño E

García-Laraña J, *see* Arranz R

Garcia-Patiño E, Gomendio B, Provencio M, Silva JM, Garcia JM, España P, Bonilla F. Germ-line BRCA1 mutations in women with sporadic breast cancer: Clinical correlations, 115
Garcia S, *see* Charpin C
García-Valdecasas JC, *see* Grau JJ
Gardin G, *see* Dombernowsky P
Gardner S, *see* Dunkel IJ
— *see* Gururangan S
— *see* Mason WP
Garofalo A, *see* Benevolo M
Garrett T, *see* Hesdorffer C
Garvin J, *see* Dunkel IJ
— *see* Gururangan S
— *see* Mason WP
Gatzemeier U, *see* Steward WP
Gause BL, *see* Curti BD
Gay F, *see* Grimaldi C
Gaynon PS, *see* Heerema NA
— *see* Uckun FM
Gebhardt MC, *see* Skapek SX
Gebski V, *see* Gurney HP
Geddie W, *see* Andrulis IL
Gee A, *see* Khouri IF
Geelen FAMJ, Vermeer MH, Meijer CJLM, Van der Putte SCJ, Kerkhof E, Kluin PM, Willemze R. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related, 2080
Geisler DK, *see* Ueno NT
Gelber RD, *see* Cole BF
— *see* Dalton VMK
— *see* Goldhirsch A
Geldard H, *see* Clarke K
Geller G, Bernhardt BA, Doksum T, Helzlsouer KJ, Wilcox P, Holtzman NA. Decision-making about breast cancer susceptibility testing: How similar are the attitudes of physicians, nurse practitioners, and at-risk women?, 2868
Gelmann EP, *see* Stearns V
Gelman R, *see* Chabner E
— *see* Nixon AJ
— *see* Shapiro C
Gelmon K, *see* Murray N
— *see* Shepherd F
— *see* Westeel V
Gentet JC, *see* Pein F
Gentilhomme O, *see* Davi F
Geoffrois L, *see* Ravaud A
George S, *see* Berenson JR
Georgii A, *see* Diehl V
Gerald W, Ladanyi M, de Alava E, Cuatrecasas M, Kushner BH, LaQuaglia MP, Rosai J. Clinical, pathologic, and molecular spectrum of tumors associated with t(11;22)(p13;q12): Desmoplastic small round-cell tumor and its variants, 3028
— *see* Boulad F
— *see* Cheung N-KV
— *see* de Alava E
Gerbing R, *see* Matthay K
Gerl A, *see* Steyerberg EW
Gerlag PGG, *see* van Halteren HK
German Hodgkin's Lymphoma Study Group, *see* Diehl V
Gershenson DM, *see* Brader KR
— *see* Morris M
Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C-h, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma, 2253
Gerstbrein J, *see* Kahn D
Geslin J, *see* Gamelin É
Gesta P, *see* Gamelin É
Ghahremani M, *see* Diller L
Ghavimi F, *see* Boulad F
Gherlinzoni F, *see* Zinzani PL
Ghislandi E, *see* Fossati R
Ghossein RA, *see* Tallini G
Giaccone G, Splinter TAW, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE for the European Organization for Research and Treament of Cancer Lung Cancer Cooperative Group. Randomized study of paclitaxel-cisplatin *versus* cisplatin-teniposide in patients with advanced non-small-cell lung cancer, 2133
— *see* Curran D
— *see* Scagliotti G
Giannarelli D, *see* Benevolo M
— *see* Lopez M
Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, Serrano J, Venzon DJ, Jensen RT. Bone metastases in patients with gastrinomas: A prospective study of bone scanning, somatostatin receptors scanning, and magnetic resonance image in theor detection, frequency, location, and effect of theior detection on management, 1040
Gieser P, *see* Harris MB
— *see* Shuster JJ
Giguere JK, *see* Hahm HA
Gilbert M, *see* Chang SM
Gilchrist GS, *see* Hutchinson RJ
Gilewski T, *see* Robson M
Gill C, *see* Weaver A
Gillenwater AM, *see* Shin DM
Gillies SD, *see* Yu AL
Gillio AP, *see* Boulad F
— *see* Pecora AL
Gill J, *see* Tallini G
Gill PS, *see* Dezube BJ
— *see* Tulpule A
Giner V, *see* Sculier J-P
Ginsberg J, *see* de Alava E
Ginsberg L, *see* Clayman GL
— *see* Shin DM
Giordano A, *see* Susini T
Giralt S, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Giri PGS, *see* Al-Sarraf M
Giroux DJ, *see* Jaeckle KA
Gisselbrecht C, *see* Cole BF
— *see* Guglielmi C
— *see* Lundin J
Giuliano AE, *see* Bostick PJ
Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: Is intrathecal chemotherapy necessary?, 1561, *see* Akerley W

Glaspy JA, *see* Pegram MD
Glassman AB, *see* Eton O
Glatstein E, *see* Yang JC
Gleim GW, *see* Pecora AL
Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-year results of the intergroup trial, 19
Glimelius B, Linné T, Hoffman K, Larsson L, Svensson JH, Näsman P, Svensson B, Helmers C. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer, 434
Glisson B, *see* Brockstein B
— *see* Shin DM
Glunz A, *see* Diehl V
Gobar L, *see* Lowe VJ
Gockerman J, *see* Laughlin MJ
Goddard K, *see* Westeel V
Godleski J, *see* Kwiatkowski DJ
Goebel FD, *see* Stewart S
Goepfert H, *see* Clayman GL
Goey SH, *see* Keilholz U
Goldberg RA, *see* Siu LL
Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day 100 mortality among blood stem-cell and bone marrow transplant recipients, 3796
Goldhirsch A, Coates AS, Colleoni M, Castiglione-Gertsch M, Gelber RD. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophoisphamide, methotrexate, and fluorouracil dose and schedule may make a difference, 1358
— *see* Cole BF
— *see* Colleoni M
Goldman S, *see* Dunkel IJ
— *see* Gururangan S
Goldspiel B, *see* Herscher LL
Goldstein DS, *see* DeNardo GL
Goldstone AH, *see* Watts MJ
Gollamudi S, *see* Gururangan S
Gollub M, *see* Seidman AD
Golomb HM, *see* Masters GA
— *see* Mauer AM
Gomendio B, *see* García-Patiño E
Gomez F, *see* Guglielmi C
— *see* Ravaud A
Gómez H, Hidalgo M, Casanova L, Colomer R, Pen DLK, Otero J, Rodríguez W, Carracedo C, Cortés-Funes H, Vallejos C. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: Results of a multivariate analysis, 2065
—, Mas L, Casanova L, Pen DLK, Santillana S, Valdivia S, Otero J, Rodriguez W, Carracedo C, Vallejos C. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity, 2352
Gonin R, *see* Loehrer PJ Sr
— *see* Saxman SB
González JF, *see* Aceñero MJF
Goodfellow PJ, *see* Ogunbiyi OA
Goodwin PJ, Shepherd FA. Economic issues in lung cancer: A review, 3900
Gooley TA, *see* Liu SY
Goorin AM, *see* Harris MB
Gordon A, *see* Bookman MA
Gordon RJ, *see* Budman DR
Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer, 2426
— *see* Keilholz U
— *see* Schrijvers D
Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT. Pharmacokinetics of an intravenous-oral *versus* intravenous mesna regimen in lung cancer patients receiving ifosfamide, 616
Gorin NC, *see* Fouillard L
Gorlick R, Metzger R, Danenberg KD, Salonga D, Miles JS, Longo GSA, Fu J, Banerjee D, Klimstra D, Jhanwar S, Danenberg PV, Kemeny N, Bertino JR. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma, 1465
—, Meyers P, Kellick M, Bertino JR. Monitoring methotrexate levels in osteosarcoma (letter), 2290
— *see* Meyers P
Goroff DK, *see* Serafini AN
Gospodarowicz M, *see* Warde P
Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer, 338
—, Sierra S. In reply (letter), 2286
Goswitz MS, *see* Pisters PWT
Goudier MJ, *see* Gamelin É
Goulden NJ, *see* Marks DI
Grabenbauer GG, *see* Wendt TG
Graffeo R, *see* Colleoni M
Grafton C, *see* Murray N
— *see* Westeel V
Graham ID, *see* Browman GP
Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy, 1568
Grande L, *see* Grau JJ
Granick JL, *see* Miller DR
Grankvist K, *see* Linderholm B
Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI. Decision analysis of prophylactic mastectomy and oophrectomy in *BRCA1*-positive of *BRCA2*-positive patients, 979
—, Panageas KS, Antman KH, Whang W, Neugut AI. In reply (letter), 2575
Granovsky MO, Mueller BU, Nicholson HS, Rosenberg PS, Rabkin CS. Cancer in human immundeficiency virus-infected children: A case series from the Children's Cancer Group and the National Cancer Institute, 1729
Granovsky S, *see* Groeger JS
Granowetter L, *see* Skapek SX
Grau JJ, Estapé J, Fuster J, Visa J, Terés J, Soler G, Albiol S, García-Valdecasas JC, Grande L, Bombí J, Bordas J, Alcobendas F. Randomized trial of adjuvant chemotherapy with mutomy-

cin plus ftorafur *versus* mitomycin alone in resected locally advanced gastric cancer, 1036
Gray R, *see* Fetting JH
— *see* Mansour EG
Gray RG, *see* Specht L
Graziano S, *see* Choy H
Greco FA, *see* Hainsworth JD
Greenberg R, *see* Treat J
Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PRM, Kim T, Shochat SJ, Haase GM, Ritchey ML, Kelalis PP, D'Angio GJ. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: A report from the National Wilms' Tumor Study Group, 237
—, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, Kim T, Shochat S, Haase G, Richey M, Kelalis P, D'Angio GJ. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: A report from the National Wilms' Tumor Study Group, 3744
— (letter), 3917
— *see* Diller L
Green M, *see* Ahles TA
— *see* Choi NC
— *see* Perry MC
— *see* Rafi I
Green MD, *see* Basser RL
— *see* Clarke K
Green S, Crowley J, Blumenstein B, Benedetti J. An open letter to the American Society of Clinical Oncology (letter), 3478
— *see* Taylor CW
Greenwald CA, *see* Hudson MM
Gregor A, *see* Scagliotti G
Grenier TC, *see* Vose JM
Greschuchna D, *see* Eberhardt W
Gribben JG, *see* Freedman AS
Gridelli C, Perrone F, Ianniello GP, Brancaccio L, Iaffaioli RV, Curcio C, D'Aprile M, Cioffi R, Cigolari S, Rossi A, Palazzolo G, Veltrti E, Pergola M, De Placido S, Gallo C, Monfardini S, Bianco AR. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: A phase II study, 1414
Griener JC, *see* Quinn CT
Grier H, *see* Langevin A-M
— *see* Skapek SX
Griffin T, *see* Budman DR
— *see* Mackean M
Grillo-López AJ, *see* McLaughlin P
Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, Cirera L, Cervantes A, De Greve J, Paillot B, Buset M, Nitti D, Sahmoud T, Duez N, Wils J. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: Results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial, 411
Grimer R, *see* Craft A
Grimshaw R, *see* Hoskins P
Groeger JS, Lemeshow S, Price K, Nierman DM, White P Jr, Klar J, Granovsky S, Horak D, Kish SK. Multicenter outcome study of cancer patients admitted to the intensive care unit: A probability of mortality model, 761
Groff L, *see* Ripamonti C
Groome PA, *see* Paszat LF
Groshen S, *see* Metzger R
Grossano D, *see* Nolte MJ
Grossbard ML, *see* Multani PS
Grossman SA, Wharam M, Kleinberg L, Piantadosi S. In reply (letter), 389
—, Kleinberg L, Piantadosi S. In reply (letter), 1234
Groupe Coopératif Macroglobulinémie, *see* Leblond V
Groupe Français d'Immunothérapie, *see* Ravaud A
Grovas A, *see* Mason WP
Grove-Conrad M, *see* Fetting JH
Gruber R, *see* Riethmüller G
Grunberg SM. Refractory definitions of tumor response (letter), 2291
Grund FM, *see* Serafini AN
Grundy P, *see* Diller L
— *see* Green DM
Guadagnoli E, Weeks JC, Shapiro C, Gurwitz JH, Borbas C, Soumerai SB. Use of breast-conserving surgery for treatment of stage I and stage II breast cancer, 101
Guarnaccia C, *see* Santini G
Gudgeon A, *see* Dombernowsky P
Guérin S, *see* Fizazi K
Guglielmi C, Gomez F, Philip T, Hagenbeek A, Martelli M, Sebban C, Milpied N, Bron D, Cahn J-Y, Somers R, Sonneveld P, Gisselbrecht C, Van Der Lelie H, Chauvin F. Time ot relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma Trial, 3264
Guhlmann A, *see* Moog F
Guibon O, *see* Leblond V
Guiet P, *see* Davi F
Guillet P, *see* Tourani J-M
Gulati SC, *see* Boulad F
Gulati SC, Van Poznak C. Pregnancy after bone marrow transplantation, 1978
Gupta RK, *see* Hsueh EC
Gurney HP, Ackland S, Gebski V, Farrell G. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation, 2299
Gururangan S, Dunkel IJ, Goldman S, Garvin JH, Rosenblum M, Boyett JM, Gardner S, Merchant TE, Gollamudi S, Finlay JL. Myeloablative chemotherapy with autologous bone marrow rescue in younf children with recurrent malignant brain tumors, 2486
Gurwitz JH, *see* Guadagnoli E
Gustavsson B, *see* Cocconi G

Haak H, *see* Löwenberg B
Haas B, *see* Robson M
Haase GM, *see* Green DM
— *see* Matthay K
Haas OA, *see* Laczika K
Habbema JDF, *see* Steyerberg EW
Haber M, *see* Bordow SB
Haber PS, *see* Bordow SB
Haddy TB, Adde MA, McCalla J, Domanski MJ, Datiles M III, Meehan SC, Pikus A, Shad AT, Valdez I, Vivino LL, Magrath IT. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas, 2070
Haedicke C, *see* Diehl V
Hagemeijer A, *see* Löwenberg B
Hagemeister F, *see* Khouri IF

Hagenbeek A, Carde P, Meerwaldt JH, Somers R, Thomas J, De Bock R, Raemaekers JMM, van Hoof A, De Wolf-Peeters C, van Glabbeke M for the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma, 41
— *see* Guglielmi C
Hagipantelli R, *see* Saliba F
Haglund MM, *see* Friedman HS
Hahm HA, Davidson NE, Giguere JK, DiBernardo C, O'Reilly S. Breast cancer metastastic to the choroid, 2280
Hahn SM, *see* Herscher LL
Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer, 2164
— *see* Perez EA
Haíoun C, *see* Solal-Céligny P
Hakimian D, *see* Tallman M
Hale K, *see* Christodoulou CV
Hall A, *see* Fallowfield L
Haller DG, *see* Minsky BD
Halpern S, *see* Mason WP
Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma, 670
— Adjuvant interferon for stage II melanoma (letter), 3205
Hamblin TJ, Orchard JA, Myint H, Oscier DG. Fludarabine and hemolytic anemia in chronic lymphocytic leukemia (letter), 3209
Hammond L, *see* Rowinsky E
— *see* Villalona-Calero MA
Hämpel H, *see* Frank TS
Hanada R, *see* Yamamoto K
Hancock B, *see* Keilholz U
Hancock ML, *see* Pui C-H
— *see* Walter AW
Hande KR, *see* Goren MP
Hanjani P, *see* Markman M
Hanks G, *see* Minsky BD
Hanlon A, *see* Siegelmann-Daniel N
Hanna MG Jr, *see* Serafini AN
Hanna W, *see* Andrulis IL
Hann I, *see* Surtees R
Hanover CK, *see* Saltz LB
Hanrath R-D, *see* Hiddemann W
Hansen J, *see* Ryberg M
Haraf DJ, *see* Brockstein B
— *see* Kies MS
— *see* Masters GA
— *see* Mauer AM
Hardenbergh PH, *see* Shapiro C
Harding MW, *see* Rowinsky E
Harousseau J-L, *see* Leblond V
Harper P, *see* Gore M
Harpole DH Jr, *see* Kwiatkowski DJ
Harrington D, *see* Glick JH
— *see* Shipp MA
Harris J, *see* Chabner E
— *see* Gage I
— *see* Hayman JA
— *see* Nixon AJ
— *see* Recht A
— *see* Shapiro C
Harris MB, Shuster JJ, Pullen DJ, Borowitz MJ, Carroll AJ, Behm FG, Land VJ. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: A Pediatric Oncology Group study, 2840
—, Gieser P, Goorin AM, Ayala A, Shochat SJ, Ferguson WS, Holbrook T, Link MP. Treatment of metastic osteosarcoma at diagnosis: A pediatric oncology group study, 3641
Harrison KA, *see* Serafini AN
Harris RE, *see* Ozkaynak MF
Harsanyi Z, *see* Bruera E
Harstick A, *see* Köhne C-H
Harstrick A, *see* Eberhardt W
— *see* Kollmannsberger C
Hart E, *see* Gambhir SS
Hartmann JT, *see* Kollmannsberger C
Hartmann O, *see* Ladenstein R
— *see* Pein F
Hartwick RW, *see* Andrulis IL
Harvey L, *see* Curti BD
Hasegawa B, *see* Matthay K
Haseman MK, *see* Kahn D
Hasenclever D, *see* Diehl V
— *see* Loeffler M
Hasumi K, *see* Shimizu Y
Hatschek T, *see* Dombernowsky P
Hattner RS, *see* Matthay K
Häubinger K, *see* Pantel K
Hauptman P, *see* Shapiro C
Hauteville D, *see* Tourani J-M
Hawk BJ, *see* Skapek SX
Hawkins MJ, *see* Wojtowicz-Praga S
Hayashi K, *see* Metzger R
Hayashi Y, *see* Yamamoto K
Hayat M, *see* Decuadin D
— *see* Löwenberg B
Hayes DF, *see* Pegram MD
— *see* Shapiro C
Hayman JA, Hillner BE, Harris JR, Weeks JC. Cost-effectiveness of routing radiation therapy following conservative surgery for early-stage breast cancer, 1022
Haynes B, *see* Treat J
Hazuka MB, *see* Lau DH
Head DR, *see* Pui C-H
Headlee D, *see* Senderowicz AM
Healey JH, *see* de Alava E
— *see* Lawlor ER
— *see* Meyers P
Hecker H, *see* Köhne C-H
Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM. Frequency and clinical significance of cytogenic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: A report from the Children's Cancer Group, 1270
— *see* Uckun FM
Heffernan M, *see* Berenson JR
— *see* Hortobagyi GN
Heiberg EV, *see* Lowe VJ
Heid IM, *see* Sloan JA

Heikkinen M, *see* Joensuu H
Heimann R, Hellman S. Aging, progression, and phenotype in breast cancer, 2686
Heiss J, *see* Sandor V
Heller G, *see* Boulad F
— *see* Kushner BH
— *see* Mason WP
— *see* Meyers P
Hellman S. The first century of cancer chemotherapy (editorial), 2295
— In reply (letter), 2570
— *see* Heimann R
Helmers C, *see* Glimelius B
Helm G, *see* Hiddemann W
Helzlsouer KJ, *see* Geller G
Henderson IC, *see* Fetting JH
— *see* Shapiro C
Henderson YC, *see* Clayman GL
Heney NM, *see* Shipley WU
Henriksson R, *see* Linderholm B
Henry AJ, *see* Friedman HS
Henry DH, *see* Northfelt DW
Henze E, *see* Bohuslavizki KH
Henzen-Logmans SC, *see* Foekens JA
Herait P, *see* Saliba F
Herfarth K, *see* Ogunbiyi OA
Hermann R, *see* Diehl V
Hermine O, *see* Leblond V
Hernández J, *see* Ciudad J
Herndon JE, *see* Friedman HS
Herndon JE III, *see* Perry MC
Herndon J II, *see* Ahles TA
— *see* Bigner DD
— *see* Choi NC
— *see* Kwiatkowski DJ
Herold M, *see* Zeimet AG
Herr HW, Bar-Chama N, O'Sullivan M, Sagani PC. Paternity in men with stage I testis tumors on surveillance, 733
—, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: Ten-year outcome, 1298
— Extravesical tumor relapse in patients with superficial bladder tumors, 1099
— *see* Bajorin DF
Herrmann R, *see* Betticher DC
— *see* Hiddemann W
Herrmann T, *see* Baumann M
Herscher LL, Hahn SM, Kroog G, Pass H, Temeck B, Goldspiel B, Cook J, Mitchell JB, Liebmann J. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer, 635
Hersey P, *see* Curry BJ
Hertz H, *see* Nysom K
Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation, 165
Hesketh P, *see* Gralla RJ
— *see* Perez EA
Hess KR, *see* Ayoub J-P
Hetelekidis S, *see* Chabner E
— *see* Nixon AJ
Heyman MR, *see* McLaughlin P
Hidalgo M, *see* Gómez H
Hiddemann W, Unterhalt M, Herrmann R, Wöltjen H-H, Kreuser E-D, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath R-D, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: Results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group, 1922
— *see* Köhne C-H
— *see* Wulf G
Hieken TJ, *see* Mehta RR
Hietanen P, *see* Joensuu H
Hietschold SM, *see* Cocconi G
Higashiyama M, *see* Adachi M
Higgins G, *see* Bajorin DF
Hilgarth B, *see* Laczika K
Hille D, *see* Bruno R
Hill JS, *see* Clarke K
Hill K, *see* Senderowicz AM
Hillner BE, McDonald MK, Desch CE, Smith TJ, Penberthy LT, Maddox P, Retchin SM. Costs of care associated with non-small-cell lung cancer in a commercially insured cohort, 1420
— *see* Hayman JA
Hilsenbeck SG, *see* Diab SG
Hilton S, *see* Bajorin DF
Hines J, *see* Rafi I
Hiraoka A, *see* Asou N
Hirashima T, *see* Masuda N
Hirschaut Y, *see* Robson M
Hirsche H, *see* Riethmüller G
Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Reasearch and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQ=C30 (+3), 1188
Ho AD, *see* McLaughlin P
Hochberg F, *see* Glantz MJ
Hoctin-Boes G, Yates R, Steinberg M. Letrozole for advanced breast cancer (letter), 2892
Hodi FS, *see* Haluska FG
Hodson DI, *see* Browman GP
Hoehn JL, *see* Fisher B
Hoffer FA, *see* Skapek SX
Höffken K, *see* Riethmüller G
Hoffman J, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB III. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group study, 317
— *see* Minsky BD
Hoffman K, *see* Glimelius B
Hoffman PC, *see* Fleming GF
— *see* Masters GA
— *see* Mauer AM
Hofmann W, *see* Dombernowsky P
Hofstra LS, Kristensen GB, Willemse PHB, Vindevoghel A, Meden H, Lahousen M, Oberling F, Sorbe B, Crump M, Sklenar I, Sluiter WJ, Kiese B, Trope CG, de Vries EGE. Randomized trial of recombinant human interleukin-3 *versus* placebo in prevention

of bone marrow depression during first-line chemotherapy for ovarian carcinoma, 3335
Hoh CK, *see* Gambhir SS
Hohenberger P, *see* Reichardt P
Hohenberger W, *see* Köckerling F
Hohl R, *see* Venook AP
Hohneker J, *see* Schilsky RL
Holbrook T, *see* Katzenstein HM
— *see* Harris MB
Holcenberg JS, *see* Kamen BA
Holden-White J, *see* Dezube BJ
Holland JC, *see* Ahles TA
Hollema H, *see* Wisman GBA
Holli K, Isola J, Cuzick J. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy, 3115
— *see* Joensuu H
Hollis DR, *see* Lilenbaum RC
Holmberg L, *see* Sjögren S
Holmer L, *see* Diehl V
Holmes FA, *see* Valero V
Holm K, *see* Nysom K
Holowaty E, *see* Paszat LF
Holroyde C, *see* Vaughn DJ
Holtzman NA, *see* Geller G
Holzberger P, *see* Rosen HR
Holz E, *see* Riethmüller G
Homesley HD, *see* Rose PG
Hong WK, *see* Clayman GL
— *see* Shin DM
Hoon DSB, Okamoto T, Wang H-J, Elashoff R, Nizze AJ, Foshag LJ, Gammon G, Morton DL. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?, 1430
— *see* Bostick PJ
Hoover HC Jr, *see* Serafini AN
Ho P, *see* Smith M
Hoppe RT, *see* Loeffler M
Horak D, *see* Groeger JS
Hornberger U, *see* Dombernowsky P
Horning SJ, *see* Stiff PJ
Horowitz IR, *see* Markman M
Horowitz MM, *see* Lee SJ
Horschowski N, *see* Charpin C
Horsman DE, *see* Lawlor ER
Horster A, *see* Köhne C-H
Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, 2038
— *see* Berenson JR
— *see* Buzdar AU
— *see* Rahman Z
— *see* Ravdin PM
— *see* Ueno NT
— *see* Valero V
Horton J, *see* Broeckel JA
Hoskins P, Eisenhauer E, Beare S, Roy M, Drouin P, Stuart G, Bryson P, Grimshaw R, Capstick V, Zee B. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study, 2233
— *see* Latreille J
Hoskins W, *see* Aghajanian C
Houde RW, *see* Foley KM
Housset B, *see* Chouaid C
Houston S, *see* Cook GJ
— *see* Serafini AN
Houyau P, *see* Ravaud A
Howard CM, *see* Susini T
Hryniuk W, Frei E III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity, 3137
Hsueh EC, Gupta RK, Qi K, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distaant metastases receiving polyvalent melanoma cell vaccine, 2913
Huang C-I, *see* Adachi M
Huang C-S, *see* Yu AL
Huang J, *see* Straus DJ
Huang Y, *see* Ilson DH
Huberty J, *see* Matthay K
Hubner K, *see* Lowe VJ
Hudis CA, *see* Seidman AD
Hudson DV Jr, *see* Cantor SB
Hudson MM, Poquette CA, Lee J, Greenwald CA, Shah A, Luo X, Thompson EI, Wilimas JA, Kun LE, Crist WM. Increased mortality after successful treatment for Hodgkin's disease, 3592
— *see* Walter AW
Hughes C, *see* Lerman C
Huhn D, *see* Lundin J
Hulburd K, *see* Varterasian ML
Humbert J, *see* Shuster JJ
Hum M, *see* Ratliff AF
Humphrey R, *see* Welles L
— *see* Wilson WH
Huovinen R, *see* Joensuu H
Hurd D, *see* Ayash LJ
Hursting SD, *see* Chang S
Hussain M, *see* Redman BG
Hutchinson R, *see* Uckun FM
Hutchinson RJ, Fryer JH, Davis, PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP of radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group phase III trial, 897
Hutchinson RS, *see* Heerema NA
Huvos AG, *see* de Alava E
— *see* Lawlor ER
— *see* Meyers P
Huynh KT, *see* Bostick PJ

Iaffaioli RV, *see* Gridelli C
Ianniello GP, *see* Gridelli C
Ibrahim J, *see* Ayash LJ
— *see* Falkson CI
Ichikawa M, *see* Yamamoto K
Ilaw M, *see* Tulpule A
Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP. Phase II trial of

paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus, 1826
— *see* Saltz LB
Imeson J, *see* Craft A
Imrie K, *see* Schimmer AD
Ingle JN, *see* Taylor CW
Ingonäs M, *see* Sjögren S
International Bone and Cancer Study Group, *see* Body JJ
Ippoliti C, *see* Khouri IF
Iro H, *see* Wendt TG
Isaacs C, *see* Frank TS
Isaacs R, *see* Pecora AL
Ishiya T, *see* Shimizu Y
Isnard F, *see* Fouillard L
Isola J, *see* Holli K
Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis, 2937
Izbicki JR, *see* Pantel K

Jabar S, *see* Paulussen M
Jablonowski H, *see* Stewart S
Jack AS, *see* Evans PAS
Jacob H, *see* Schrijvers D
Jacobsen JR, *see* Nysom K
Jacobsen PB, *see* Broeckel JA
Jacobs P, *see* Loeffler M
Jacobs SA, *see* Chen J
Jaeckle KA, Eyre HJ, Townsend JJ, Schilman S, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosurea: A Southwest Oncology Group study, 3310
Jaeger U, *see* Laczika K
— *see* Lundin J
Jaffe E, *see* Sandor V
— *see* Wilson WH
Jagannath S, *see* Desikan KR
Jahan TM, *see* Venook AP
Jain V, *see* McLaughlin P
Jakimowicz K, *see* Villalona-Calero MA
James K, *see* Zee B
James R, *see* Zalcberg J
Janik JE, *see* Curti BD
Janisch L, *see* Schilsky RL
Janjan NA, *see* Pisters PWT
Janot F, *see* De Crevoisier R
Jansen PP, *see* Levendag PC
Januszewicz H, *see* Toner GC
Japan Adult Leukemia Study Group, *see* Asou N
Japan Clinical Oncology Group, *see* Furuse K
Jatzko G, *see* Rosen HR
Jayaraman J, *see* Silber JH
Jeffers S, *see* Garcia AA
Jenkins B, *see* Weaver A
Jennis A, *see* Pecora AL
Jensen BV, *see* Ryberg M
Jensen RT, *see* Gibril F
Jewett M, *see* Warde P
Jhanwar S, *see* de Alava E
— *see* Gorlick R
— *see* Kushner BH
Ji H, *see* Anttila M
Jiminez U, *see* Schrijvers D
Jocgla A. In reply (letter), 809
Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, Huovinen R. Combination chemotherapy *versus* single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial, 3720
Jóhannsson OT, Ranstam J, Borg Å, Olsson H. Survival of *BRCA1* breast and ovarian cancer patients: A population-based study from southern Sweden, 397
Johansson B, *see* Pedersen-Bjergaard J
John M, *see* Minsky BD
Johnson D, *see* Goren MP
— *see* Mehta MP
Johnson E, *see* Treat J
Johnson J, *see* Schrijvers D
Johnson M, *see* Wojtowicz-Praga S
Johnson PJ, *see* Yeo W
Johnson T, *see* Macfarlane DJ
Johnston D, *see* Latreille J
— *see* Zee B
Johnstone A, *see* Rafi I
Johnston S, *see* Eisen T
Jones CG, *see* Marks DI
Jones E, *see* Markman M
Jones J, *see* Spiridonidis CH
Jones RB, *see* Cagnoni PJ
— *see* Nieto Y
Jones SE, *see* Valero V
Joos S, *see* Scheurlen WG
Joseph P, *see* Akerley W
Joshi VV, *see* Katzenstein HM
Jouet JP, *see* Fouillard L
Juhola M, *see* Anttila M
Julian-Reynier C, *see* Eisinger E
Julieron M, *see* De Crevoisier R
Jürgens H, *see* Paulussen M
Juttner C, *see* Basser RL

Kaasa S, *see* Hjermstad MJ
— *see* Risberg T
Kageyama S, *see* Asou N
Kahn D, Williams RD, Haseman MK, Reed NL, Miller SJ, Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy, 284
Kahn M, *see* O'Connell MJ
Kaiko RF, *see* Kaplan R
Kaiser U, *see* Hiddemann W
Kalemkerian GP, *see* Ramalingam S
Kalil N, *see* Senderowicz AM
Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Muraca PJ, Ross JS. Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/*neu* oncogene amplification with recurrence in prostatic adenocarcinomas, 1302
Kamby C, *see* Sangelov
Kamen BA, Winick N, Holcenberg JS. Oral *versus* intravenous methotrexate: Another opinion (letter), 2283

— *see* Quinn CT
— *see* Ratliff AF
Kanamaru A, *see* Asou N
Kanis JA, *see* Body JJ
Kanowitz J, *see* Saltz LB
Kantarjian H, *see* Cortes J
— *see* Gandhi V
— *see* Khouri IF
— *see* Kurzrock R
— *see* Rodriguez J
— *see* Sacchi S
Kantoff PW, *see* Talcott JA
Kanz L, *see* Kollmannsberger C
Kao C-H, ChangLai S-P, Chieng P-U, Yen R-F, Yen T-C. Detection of recurrent or persistent nasopharyngeal carcinomas after radiotherapy with 18-fleuro-2-deoxyglucose positron emission tomography and comparison with computed tomography, 3550
Kaplan I, *see* D'Amico AV
— *see* Talcott JA
Kaplan J, *see* Bennett CL
Kaplan LD, *see* Northfelt DW
— *see* Straus DJ
Kaplan R, Parris WC-V, Citron ML, Zhukovsky D, Reder RF, Buckley BJ, Kaiko RF. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain, 3230
Karis J, *see* Lowe VJ
Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma V-M. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma, 3584
Kastan MB, *see* Kirsch DG
Kato A, *see* Usui N
Katori M, *see* Usui N
Katsumata N, *see* Yamamoto N
Kattan MW, *see* Leibman BD
Katz A, *see* Andrulis IL
— *see* Minsky BD
Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EI, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL. Prognostic significance of age, *MYCN* oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group experience-A Pediatric Oncology Group study, 2007
Kaubisch A, *see* Hesdorffer C
Käufer C, *see* Köhne C-H
Kaufman DS, *see* Shipley WU
Kaufman RP Jr, *see* Kallakury BV
Kavanah M, *see* Fisher B
Kavolius JP, Mastorakos DP, Pavlovich C, Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma, 2261
Kawai A, *see* de Alava E
— *see* Lawlor ER
Kawase I, *see* Masuda N
Kaye AH, *see* Clarke K
Kaye S, Mead GM, Fossa S, Cullen M, deWit R, Bodrogi I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, deMulder P. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastic nonseminomatous germ cell tumor: A randomized Medical Research Council/European Organization for Research and Treatment of Cancer study, 692
— *see* Bruno R
— *see* Fossâ SD
— *see* Mackean M
Kearns CM, *see* Venook AP
Keating A, *see* Schimmer AD
Keating M, *see* Cortes J
— *see* Gandhi V
— *see* Khouri IF
— *see* Sacchi S
Keil F, *see* Laczika K
Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJA, Dummer R, Avril M-F, Bröcker EB, Benhammouda A, Eggermont AMM, Pritsch M. Results of interleukin-2-based treatment in advanved melanoma: A case record-based analysis of 631 patients, 2921
Keiser WL, *see* Lau DH
Keizer HJ, *see* Steyerberg EW
Kelalis PP, *see* Green DM
Keller A, *see* Berenson JR
Kellick M, *see* Gorlick R
Kellokoski JK, *see* Karjalainen JM
Kelly K, *see* Wozniak AJ
Kelly WK, *see* Bajorin DF
Kelsen D, *see* Ilson DH
— *see* Saltz LB
Kemeny N, *see* Gorlick R
— *see* Saltz LB
Kenda R, *see* Zucali R
Kennedy A, *see* Markman M
Kennedy T, *see* Choy H
Kepner JL, *see* Mulhern RK
Kerby T, *see* Friedman HS
Keren-Rosenberg S, *see* Garcia AA
Kerkhof E, *see* Geelen FAMJ
Kerl H, *see* Pehamberger H
Kernan NA, *see* Boulad F
Kerr D, *see* Cocconi G
Kerr DJ, *see* Christodoulou CV
Kessinger A, *see* Vose JM
Keung W, *see* Eppenberger U
Khayat D, *see* Keilholz U
Kho GS, *see* Giaccone G
Khokha N, *see* Mullai N
Khor P, *see* Schilsky RL
Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: Induction of graft-*versus*-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, 2817
—, Romaguera J, Kantarjian H, Palmer JL, Pugh WC, Korbling M, Hagemeister F, Samuels B, Rodriguez A, Giralt S, Younes A, Przepiorka D, Claxton D, Cabanillas F, Champlin R. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle cell lymphoma, 3803
— *see* Popat U
— *see* Ueno NT
Khuri FR, *see* Shin DM

Kiese B, *see* Hofstra LS
Kies MS, Haraf DJ, Athanasiadis I, Kozloff M, Mittal B, Pelzer H, Rademaker AW, Wenig B, Weichselbaum RR, Vokes EE. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: Improved disease control and survival, 2715
Kikuchi A, *see* Yamamoto K
Kim T, *see* Green DM
Kinder B, *see* Tallini G
Kinoshita A, *see* Kudoh S
Kinoshita T, Nagai H, Murate T, Saito H. CD20-negative relapse in B-cell lymphoma after treatment with rituximab (letter), 3916
Kinsey S, *see* Evans PAS
Kirchner P, *see* Lowe VJ
Kirkels WJ, *see* Steyerberg EW
Kirkwood JM, *see* Cole BF
— *see* Falkson CI
Kirsch DG, Kastan MB. Tumor-suppressor p53: Implications for tumor development and prognosis, 3158
Kish SK, *see* Groeger JS
Kison PV, *see* Sugawara Y
Kisor DF, *see* Gandhi V
Kitano K, *see* Asou N
Klaasen U, *see* Köhne C-H
Klar J, *see* Groeger JS
Klastersky J, *see* Sculier J-P
Kleinberg L, *see* Grossman SA
Kleinberg SA, *see* Grossman SA
Klein JL, *see* Serafini AN
Klepsch A, *see* Brockstein B
— *see* Fleming GF
Klijn JGM, *see* Berns EMJJ
— *see* Foekens JA
Klimstra D, *see* Gorlick R
Klingebiel T, *see* Ladenstein R
Kluin-Nelemans JC, *see* Tirelli U
Kluin PM, *see* Geelen FAMJ
Klumpp TR, *see* Goldberg SL
Klutmann S, *see* Bohuslavizki KH
Knabbe C, *see* Zeimet AG
Knechtli CJC, *see* Marks DI
Knight RD, *see* Berenson JR
— *see* Hortobagyi GN
Knudson HM, *see* Jaeckle KA
Kobayashi M, *see* Masuda N
Kobayashi T, *see* Usui N
Kocha WI, *see* O'Connell MJ
Köckerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W. Influence of surgery of metachronous distant metastases an survival in rectal cancer, 324
Koda R, *see* Garcia AA
Kodner IJ, *see* Ogunbiyi OA
Kofler R, *see* Pehamberger H
Kohler D, *see* Sandor V
— *see* Wilson WH
Köhne C-H, Schöffski P, Wilke H, Käufer C, Andreesen R, Ohl U, Klaasen U, Westerhausen M, Hiddemann W, Schott G, Harstick A, Bade J, Horster A, Schubert U, Hecker H, Dörken B, Schmoll H-J. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: Results of a randomized trial in patients with advanced colorectal cancer, 418
Kokkinakis DM, *see* Friedman HS
Kok TC, *see* Grimaldi C
Kolkman-Deurloo I-KK, *see* Levendag PC
Kollmannsberger C, Beyer J, Droz J-P, Harstrick A, Hartmann JT, Biron P, Fléchon A, Schöffski P, Kuczyk M, Schmoll H-J, Kanz L, Bokemeyer C. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors, 3386
Konda B, *see* Metzger R
Konietzko N, *see* Eberhardt W
Konishi T, *see* Adachi M
Koops HS, Vaglini M, Suciu S, Kroon BBR, Thompson JF, Göhl J, Eggermont AMM, Di Filippo F, Krenentz ET, Ruiter DR, Lejeune FJ. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial, 2906
Kopecky KK, *see* Leibovitch I
Kopp WC, *see* Curti BD
Kopreski MS, *see* Curti BD
Körbling M, *see* Khouri IF
— *see* Ueno NT
Kornblau S, *see* Sacchi S
— *see* Wadler S
Kornblith AB, *see* Ahles TA
Korn EL, *see* Smith M
Koschel G, *see* Steward WP
Koscielny S, *see* De Crevoisier R
Kos J, *see* Foekens JA
Kosma V-M, *see* Anttila M
— *see* Karjalainen JM
Kosmidis P, *see* Schrijvers D
Kostashuk E, *see* Murray N
Kotzerke J, *see* Moog F
Kovacs M, *see* Berenson JR
Kozloff M, *see* Kies MS
Kraft P, *see* Heerema NA
— *see* Uckun FM
Krahn MD, *see* Bloomfield DJ
Krailo M, *see* Hutchinson RJ
— *see* Nicholson HS
— *see* Sievers EL
Krakowski I, *see* Tourani J-M
Kramar A, *see* Fizazi K
Kramer K, *see* Cheung N-KV
— *see* Kushner BH
Krans M, *see* Wisman GBA
Krasovec M, *see* Foekens JA
Krause B, *see* Eberhardt W
Krause S, *see* Diehl V
Krauss SA, *see* Masters GA
Kraut EH, Crowley JJ, Wade JL, Laufman LR, Alsina M, Taylor SA, Salmon SE. Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study, 589
Kraynak M, *see* Rowinsky E
— *see* Villalona-Calero MA
Krebs JB, *see* Bookman MA
Kremens B, *see* Ladenstein R
Krementz ET, *see* Koops HS
Kretschmar C, *see* Langevin A-M

Kreuser E-D, *see* Hiddemann W
Kricker A, *see* Cockburn J
Krischer J, *see* Friedman HS
Kris MG. In reply (letter), 1632
— *see* Demetri G
— *see* Nolte MJ
Kristensen GB, *see* Hofstra LS
Kroger LA, *see* DeNardo GL
Kroner T, *see* Betticher DC
Kroog G, *see* Herscher LL
Krook JE, *see* O'Connell MJ
Kroon BBR, *see* Koops HS
Kroon M, *see* Freedman AS
Kuczyk M, *see* Kollmannsberger C
Kudelka AP, Lenzi R, Atkinson EN, Levy LB, Freedman RS. Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram *P* values for multiple comparisons (letter), 3208
Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K, Fukuoka M. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer, 1068
Kugler JW, *see* Fleming GF
Kühl J, *see* Scheurlen WG
Kuhn JG, *see* Chang SM
Kulp B, *see* Markman M
Kung FH, *see* Yu AL
Kun LE, *see* Hudson MM
— *see* Mulhern RK
— *see* Walter AW
Kuraishi Y, *see* Usui N
Kurita Y, *see* Furuse K
Kuriyama K, *see* Asou N
Kuross SA, *see* Sloan JA
Kurtzberg J, *see* Gandhi V
Kurtz J, *see* Recht A
Kurzrock R, Estrov Z, Kantarjian H, Talpaz M. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity, 1526
Kushner BH, Heller G, Cheung N-KV, Wollner N, Kramer K, Bajorin D, Polyak T, Meyers P. High risk of leukemia after short-term dose-intensive chemotherappy in young patients woth solid tumors, 3016
—, Cheung N-KV, Kramer K, Heller G, Jhanwar SC. Neuroblastoma and treatment-related myelodysplasia/leukemia: The Memorial Sloan-Kettering experience and a literature review, 3880
— *see* Cheung N-KV
— *see* Gerald W
Kuske RR. Adjuvant chest wall and nodal irradiation: Maximize cure, minimize late cardiac toxicity (editorial), 2579
Kusunoki Y, *see* Masuda N
Kuzel T, *see* Bennett CL
— *see* Stadler WM
Kvols LK, *see* Galanis E
Kweder SL, *see* Weiss RB
Kwiatkowski DJ, Harpole DH Jr, Godleski J, Herndon JE II, Shieh D-B, Richards W, Blanco R, Xu H-J, Strauss GM, Sugarbaker DJ. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: Clinical implications, 2468
Kyle RA, *see* Body JJ
Laberge F, *see* Latreille J
Labopin M, *see* Fouillard L
Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Acheidel-Petrovic A, Scholten C, Thalhammer-Scherrer R, Brugger S, Keil F, Schwarzinger I, Haas OA, Lechner K, Jaeger U. Competitive *CBFb/MYH11* reverse transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion (16): A pilot study, 1519
Ladanyi M, *see* de Alava E
— *see* Gerald W
— *see* Lawlor ER
Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: A report from the European Bone Marrow Transplantation Solid Tumor Registry, 953
Lafitte JJ, *see* Sculier J-P
Lagios MD, *see* Silverstein MJ
Lahousen M, *see* Hofstra LS
Laidlaw CR, *see* Toner GC
Laine L, *see* Metzger R
Lallemand E, *see* Fossä SD
— *see* Kaye SB
Lamborn KR, *see* DeNardo GL
— *see* Donaldson SS
— *see* Wolden SL
Landry J, *see* Minsky BD
Land VJ, *see* Harris MB
— *see* Shuster JJ
Lane J, *see* Meyers P
Lange BJ, *see* Heerema NA
— *see* Sievers EL
— *see* Uckun FM
Langecker P, *see* Schrijvers D
Langer C, *see* Siegelmann-Daniel N
— *see* Treat J
Langevin A-M, Casto DT, Thomas PJ, Weitman ST, Kretschmar C, Grier H, Pratt C, Dubowy R, Bernstein M, Blaney S, Vietti T. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: A Pediatric Oncology Group study, 2494
Långström B, *see* Örlefors H
Lanier KS, *see* Lau DH
Lan R-S, *see* Yang C-T
Laperriere NJ, *see* Loblaw DA
Laporte JP, *see* Fouillard L
LaQuaglia M, *see* Mann GB
LaQuaglia MP, *see* Boulad F
— *see* Gerald W
Larra F, *see* Gamelin É
Larregain-Fournier D, *see* Tourani J-M
Larson RA, *see* Dann AJ
Larson SM, *see* Cheung N-KV
Larsson L, *see* Glimelius B
Lasset C, Mignotte H, Bonadona V, Chauvin F. Prognosis of tamoxifen-associated endometrial cancer (letter), 2573
— *see* Eisinger E
— *see* Ladenstein R
Lathan B, *see* Diehl V

Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, Hoskins P, Findlay B, McMurtrie E, Yelle L, Williams C, Walde D, Ernst S, Dhaliwal H, Warr D, Shepherd F, Mee D, Nishimura L, Osoba D, Zee B. Use of dexamethasone and granisetron in the control of delayed emesis for patients with receive highly emetogenic chemotherapy, 1174

Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer, 3078

Lauer S, *see* Mahoney DH Jr
— *see* Shuster JJ

Laufman LR, *see* Kraut EH
— *see* Spiridonidis CH

Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, Gockerman J, Cirrincione C, Berry D, Mills L, Defusco P, LeGrand S, Peters WP, Vredenburgh JJ. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant, 1008

Lau J, *see* Engels EA

Lauria F, *see* Cheson BD

Laurie JA, *see* O'Connell MJ

Lau WH, *see* Cheung MMC

Lavaut M-N, *see* Charpin C

Laver J, Amylon M, Desai S, Link M, Schwenn M, Mahmoud H, Shuster J. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group study, 522

Lavilla E, *see* Arranz R

Lawhorn K, *see* Shin DM

Lawlor ER, Mathers JA, Bainbridge T, Horsman DE, Kawai A, Healey JH, Huvos AG, Bridge JA, Ladanyi M, Sorensen PHB. Peripheral primitive neuroectodermal tumors in adults: Documentation by molecular analysis, 1150
— *see* de Alava E

Lawrence TS, *see* McGinn CJ

Lawson M, *see* Lowe VJ

Lazarus HM, *see* Cooper BW

Le Beau MM, *see* Dissing M

LeBlanc M, *see* Al-Sarraf M
— *see* Press OW
— *see* Stiff PJ

Leblond V, Davi F, Charlotte F, Dorent R, Bitker M-O, Sutton L, Gandjbakhch I, Binet J-L, Raphael M. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity?, 2052
—, Ben-Othman T, Deconinck E, Taksin A-L, Harousseau J-L, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel J-P, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N for the Groupe Coopératif Macroglobulinémie. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: A report of 71 cases, 2060

Le Cesne A, *see* Fizazi K

Le Chevalier T, *see* Fizazi K

Lechner K, *see* Laczika K

Lecomte J, *see* Sculier J-P

Lee J, *see* Hudson MM

Lee JE, *see* Gershenwald JE
— *see* Pisters PWT

Lee JJ, *see* Gershenwald JE
— *see* Shin DM

Lee MH, *see* Yang C-T

Lee S, *see* Tai Y-T

Lees AW, *see* Fisher B

Lee SJ, Anasetti C, Horowitz MM, Antin JH. Initial therapy for chronic myelogenous leukemia: Playing the odds (editorial), 2897

Lee WR, *see* Shipley WU

Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N. Development of a biochemical regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastic melanoma, 1752
— *see* Eton O
— *see* Keilholz U

LeGrand S, *see* Laughlin MJ

Leibel SA, *see* Merchant TE
— *see* Zelefsky MJ

Leibman BD, Dillioglugil O, Scardino PT, Abbas F, Rogers E, Wolfinger RD, Kattan MW. Prostate-specific antigen doubling times are similar in patients with recurrence after radical prostatectomy or radiotherapy: A novel analysis, 2267

Leibovitch I, Foster RS, Kopecky KK, Albers P, Ulbright TM, Donohue JP. Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment, 261

Leichman CG, *see* Metzger R

Leichman L, *see* Metzger R

Leigh B, *see* Lau DH

Lejeune FJ, *see* Koops HS

Lemeshow S, *see* Groeger JS

Le Mevel A, *see* Blay J-Y

Lemonnier MP, *see* Fouillard L

Lemon SJ, *see* Lerman C

Lenz H-J, *see* Metzger R

Lenzi R, *see* Ayoub J-P
— *see* Kudelka AP
— *see* Pisters PWT

Leonard R, *see* Dombernowsky P

Leone L, *see* Akerley W
— *see* Choi NC

Leoni P, *see* Santini G

Lepage E, *see* Cole BF
— *see* Solal-Céligny P

Leridant AM, *see* De Crevoisier R

Lerman C, Hughes C, Lemon SJ, Main D, Snyder C, Durham C, Narod S, Lynch HT. What you don't know can hurt you: adverse psychological effects in members of *BRCA1*-linked and *BCRA2*-linked families who decline genetic testing, 1650
— *see* Audrain J

Lerski RA, *see* Serafini AN

Lerut TE, *see* Vansteenkiste JF

Lesage S, *see* Fouillard L

Lesimple T, *see* Ravaud A

Lesser ML, *see* Robson M

Levenback C, *see* Brader KR
— *see* Morris M

Levendag PC, Schmitz PI, Jansen PP, Eijkenboom WM, Visser AG, Kolkman-Deurloo I-KK, Sipkema D, Visch LL, Senan S,

Fractionated high-dose-rate brachytherapy in primary carcinoma of the nasopharynx, 2213
Leverett D, *see* Watts MJ
Levesque MA, Yu H, Clark GM, Diamandis EP. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: A prognostic factor in a large breast cancer cohort, 2641
Levin D, *see* Robson M
Levine AM, *see* Straus DJ
Levine M, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D for the National Cancer Institute of Canada Clinical Trials Group. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer, 2651
—, Pritchard K, Bramwell V, Shepherd L. In reply (letter), 3917
Levin MN, *see* Browman GP
Levin VA, *see* Meyers CA
Levy L, *see* Brader KR
— *see* Kudelka AP
Levy NB, *see* DeNardo GL
Levy R, *see* McLaughlin P
Lewensohn R, *see* Schrijvers D
Lewinsky BS, *see* Silverstein MJ
Lewis I, *see* Craft A
Lewis IJ, *see* Smith M
Lewis JP, *see* DeNardo GL
Leyvraz S, *see* Benhattar J
Lianes P, *see* Giaccone G
Liberati A, *see* Fossati R
Libutti SK, *see* Alexander HR Jr
Lichtenstein A, *see* Berenson JR
Lichtiger B, *see* Cantor SB
Lichtman SM, *see* Budman DR
Lickley L, *see* Andrulis IL
Liebmann J, *see* Herscher LL
Lietzau J, *see* Welles L
Li F, *see* Dalton VMK
— *see* Diller L
Liggett WH Jr, Sidransky D. Role of the *p16* tumor suppressor gene in cancer, 1197
Li H, *see* Dunkel IJ
Li JT, *see* Goren MP
Lilenbaum RC, Miller AA, Batist G, Bernard S, Hollis DR, Rosner GL, Egorin MJ, Schilsky RL, Ratain MJ. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: A Cancer and Leukemia Group B study, 3302
Lilja A, *see* Örlefors H
Linassier C, *see* Ravaud A
Linch DC, *see* Watts MJ
Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma, 3121
Lindgren A, *see* Sjögren S
Lindley C, Vasa S, Sawyer WT, Winer EP. Quality of life and preferences for treatment following systemic adjuvant therapy for early-stage breast cancer, 1380
Lind M, *see* Weaver A
Lind MJ, *see* Rafi I
Lindsley K, *see* Boulad F
— *see* Mason WP
Ling CC, *see* Zelefsky MJ
Link BK, *see* McLaughlin P
Link M, *see* Harris MB
— *see* Laver J
Linné T, *see* Glimelius B
Lin P, *see* Bajorin DF
Lipa M, *see* Andrulis IL
Lipkin M, *see* Fallowfield L
Lipman RJ, *see* Meropol NJ
Lippman SM, *see* Brockstein B
— *see* Clayman GL
— *see* Shin DM
Lipshultz SE, *see* Nysom K
Lipsitz S, *see* Hoffman JP
— *see* Nysom K
Lipton A, *see* Berenson JR
— *see* Hortobagyi GN
— *see* Pegram MD
Lisborg P, *see* Rosen HR
Lissoni A, *see* Bookman MA
Lister J, *see* McLaughlin P
Li T, *see* Zee B
Litschgi M, *see* Eppenberger U
Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant, 584
— *see* Wilson WH
Liu-Mares W, *see* Nicholson HS
— *see* Sievers EL
Liu P-Y, *see* Margolin KA
Liu SY, Eary JF, Petersdorf SH, Martin PJ, Maloney DG, Appelbaum FR, Matthews DC, Bush SA, Durack LD, Fisher DR, Gooley TA, Bernstein ID, Press OW. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue, 3270
Liu T-J, *see* Clayman GL
Livingston RB. Concurrent is the key: Combined modality small-cell lung cancer (letter), 1631
— (letter), 3917
— *see* Lau DH
— *see* Wozniak AJ
Loader S, *see* Frank TS
Loblaw DA, Laperriere NJ. Emergency treatment of malignant extradural spinal cord compression: An evidence-based guideline, 1613
Loeffler M, Brosteanu D, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Crowther D, Diehl V, Fisher RI, Hoppe RT, Jacobs P, Pater S, Pavlovsky S, Thompson E, Wiernik P. Meta-analysis of chemotherapy *versus* combined modality treatment trials in Hodgkin's disease, 818
—, Brosteanu O, Hasenclever D. In reply (letter), 2894
— *see* Diehl V
Loehrer PJ, *see* Nichols CR
Loehrer PJ Sr, Gonin R, Nichols CR, Weathers T, Einhorn LH. Vinblastine plus ifosfamide plus cisplatin as initial slavage therapy in recurrent germ cell tumor, 2500
Lohr F, *see* Pirzkall A
Lombard I, Vincent-Salomon A, Validire P, Zafrani B, de la Rochefordière A, Clough K, Favre M, Pouillart P, Sastre-Garau X,

Human papillomavirus genotype as a major determinant of the course of cervical cancer, 2613
Longo DL. Interferon toxicity worse in retrospect; impact on Q-TWIST? (letter), 3716
— *see* Curti BD
— *see* Little R
Longo GSA, *see* Gorlick R
Look AT, *see* Katzenstein HM
— *see* Shuster JJ
Look MP, *see* Berns EMJJ
— *see* Foekens JA
Lopez-Berges MC, *see* Ciudad J
López-Guillermo A, *see* Terol M-J
López J, *see* Arranz R
Lopez L, *see* Sanchez E
Lopez M, Vici P, Di Lauro L, Conti F, Paoletti G, Ferraironi A, Sciuto R, Giannarelli D, Maini CL. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas, 86
— *see* Fouillard L
Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors, 2377
— *see* Barton DL
— *see* Sloan JA
Loret C, *see* Zalcberg J
Lortholary A, *see* Gamelin É
Loughlin KR, *see* D'Amico AV
— *see* Talcott JA
Lovell S, *see* Friedman HS
Löwenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, Dekker AW, Berneman ZN, Thyss A, van der Lelie J, Sonneveld P, Visani G, Fillet G, Hayat M, Hagemeijer A, Solbu G, Zittoun R. Mitoxantrone *versus* daunrubicin in induction-consolidation chemotherapy— The value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leokemia in the elderly: Final report of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group Randomized Phase III Study AML-9, 872
Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, Karis J, Hubner K, Delbeke D, Heiberg EV, Patz EF, Coleman RE. Prospective investigation of positron emission tomography in lung nodules, 1075
Lozano M, *see* Arranz R
Lozza L, *see* Zucali R
Luboinski B, *see* De Crevoisier R
Lucarelli CD, *see* Nolte MJ
Lucas KR, *see* Brader KR
Lucas V, *see* Tourani J-M
Lucas VS, *see* Schilsky RL
Luescher K, *see* Eppenberger U
Lukens JN, *see* Matthay K
— *see* Nachman J
Lund B, *see* Sangelov
Lund E, *see* Risberg T
Lundin J, Österborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H. CAMPATH-1H Monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study, 3257
Luo X, *see* Hudson MM
Lush R, *see* Senderowicz AM
— *see* Welles L
Lusinchi A, *see* De Crevoisier R
Lyass O, *see* Zelefsky MJ
Lyden D, *see* Mason WP
Lyman GH, *see* Broeckel JA
— *see* Extermann M
Lynch C, *see* Ayash LJ
Lynch HT, Watson P, *BRCA1*, pathology, and survival, 395
— *see* Lerman C
Lynch JC, *see* Vose JM
Lyons J, *see* Simone JV

Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-Deoxy-D-Glucose positron emmission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma, 1770
MacFarlane V, *see* Gore M
Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, Reigner B, Griffin T, Kaye S, Verweij. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capeccitabine in patients with advanced and/or metastatic cancer, 2977
MacKenzie R, *see* Levine M
Mackillop WJ, *see* Paszat LF
Macklis R, Meier T, Weinhous MS. Error rates in clinical radiotherapy, 551
—, Weinhous M. In reply (letter), 2289
MacWilliam L, *see* Fernandez CV
Maddox P, *see* Hillner BE
Maes A, *see* Vansteenkiste JF
Magagnoli M, *see* Zinzani PL
Magdalinski AJ, *see* Goldberg SL
Magdelenat H, *see* Fagnou C
Magrath IT, *see* Haddy TB
Maher D, *see* Basser RL
— *see* Clarke K
Mahjoubi M, *see* Saliba F
Mahmoud H, *see* Laver J
Mahmoud R, *see* Payne R
Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, Camitta B. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A pediatric oncology group phase III trial, 246
—, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: An association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-A Pediatric Oncology Group study, 1712
— In reply (letter), 2284
— *see* Shuster JJ
Mahoney MR, *see* Sloan JA
Mahon I, *see* Minsky BD
Maigre M, *see* Gamelin É
Maillart P, *see* Gamelin É

Maillet ML, *see* Gamelin É
Mailliard JA, *see* Galanis E
— *see* O'Connell MJ
— *see* Taylor CW
Main D, *see* Lerman C
Maini CL, *see* Lopez M
Mainwaring P, *see* Gore M
Maisey MN, *see* Cook GJ
Majlis A, *see* Cortes J
Majolino I, *see* Santini G
Major P, *see* Berenson JR
Mak C, *see* Andrulis IL
Makhija S, *see* Spriggs D
Maki N, *see* Usui N
Malaurie E, *see* Tourani J-M
Malcolm A, *see* Craft A
Malec M, *see* Chang SM
Malkowicz SB, *see* D'Amico AV
— *see* Vaughn DJ
Maloisel F, *see* Leblond V
Malone D, *see* Fleming GF
Maloney DG. In reply (letter), 1636
— *see* Liu SY
Malström H, *see* Bookman MA
Mamelle G, *see* De Crevoisier R
Mamelock RD, *see* Northfelt DW
Mamounas E, *see* Fisher B
— *see* Fisher B
Mandard A-M, *see* Clahsen PC
Mangan KF, *see* Goldberg SL
Mangoni L, *see* Santini G
Manley SA, *see* Frank TS
Mann GB, Conlon KC, LaQuaglia M, Dougherty E, Moskowitz CH, Zelenetz AD. Emerging role of laparoscopy in the diagnosis of lymphoma, 1909
Manola J, *see* Chabner E
— *see* Nixon AJ
Mansfield PF, *see* Gershenwald JE
Mansfield R, *see* Basser RL
Mansi J, *see* Gore M
Mansour EG, Gray R, Shatila AH, Tormey DC, Cooper MR, Osborne CK, Falkson G. Survival advantage of adjuvant chemotherapy in high-risk node-negative breast cancer: Ten-year analysis-An intergroup study, 3486
Mantel M, *see* Amatruda JF
Manzo J, *see* Siu LL
Marandas P, *see* De Crevoisier R
Marchev F, *see* Friedman HS
Marcus R, *see* Lundin J
Marcus RB, Weiner MA, Chauvenet AR. In reply (letter), 392
Margolese R, *see* Fisher B
Margolin KA, Liu P-Y, Flaherty LE, Sosman JA, Walker MJ, Smith JW III, Fletcher WS, Weiss GR, Unger JM, Sondak VK. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: A southwest oncology group study, 664
— *see* Fetting JH
Mariani L, *see* Zucali R
Mariette X, *see* Leblond V
Marino G, *see* Santini G
Mariz S, *see* Andrulis IL
Markman M, Rose PG, Jones E, Horowitz IR, Kennedy A, Webster K, Belinson J, Fusco N, Fluellen L, Kulp B, Peterson G, McGuire WP. Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens, 1849
—, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: A Gynecologic Oncology Group study, 2620
—, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Paclitaxel administration to gynecologic cancer patients with major cardiac risk factors, 3483
— *see* Perez EA
Marks DI, Bird JM, Cornish JM, Goulden NJ, Jones CG, Knechtli CJC, Pamphilon DH, Steward CG, Oakhill A. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia, 931
Marks LB, Prosnitz LR. Elective internal mammary node irradiation: It is not an all or nothing question (letter), 3918
Marler KC, *see* Mehta RR
Marling-Cason M, *see* Ratliff AF
Marmont F, *see* Pich A
Marone C, *see* Colleoni M
Maroun JA, *see* Browman GP
Marshall GM, *see* Bordow SB
Marshall J, *see* Wojtowicz-Praga S
Martelli M, *see* Guglielmi C
Marth C, *see* Zeimet AG
Martinelli G, *see* Colleoni M
Martinez B, *see* Sanchez E
Martinez-Montero JC, *see* Sanchez E
Martini F, *see* Charpin C
Martin L, *see* Ilson DH
— *see* Mehta MP
Martinoni C, *see* Colleoni M
Martino S, *see* Silverstein MJ
— *see* Taylor CW
Martin PJ, *see* Liu SY
Marty J, *see* Basser RL
Marubini E, *see* Zucali R
Mas L, *see* Gómez H
Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller G, Rosenblum M, Gardner S, Lyden D, Sands S, Puccetti D, Lindsley K, Merchant TE, O'Malley B, Bayer L, Petriccione MM, Allen J, Finlay JL. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors, 210
Mâsse B, *see* Dorval M
Massi D, *see* Susini T
Massi G, *see* Susini T
Masters GA, Haraf DJ, Hoffman PC, Drinkard LC, Krauss SA, Ferguson MK, Olak J, Samuels BL, Golomb HM, Vokes EE. Phase I study of vinorelbine, cisplatin, and concomitant thoracic radiation in the treatment of advanced chest malignancies, 2157
— *see* Mauer AM
Mastorakos DP, *see* Kavolius JP
Masuda N, Matsui K, Negoro S, Takifuji N, Takeda K, Yana T, Kobayashi M, Hirashima T, Kusunoki Y, Ushijima S, Kawase I, Tada T, Sawaguchi H, Fukuoka M. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer, 3329
Mateos G, *see* Ciudad J

Mateos MV, *see* Ciudad J
Mathers JA, *see* Lawlor ER
Mathias SD, *see* Payne R
Matsuda S, *see* Asou N
Matsui K, *see* Masuda N
Matter A, *see* Eppenberger U
Matthay K, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D. Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma, 229
—, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN. Successful treatment of stage II neuroblastoma based on prospective biologic staging: A Children's Cancer Group study, 1256
— *see* Ozkaynak MF
— Stage 4S neuroblasoma: What makes it special? (editorial), 2003
Matthes S, *see* Cagnoni PJ
Matthews DC, *see* Liu SY
Matthews JP, *see* Toner GC
Mattox S, *see* Desikan KR
Mauch P. What is the role for adjuvant radiation therapy in advanced Hodgkin's disease (editorial), 815
— *see* Freedman AS
Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE. Phase I study of docetaxel with concomitant thoracic radiation therapy, 159
Maunsell E, *see* Dorval M
Maurer LH, *see* Ahles TA
Mayer AR, *see* Rose PG
Mayer RJ. The state of the society: A year of continued growth, 3191
— *see* Shipp MA
Mayeur D, *see* Tourani J-M
Mazumdar M, *see* Bajorin DF
McCaffrey JA, *see* Bajorin DF
McCalla J, *see* Haddy TB
McCall AR, *see* Stiff PJ
McClure M, *see* Frank TS
McCormick B, *see* Recht A
McCrae J, *see* Schimmer AD
McCready D, *see* Andrulis IL
McDermott JH, *see* Mehta RR
McDonald MK, *see* Hillner BE
McDonald MV, *see* Passik SD
McGahan JP, *see* DeNardo GL
McGaughey DS, *see* Laughlin MJ
McGinn CJ, Ten Haken RK, Ensminger WD, Walker S, Wang S, Lawrence TS. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model, 2246
McGuire WP, *see* Markman M
McKeage M, *see* Zalcberg J
McKenzie M, *see* Westeel V
McKeon A, *see* Treat J
McKillop JH, *see* Serafini AN
McKinna J, *see* Ellis P
McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program, 2825
McLendon RE, *see* Bigner DD
— *see* Friedman HS
McMurtrie E, *see* Latreille J
Mead GM, *see* Fosså SD
— *see* Kaye SB
Meadows AT, *see* Bhatia S
Meden H, *see* Hofstra LS
Mee D, *see* Latreille J
Meehan L, *see* Treat J
Meehan SC, *see* Haddy TB
Meerwaldt JH, *see* Hagenbeek A
Mehra R, *see* Popat U
— *see* Ueno NT
Mehta J, *see* Desikan KR
Mehta MP, Tannehill SP, Adak S, Martin L, Petereit DG, Wagner H, Fowler JF, Johnson D. Phase II trial of hyperfractionated accelerated radiation therapy for nonresectable non-small-cell lung cancer: Results of eastern cooperative oncology group 4593, 3518
— *see* Chang SM
— *see* Chappell R
Mehta RR, McDermott JH, Hieken TJ, Marler KC, Patel MK, Wild LD, Das Gupta TK. Plasma c-*erb*B-2 levels in breast cancer patients: Prognostic significance in predicting response to chemotherapy, 2409
Meier T, *see* Macklis RM
Meijer CJLM, *see* Geelen FAMJ
Meijer-van Gelder ME, *see* Berns EMJJ
— *see* Foekens JA
Meijs PJM, *see* de Vries EGE
Mejean A, *see* Tourani J-M
Mellars K, *see* Hortobagyi GN
Mellstedt H, *see* Lundin J
Menchaca D, *see* Basser RL
Menker H, *see* Eberhardt W
Mennel RG, *see* Valero V
Mercadante S, Casuccio A, Agnello A, Serretta R, Calderone L, Barresi L. Morphine *versus* methadone in the pain treatment of advanced-cancer patients followed up at home, 3656
Merchant TE, Davis BJ, Sheldon JM, Leibel SA. Radiation therapy for relapsed CNS germinoma after primary chemotherapy, 204
— *see* Gururangan S
— *see* Mason WP
Mercuri M, *see* Bacci G
Merino MJ, *see* Yang JC
Merlet M, *see* Leblond V
Meropol NJ, Wood DE, Nemunaitis J, Petrelli NJ, Lipman BJ, Agosti JM, Whitmore JB. Randomized, placebo-controlled, multicenter trial of granulocyte-macrophage colony-stimulating factor as infection prophylaxis in oncologic surgery, 1167
— *see* Budman DR
Merritt JA, *see* Clayman GL
Messner M, *see* Grimaldi C
Messori A, Costantini M, Bonistalli L, Alterini R. Second bone marrow transplantation in non-Hodgkin's lymphoma (letter), 804
—, Trippoli S. Can the Q-TWIST method provide information on patients' preferences without collecting preference data from the patients? (letter), 3716
Mester J, *see* Bohuslavizki KH

Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer, 301
— Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors, 3537
Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz H-J, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L. *ERCC1* mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy, 309
— *see* Gorlick R
Meyerowitz BE, *see* Ganz PA
Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients, 2522
Meyers M, *see* Bajorin DF
Meyers P, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) protocol, 2452
— *see* de Alava E
— *see* Gorlick R
— *see* Kushner BH
Michael M, *see* Siu LL
Michaelsen KM, *see* Nysom K
Michelis MA, *see* Pecora AL
Michel J, *see* Dombernowsky P
Michon J, *see* Fagnou C
— *see* Ladenstein R
— *see* Pein F
Mick R, *see* Vaughn DJ
Middeke H, *see* Hiddemann W
Miggiano MC, *see* Santini G
Mignard D, *see* Saliba F
Mignotte H, *see* Lasset C
Mihura J, *see* Ravaud A
Miles JS, *see* Gorlick R
Miller AA, *see* Lilenbaum RC
Miller BJ, *see* Northfelt DW
Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer, 3649
Miller LL, *see* Saltz LB
Miller SJ, *see* Kahn D
Miller W Jr, *see* Treat J
Mills L, *see* Laughlin MJ
Mills P, *see* Glantz MJ
Millward MJ, *see* Toner GC
Milpied N, *see* Guglielmi C
Milward M, *see* Zalcberg J
Mimori K, *see* Mori M
Minami H, *see* Daugherty CK
Minsky BD, Coia L, Haller DG, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Berkey B, Katz A, Hanks G. Radiation therapy for rectosigmoid and rectal cancer: Results of the 1992-1994 Patterns of Care Process Survey, 2542
Miranpuri SS, *see* Chappell R
Mirza NQ, *see* Ueno NT
Mischer P, *see* Pehamberger H
Miser AW, *see* Sloan JA
Misset J-L, *see* Saliba F
Mitchell BS, *see* Gandhi V
Mitchell E, *see* Wadler S
Mitchell JB, *see* Herscher LL
Mitchell SV, *see* Toner GC
Mittal B, *see* Kies MS
Mitterbauer G, *see* Laczika K
Mitterbauer M, *see* Laczika K
Miyake M, *see* Adachi M
Miyawaki S, *see* Asou N
Modrich PL, *see* Friedman HS
Moertel CG, *see* O'Connell MJ
Mohammad RM, *see* Varterasian ML
Mohide EA, *see* Browman GP
Moley JF, *see* Ogunbiyi OA
Mølgaard C, *see* Nysom K
Moliterni A, *see* Bonadonna G
Mollenhauer J, *see* Scheurlen WG
Mommen P, *see* Sculier J-P
Mone SM, *see* Nysom K
Monfardini S, *see* Gridelli C
Monnet I, *see* Chouaid C
Monnier A, *see* Tourani J-M
Monson JM, *see* Gage I
Montello MJ, *see* Cheson BD
Montserrat E, *see* Terol M-J
Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow, 603
Moon TE, *see* Eton O
Moore J, *see* Dezube BJ
Moore M, *see* Warde P
Moore MJ, *see* Bloomfield DJ
— *see* Siu LL
Morel P, *see* Fouillard L
— *see* Leblond V
Morgan DJ, *see* Clarke K
Morgan GJ, *see* Evans PAS
Morgan J, *see* Diller L
Morgan M, *see* Dombernowsky P
Morgner A, *see* Thiede C
Mori M, Mimori K, Ueo H, Tsuji K, Shiraishi T, Barnard GF, Sugimachi K, Akiyoshi T. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas, 128
Moritani T, *see* Yamamoto K
Moro MJ, *see* Ciudad J
Morris J, *see* Westeel V
Morris M, Brader KR, Levenback C, Burke TW, Atkinson EN, Scott WR, Gershenson DM. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix, 1094
— *see* Brader KR
Mortelmans LA, *see* Vansteenkiste JF
Morton DL, *see* Hoon DSB
— *see* Hsueh EC
Morton RF, *see* Galanis E
Moschel RC, *see* Friedman HS
Moser T, *see* Alexander HR Jr

Moskowitz CH, *see* Mann GB
Moss TJ, *see* Cooper BW
Mottolese M, *see* Benevolo M
Motzer RJ, *see* Bajorin DF
Moulopoulos LA, *see* Dimopoulos MA
Moynahan ME, *see* Seidman AD
Mueller BU, *see* Granovsky MO
Mueller H, *see* Eppenberger U
Müeller MR, *see* Eberhardt W
Muggia FM. Doxil in breast cancer (letter), 811
— *see* Garcia AA
Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study, 1723
Mullai N, Khokha N, Shiomoto G. Bleomycin cutaneous toxicity, 1625
Müller-Holzner E, *see* Zeimet AG
Müller J, *see* Nysom K
Mullineau L, *see* Frank TS
Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies, 3691
Mumm A, *see* Willenbacher W
Munck J-N, *see* Decuadin D
Mundy GR, *see* Body JJ
Münger K, *see* Alani RM
Muñoz E, *see* Sanchez E
Munshi N, *see* Desikan KR
Muraca PJ, *see* Kallakury BV
Murate T, *see* Kinoshita T
Murphy K, *see* Westeel V
Murray KJ, *see* Shipley WU
Murray N. Timing of thoracic irradiation for limited small-cell lung cancer (letter), 1633
—, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, Coppin C, Coldman A, Page R. Abbreviated treatment for elderly, infirm, of noncompliant patients with limited-stage small-cell lung cancer, 3323
— *see* Westeel V
Myeloma Trialists' Collaborative Group. combination chemotherapy *versus* melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials, 3832
Myers A, *see* Tulpule A
Myers K, *see* Curry BJ
Myint H, *see* Hamblin TJ
Myles J, *see* Levine M
— *see* Osoba D
Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group, 920
— *see* Heerema NA
— *see* Hutchinson RJ
— *see* Uckun FM
Nackaerts KL, *see* Vansteenkiste JF
Nademanee AP, *see* Stiff PJ
Nadler LM, *see* Freedman AS
Nagai H, *see* Kinoshita T
Nagamine M, *see* Usui N
Nagorney DM, *see* O'Connell MJ
Najman A, *see* Fouillard L
Narabayashi M, *see* Yamamoto N
Narod S, *see* Lerman C
Narod SA, *see* Foulkes WD
Nasca S, *see* Bécouarn Y
Nash MB, *see* Katzenstein HM
Näsman P, *see* Glimelius B
Natale RB, *see* Taylor CW
Natali PG, *see* Benevolo M
National Cancer Institute of Canada Clinical Trials Group, *see* Levine M
National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group, *see* Straus DJ
National Surgical Adjuvant Breast and Bowel Project B-17, *see* Fisher B
Nati S, *see* Santini G
Navari RM, *see* Gralla RJ
Nedellec G, *see* Decuadin D
Negoro S, *see* Masuda N
Négrier S, *see* Ravaud A
Neiman R, *see* Glick JH
Nelson E, *see* Curti BD
Nelson J, *see* Desikan KR
Nemunaitis J, *see* Meropol NJ
Neogi T, *see* Bloomfield DJ
Neri A, *see* Pignataro L
Ness E, *see* Wojtowicz-Praga S
Neubauer A, *see* Hiddemann W
— *see* Thiede C
Neuberg D, *see* Diller L
— *see* Freedman AS
Neudorfer H, *see* Rosen HR
Neugut AI, *see* Grann VR
Neville A, *see* Bloomfield DJ
Newell DR, *see* Rafi I
Newman TE, *see* Browman GP
Ngan RKC, *see* Cheung MMC
Ng CS, *see* Cheung MMC
Nguyen TD, *see* Bécouarn Y
Nichols C, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin of ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology study, Southwest Oncology Group, and Cancer and Leukemia Group B study, 1287
— *see* Loehrer PJ Sr
— *see* Zon RT
Nicholson HS, Krailo M, Ames MM, Seibel NL, Reid JM, Liu-Mares W, Vezina LG, Ettinger AG, Reaman GH. Phase I study of temozolomide in children and adolescents with recurrent solid tumors: A report from the Children's Cancer Group, 3037
— *see* Granovsky MO
Nicol S, *see* Spiridonidis CH
Nielsen D, *see* Ryberg M
Nielsen OS, *see* Bentzen SM
— *see* Work E
Nierman DM, *see* Groeger JS
Nieto Y, Cagnoni PJ, Jones RB. Standard *versus* high-dose therapy in 10+ breast cancer (letter), 810
— *see* Cagnoni PJ
Niloff E, *see* Tai Y-T

Ninane V, *see* Sculier J-P
Nishikawa K, *see* Asou N
Nishimura L, *see* Latreille J
Nishiwaki Y, *see* Furuse K
Nissen N, *see* Lundin J
Nitschke R, *see* Mahoney DH Jr
Nitti D, *see* Grimaldi C
Nixon A, Manola J, Gelman R, Bornstein B, Abner A, Hetelekidis S, Recht A, Harris JR, No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques, 1374
— *see* Chabner E
— *see* Hoon DSB
Noda K, *see* Furuse K
Noël-Walter MP, *see* Fouillard L
Noguès C, *see* Eisinger E
Nolte MJ, Berkery R, Pizzo B, Baltzer L, Grossano D, Lucarelli CD, Kris MG, Assuring the optimal use of serotonin antagonist antiemetics: The process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center, 771
Non-Hodgkin's Lymphoma Classification Project, *see* Armitage JO
Noordijk EM, *see* Tirelli U
Nordbrock E, *see* Christie JM
Norris BD, *see* Levine M
Norris CM, *see* Colevas AD
Norris MD, *see* Bordow SB
Northfelt DW, Dezube BJ, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, Du Mond C, Mamelok RD, Henry DH, Pegylated-liposomal doxorubicin *versus* doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial, 2445
Norton L, *see* Aghajanian C
— *see* Robson M
— *see* Seidman AD
Novak M, *see* Laczika K
Novotny P, *see* Barton DL
— *see* Galanis E
— *see* Loprinzi CL
Nowak BJ, *see* Gandhi V
Noy J, *see* Gralla RJ
Nussenblat R, *see* Sandor V
Nysom K, Holm K, Lipsitz SR, Mone SM, Colan SD, Orav EJ, Sallan SE, Olsen JH, Hertz H, Jacobsen JR, Lipshultz SE, Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia, 545
—, Holm K, Michaelsen KM, Hertz H, Müller J, Mølgaard C, Bone mass after treatment for acute lymphoblastic leukemia in childhood, 3752
Oakhill A, *see* Marks DI
Öberg K, *see* Örlefors H
Oberling F, *see* Hofstra LS
Oberlin O, *see* Fagnou C
O'Brien M, *see* Berg SL
O'Brien RT, *see* Hutchinson RJ
O'Brien S, *see* Cortes J
— *see* Gandhi V
— *see* Khouri IF
— *see* Rodriguez J
— *see* Sacchi S
Ochoa AC, *see* Curti BD
Ochs JS, *see* Walter AW
O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A, Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer, 295
—, Nagorney DM, Bernath AM, Schroeder G, Fitzgibbons RJ, Mailliard JA, Burch P, Bolton JS, Colon-Otero G, Krook JE, Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver, 2528
O'Conner K, *see* Aghajanian C
Ocqueteau M, *see* Ciudad J
Odom J, *see* Welles L
Oeffinger KC, Eshelman DA, Tomlinson GE, Buchanan GR, Programs for adult survivors of childhood cancer, 2864
O'Fallon JR, *see* Sloan JA
— *see* Taylor BV
Offit K, *see* Frank TS
— *see* Robson M
Offner FA, *see* Zeimet AG
O'Flaherty C, *see* Aghajanian C
Ogawa M, *see* Usui N
Ogihara A, *see* Usui N
Oguma E, *see* Yamamoto K
Ogunbiyi OA, Goodfellow PJ, Herfarth K, Gagliardi G, Swanson PE, Birnbaum EH, Read TE, Fleshman JW, Kodner IJ, Moley JF, Confirmation that chromosome *18q* allelic loss in colon cancer is a prognostic indicator, 427
Oh H, *see* Asou N
Ohl U, *see* Köhne C-H
Ohno R, *see* Asou N
Ohtake S, *see* Asou N
Oian P, *see* Semb KA
Okamoto T, *see* Hoon DSB
Oken MM, *see* Glick JH
Olak J, *see* Masters GA
Oliphant A, *see* Frank TS
Oliveira J, *see* Schrijvers D
Olivieri A, *see* Santini G
Olivotto IA, *see* Recht A
Olopade OI, *see* Frank TS
Olsen JH, *see* Nysom K
Olsson H, *see* Jóhannsson OT
Olver I, *see* Basser RL
O'Malley B, *see* Mason WP
Omoto E, *see* Asou N
Omuro Y, *see* Yamamoto N
Orav EJ, *see* Nysom K
Orchard JA, *see* Hamblin TJ
O'Reilly RJ, *see* Boulad F
O'Reilly S, *see* Hahm HA
Orfao A, *see* Ciudad J
Orihuela E, *see* Serafini AN
Örlefors H, Sundin A, Alhström H, Bjurling P, Bergström M, Lilja A, Långström B, Öberg K, Eriksson B, Positron emission tomography with 5-hydroxytryptophan in neuroendocrine tumors, 2534
O'Rourke TJ, *see* Press OW
Orradre JL, *see* Sanchez E
Osborne CK, *see* Diab SG

— *see* Fetting JH
— *see* Mansour EG
— *see* Taylor CW
Osborne R, *see* Gore M
Oscier DG, *see* Hamblin TJ
Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores, 139
— *see* Latreille J
Österborg A, *see* Lundin J
Osterwalder B, *see* Budman DR
— *see* Mackean M
O'Sullivan M, *see* Herr HW
Otero J, *see* Gómez H
Ottaway J, *see* Levine M
Overcash J, *see* Extermann M
Owen J, *see* Minsky BD
Owen RG, *see* Evans PAS
Oza AM, *see* Siu LL
Ozkaynak, MF, Matthay K, Cairo M, Harris RE, Feig S, Reynolds CP, Buckley J, Villablanca JG, Seeger RC. Double-alkylator non-total-body irradiation regimen with autologous hematopoietic stem-cell transplantation in pediatric solid tumors, 937

Pachinger W, *see* Pehamberger H
Padmore R, *see* Siegelmann-Daniel N
Paesmans M, *see* Sculier J-P
Page R, *see* Murray N
— *see* Westeel V
Paillot B, *see* Bécouarn Y
— *see* Grimaldi C
Palazzolo G, *see* Gridelli C
Paleologos N, *see* Bigner DD
Pallud C, *see* Clahsen PC
Palmer JL, *see* Khouri IF
Palshof T, *see* Work E
Pamphilon DH, *see* Marks DI
Panageas KS, *see* Grann VR
Panasci L, *see* Dombernowsky P
Pandya K, *see* Fetting JH
Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R, Häubinger K, Thetter O, Izbicki JR, Riethmüller G. Reduced expression of plakoglobin indicates and unfavorable prognosis in subsets of patients with non-small-cell lung cancer, 1407
— *see* Zippelius A
Panzarella T, *see* Bloomfield DJ
— *see* Warde P
Paoletti G, *see* Lopez M
Paolucci P, *see* Ladenstein R
Papadimitrakopoulou V, *see* Shin DM
Papadopoulos N, *see* Eton O
— *see* Legha SS
Paradelo JC, *see* Taylor CW
Paras PR, *see* Dolan ME
Pardo-Mindan FJ, *see* de Alava E
Parimoo D, *see* Garcia AA
Parmar MKB, *see* Bailey AJ
Parris WC-V, *see* Kaplan R
Parr J, *see* Extermann M
Parsons C, *see* Westeel V
Parwaresch R, *see* Hiddemann W
Pas-Ares L, *see* Garcia-Carbonero R
Pass H, *see* Herscher LL
Passik SD, Dugan W, McDonald MV, Rosenfeld B, Theoblad DE, Edgerton S. Oncologists' recognition of depression in their patients with cancer, 1594
Passlick B, *see* Pantel K
Pasta DJ, *see* Payne R
Paszat LF, Mackillop WJ, Groome PA, Boyd C, Schulze K, Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries, 2625
Patel MK, *see* Mehta RR
Patel P, *see* Ilson DH
Pater J, *see* Latreille J
— *see* Osoba D
— *see* Zee B
Pater S, *see* Loeffler M
Paterson AHG, *see* Body JJ
Patronas N, *see* Sandor V
Patterson K, *see* Frangoul HA
Patterson WB, *see* Emanuel EJ
Patt R, *see* Christie JM
Patz EF, *see* Lowe VJ
Paule B, *see* Tourani J-M
Paulussen M, Ahrens S, Craft AW, Dunst J, Frölich B, Jabar S, Rübe C, Winkelmann W, Wissing S, Zoubek A, Jürgens H. Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) cooperative Ewing's sarcoma studies patients, 3044
Paulus U, *see* Diehl V
Pauly MV, *see* Silber JH
Pavlovich C, *see* Kavolius JP
Pavlovsky S, *see* Loeffler M
Pavolvitch J-M, *see* Tourani J-M
Pawlish K, *see* Ramalingam S
Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: Satisfaction and side effects with transdermal fentanyl *versus* oral morphine, 1588
Pazdur R, *see* Ilson DH
— *see* O'Connell MJ
Pearson A, *see* Ladenstein R
— *see* Smith M
Pearson D, *see* Sandor V
— *see* Wilson WH
Pecking A, *see* Serafini AN
Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S, Doria L, Isaacs R, Gillio AP, Michelis MA, Brochstein JA. CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients, 2093
Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors, 1897
— *see* Dissing M
Pegg AE, *see* Friedman HS
Pegram CN, *see* Bigner DD
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/*neu* monoclonal antibody plus cisplatin in patients with HER2/*neu*-overexpressing

metastatic breast cancer refractory to chemotherapy treatment, 2659
Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auböck J, Fritsch P, Kerl H, Wolff K. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma, 1425
Pein F, Michon J, Valteau-Couanet D, Quintana E, Frappaz D, Vannier JP, Philip T, Bergeron C, Baranzelli MC, Thyss A, Stephan JL, Boutard P, Gentet JC, Zucker JM, Tournade MF, Hartmann O. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: A French Society of Pediatric Oncology study, 3295
— *see* Smith M
Pelletier J, *see* Diller L
Pelzer H, *see* Kies MS
Pemberton PA, *see* Varterasian ML
Penberthy LT, *see* Hillner BE
Pen DLK, *see* Gómez H
Penna A, *see* Fossati R
Pennucci MC, *see* Giaccone G
Perey L, *see* Benhattar J
Perez C, *see* Matthay K
Perez CA, *see* Shipley WU
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron *versus* intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study, 754
— Paclitaxel and cardiotoxicity (editorial), 3481
— *see* Loprinzi CL
Pérez G, *see* Arranz R
Pérez-Manga G, *see* Arranz R
Pergola M, *see* Gridelli C
Periman P. Suicide among cancer patients (letter), 2292
Perrone F, *see* Gridelli C
Perry AR, *see* Watts MJ
Perry MC, Herndon JE III, Eaton WL, Green MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B study 8083, 2466
— *see* Ahles TA
Person-Joly MC, *see* Gamelin É
Pescosta N, *see* Santini G
Peshkin B, *see* Audrain J
— *see* Frank TS
Petereit DG, *see* Mehta MP
Peter M, *see* Fagnou C
Petersdorf SH, *see* Liu SY
Peters ES, *see* Colevas AD
Peters FPJ, Thunnissen FBJM, ten Velde GPM. Pulmonary cavitating squamous cell carcinoma, 363
Peters H, *see* van Halteren HK
Peters HA, *see* Foekens JA
Peterson BA, *see* Glick JH
Peterson G, *see* Markman M
Peterson LA, *see* Tallman M
Peters R, *see* Benhattar J
Peters WP, *see* Laughlin MJ
Peto R, *see* Specht L
Petrelli NJ, *see* Meropol NJ
Petriccione MM, *see* Mason WP
Pettengell R, *see* Weaver A
Pettit GR, *see* Varterasian ML
Pfeifer W, *see* Steward WP
Pfister C, *see* Tourani J-M
Pfreundschuh M, *see* Diehl V
Phelps ME, *see* Gambhir SS
Philip T, *see* Guglielmi C
— *see* Ladenstein R
— *see* Pein F
Phillips K-A, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy, 3179
Piantadosi S, *see* Grossman SA
Picci P, *see* Bacci G
Pich A, Chiusa L, Audisio E, Marmont F. Nucleolar organizer region counts predict complete remission, remission duration, and survival in adult acute myelogenous leukemia patients, 1512
Pichlmaier H, *see* Riethmüller G
Pichlmayr R, *see* Riethmüller G
Picon L, *see* Gamelin É
Pienta KJ, *see* Smith DC
Pierce S, *see* Sacchi S
Pietersen AM, *see* Somers VA
Pignataro L, Pruneri G, Carboni N, Capaccio P, Cesana BM, Neri A, Buffa R. Clinical relevance of cyclin D1 protein overexpression in laryngeal squamous cell acrcinoma, 3069
Pignon B, *see* Solal-Céligny P
Pikus A, *see* Haddy TB
Pileri S, *see* Zinzani PL
Pinkel D. Cancer chemotherapy and body surface area (letter), 3714
Pinkerton R, *see* Ladenstein R
Piris MA, *see* Sanchez E
Pirzkall A, Debus J, Lohr F, Fuss M, Rhein B, Engenhart-Cabillic R, Wannenmacher M. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases, 3563
Pisansky T, *see* Hoffman JP
— *see* Loprinzi CL
— *see* Minsky BD
Pisters PWT, Abbruzzese JL, Janjan NA, Cleary KR, Charnsangavej C, Goswitz MS, Rich TA, Raijman I, Wolff RA, Lenzi R, Lee JE, Evans DB. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma, 3843
Pistotti V, *see* Fossati R
Pitushkin E, *see* Bruera E
Pizzo B, *see* Nolte MJ
Plager C, *see* Eton O
— *see* Legha SS
Planting A, *see* Mackean M
Plaza MM, *see* Sanchez E
Pluda J, *see* Friedman HS
— *see* Varterasian ML
— *see* Welles L
Plunkett W, *see* Gandhi V
Polastri D, *see* Ripamonti C
Pollack I, *see* Chang SM
Poller W, *see* Fisher B
Polyak T, *see* Kushner BH
Ponti A, *see* Degiuli M

Popat U, Przepiork D, Champlin R, Pugh W, Amin K, Mehra R, Rodriguez J, Giralt S, Romaguera J, Rodriguez A, Preti A, Andersson B, Khouri I, Claxton D, de Lima M, Donato M, Anderlini P, Gajewski J, Cabanillas F, van Besien K. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: Mediastinal localization predicts for a favorable outcome, 63
Popella C, *see* Wendt TG
Poplack DG, *see* Berg SL
Popovic W, *see* Gralla RJ
Poquette CA, *see* Hudson MM
Porcellini A, *see* Santini G
Portengen H, *see* Berns EMJJ
Portenoy RK, *see* Christie JM
Porter L, *see* Berenson JR
— *see* Hortobagyi GN
Portlock CS, *see* Schechter NR
Posner MR, *see* Colevas AD
Possinger K, *see* Cocconi G
Postmus PE, *see* Curran D
— *see* Giaccone G
— *see* Tjan-Heijnen VCG
Potena MI, *see* Ciarmiello A
Potre S, *see* Rosen HR
Pouillart P, *see* Fizazi K
— *see* Lombard I
Poulin M, *see* Colevas AD
Powers GC, *see* Curti BD
Poynton C, *see* Lundin J
Prados MD, *see* Chang SM
Pratt C, *see* Langevin A-M
— *see* Smith M
— *see* Walter AW
Prendiville J, *see* Eisen T
Pressman P, *see* Robson M
Press OW, LeBlanc M, O'Rourke TJ, Gagnet S, Chapman RA, Balcerzak SP, Fisher RI. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246, 574
— In reply (letter), 2290
— *see* Liu SY
Preti A, *see* Popat U
Preti RA, *see* Pecora AL
Price D, *see* Matthay K
Price K, *see* Groeger JS
Pritchard J, *see* Ladenstein R
Pritchard K, *see* Browman GP
— *see* Levine M
Pritsch M, *see* Keilholz U
Pritzker KPH, *see* Andrulis IL
Propert KJ, *see* Talcott JA
Prosnitz LR, *see* Marks LB
Protocol 19 Aredia Breast Cancer Study Group, *see* Hortobagyi GN
Proulx GM, McCarthy P, Epidural chloroma of the lower spinal canal, 3201
Provencio M, *see* Garcia-Patiño E
Provenzale JM, *see* Bigner DD
— *see* Friedman HS
Pruneri G, *see* Pignataro L
Przepiorka D, *see* Khouri IF
— *see* Popat U
— *see* Ueno NT
Puccetti D, *see* Mason WP
Pugh W, *see* Khouri IF
— *see* Popat U
Pui C-H, Rubnitz JE, Hancock ML, Downing JR, Raimondi SC, Rivera GK, Sandlund JT, Ribeiro RC, Head DR, Relling MV, Evans WE, Behm FG. Reappraisal of the clinical and biologic significance of myeloid-associated antigen expression in childhood acute lymphoblastic leukemia, 3768
— *see* Consolini R
— *see* Walter AW
Pullen J, *see* Harris MB
— *see* Shuster JJ
Punt CJA, *see* Keilholz U
Puolakka J, *see* Anttila M
Purnell GL, *see* Serafini AN

Qi K, *see* Hsueh EC
Qizilbash A, *see* Andrulis IL
Quashu N, *see* Cheson BD
Quatermain M, *see* Schimmer AD
Quella SK, *see* Barton DL
— *see* Loprinzi CL
Quesnell N, *see* Blay J-Y
Quick DP, *see* Serafini AN
Quinn CT, Griener JC, Bottiglieri T, Kamen BA. Methotrexate, homocysteine, and seizures (letter), 393
Quintana E, *see* Pein F

Raab R, *see* Riethmüller G
Raber MN, *see* Ayoub J-P
Rabkin CS, *see* Granovsky MO
Rabl H, *see* Rosen HR
Rademaker AW, *see* Kies MS
Radford JA, *see* Weaver A
Raemaekers JMM, *see* Hagenbeek A
Rafi I, Bloddy AV, Calvete JA, Taylor GA, Newell DR, Bailey NP, Lind MJ, Green M, Hines J, Johnstone A, Clendenin N, Calvert AH. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumors, 1131
Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes, 2018
Rahman Z, Buzdar A, Hortobagyi GN. In reply (letter), 1239
— *see* Ueno NT
— *see* Valero V
Raijman I, *see* Pisters PWT
Raimondi SC, *see* Consolini R
— *see* Pui C-H
Rajan P, *see* Robson M
Rakusin A, *see* Wu C
Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a surveillance, epidemiology, and end results database, 651
Ramchandani P, *see* Vaughn DJ
Rankin C, *see* Chang SM
Rankin E, *see* Lundin J

Ranson MR. In reply (letter), 811
Ranstam J, *see* Jóhannsson OT
Rao PV, *see* Katzenstein HM
Raoul J-L, *see* Bécouarn Y
Raphael M, *see* Leblond V
Raphaël M, *see* Davi F
Rapi S, *see* Susini T
Rasheed K, *see* Friedman HS
Rasmussen HS, *see* Wojtowicz-Praga S
Ratain MJ. Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? (editorial), 2297
— In reply (letter), 3715
— *see* Brockstein B
— *see* Daugherty CK
— *see* DeMario MD
— *see* Dolan ME
— *see* Fleming GF
— *see* Lilenbaum RC
— *see* Schilsky RL
— *see* Venook AP
Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies, 1458
Ratschiller D, *see* Betticher DC
Ravaioli A, *see* Tassinari D
Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard J-Y, Caty A, Geoffrois L, Ferrero J-M, Linassier C, Drevon M, Négrier S for the Groupe Français d'Immunothérapie. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial, 2728
—, Chevreau C, Cany L, Houyau P, Dohollou N, Roché H, Soubeyran P, Bonichon F, Mihura J, Eghbali H, Tabah I, Bui BN. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: Results of a randomized phase III trial, 2930
Ravdin PM, Callander NS, Hortobagyi GN. Registry results and high-dose therapy (letter), 387
—, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy, 515
— *see* Bruno R
— *see* Diab SG
— *see* Valero V
Rayón C, *see* Arranz R
Razvillas B, *see* Villalona-Calero MA
Read S, *see* Shepherd F
Read TE, *see* Ogunbiyi OA
Reaman G, *see* Heerema NA
— *see* Nicholson HS
— *see* Smith M
— *see* Uckun FM
Reardon D, *see* Hutchinson RJ
Recht A, Bartelink H, Fourquet A, Fowble B, Harris JR, Kurtz J, McCormick B, Olivotto IA, Rutqvist L, Solin LJ, Yarnold J. Postmastectomy radiotherapy: Questions for the twenty-first century, 2886
— *see* Chabner E
— *see* Gage I
— *see* Nixon AJ
— *see* Shapiro C
Recht L, *see* Glantz MJ
Rector D, *see* Taylor CW
Reder RF, *see* Kaplan R
Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma, 1844
Redman S, *see* Cockburn J
Reed C, *see* Ilson DH
Reed NL, *see* Kahn D
Reeves C, *see* Diller L
Reeves J, *see* Perez EA
Rege V, *see* Akerley W
Regimbeau C, *see* Gamelin É
Reichardt P, Tilgner J, Hohenberger P, Dörken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study, 1438
Reichard U, *see* Wulf G
Reich E, *see* Ayash LJ
Reich L, *see* Aghajanian C
Reid JM, *see* Nicholson HS
Reid RH, *see* Serafini AN
Reigner B, *see* Budman DR
— *see* Mackean M
Reisfeld RA, *see* Yu AL
Reiss R, *see* Hesdorffer C
Reitsma DJ, *see* Berenson JR
— *see* Hortobagyi GN
Relling MV, *see* Pui C-H
Remick SC, *see* Dezube BJ
Renshaw AA, *see* D'Amico AV
Repse S, *see* Rosen HR
Resche I, *see* Serafini AN
Reske SN, *see* Moog F
Retchin SM, *see* Hillner BE
Reuss-Borst M, *see* Hiddemann W
Reyes F, *see* Cole BF
Reymond MA, *see* Köckerling F
Reynolds CP, *see* Matthay K
— *see* Ozkaynak MF
Reynolds JC, *see* Gibril F
Rhein B, *see* Pirzkall A
Rhodes VA, *see* Spiridonidis CH
Ribeiro RC, *see* Pui C-H
Riccardi R, *see* Smith M
Richardson D, *see* Miller DR
Richardson P, *see* Ayash LJ
Richards W, *see* Kwiatkowski DJ
Richey M, *see* Green DM
Richie JP, *see* D'Amico AV
— *see* Talcott JA
Rich J, *see* Friedman HS
Rich TA, *see* Pisters PWT
Ridge JA, *see* Siegelmann-Daniel N
Rieger P, *see* Frank TS
Rieker P, *see* Talcott JA
Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirsche H, Buggisch P, Witte J, Pichlmayr R. Monoclonal antibody therapy for resected

Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial, 1788
— *see* Pantel K
— *see* Zippelius A
Rigas JR, *see* Bruno R
Rilke F, *see* Zucali R
Rimer B, *see* Audrain J
— *see* Gail M
Ring S, *see* Eton O
— *see* Legha SS
Rios A, *see* Stewart S
Rios MB, *see* Cortes J
— *see* Rodriguez J
Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain: What is the equianalgesic dose ratio?, 3216
Risberg T, Lund E, Wist E, Kaasa S, Wilsgaard T. Cancer patients use of nonproven therapy: A 5-year follow-up study, 6
Rischin D, *see* Toner GC
— *see* Zalcberg J
Ritchey ML, *see* Green DM
Ritter M, *see* Thiede C
Ritz J, *see* Freedman AS
Riva A, *see* Bruno R
Rivera GK, *see* Pui C-H
— *see* Walter AW
Riviere A, *see* Schrijvers D
Rivkin SE, *see* Salmon SE
Rizzieri D, *see* Laughlin MJ
Rizzo J, *see* Chang SM
Rizzoli V, *see* Santini G
Roach RW, *see* Salmon SE
Robbins B, *see* Tetreault S
Robbins K, *see* Schrijvers D
Robbins R, *see* Tallini G
Robert J, *see* Gamelin É
— *see* Levine M
Robert N, *see* Fetting JH
— *see* Taylor CW
Robertson LE, *see* Gandhi V
Robidoux A, *see* Fisher B
Robins HI, *see* Chang SM
Robison LL, *see* Bhatia S
Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P, Hirschaut Y, Pressman P, Rosen PP, Lesser ML, Norton L, Offit K. BRCA-Associated breast cancer in young women, 1642
—, Offit K. In reply (letter), 3207
— *see* Frank TS
Roché H, *see* Ravaud A
Rödel CM, *see* Wendt TG
Rodenhuis S, *see* de Vries EGE
Rodrigues B, *see* Akerley W
Rodrigues G, *see* Osoba D
Rodriguez A, *see* Khouri IF
— *see* Popat U
Rodriguez CO Jr, *see* Gandhi V
Rodriguez DH, *see* Varterasian ML
Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia, 3782
— *see* Popat U
Rodriguez M, *see* Rose PG
Rodriguez R, *see* Treat J
Rodríguez W, *see* Gómez H
Roesel JL, *see* Eppenberger U
Rogers E, *see* Leibman BD
Rogers M, *see* Garcia AA
Rohloff R, *see* Wendt TG
Roila F, *see* Ballatori E
Romaguera J, *see* Khouri IF
— *see* Popat U
Rondón G, *see* Ueno NT
Rosai J, *see* Gerald W
— *see* Tallini G
Rose K, *see* Ratliff AF
Rosenberg PS, *see* Granovsky MO
Rosenberg SA, *see* Alexander HR Jr
— *see* Yang JC
Rosenblum M, *see* Dunkel IJ
— *see* Gururangan S
— *see* Mason WP
Rosen DM, *see* Egorin MJ
Rosenfeld B, *see* Passik SD
Rosenfield NS, *see* Boulad F
Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M. Adjuvant intraperitoneal chemotherapy with carbon-absorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology, 2733
Rosenman J, *see* Choi NC
Rosen PP, *see* Robson M
Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: A Gynecologic Oncology Group Study, 405
—, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian aor peritoneal carcinoma, 1494
— *see* Markman M
Rosner F. Hand-foot syndrome in sickle cell disease (letter), 808
Rosner GL, *see* Lilenbaum RC
— *see* Venook AP
Ross AA, *see* Cooper BW
Rossi A, *see* Gridelli C
Rossi E, *see* Santini G
Rossi J-F, *see* Solal-Céligny P
Ross JS, *see* Kallakury BV
Ross M, *see* Cagnoni PJ
— *see* Laughlin MJ
Ross MI, *see* Gershenwald JE
Rosti G, *see* Tirelli U
Roth JA, *see* Clayman GL
Roth-Roemer SL, *see* Syrjala KL
Rougier P, *see* Bécouarn Y
— *see* Bleiberg H
— *see* Grimaldi C
Rowe ST, *see* Katzenstein HM
Rowinsky E, Smith L, Wang Y-M, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, Drengler R, Stephenson J Jr, Harding MW, Von Hoff DD. Phase

I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both *MDR1* and MRP, 2964
— *see* Villalona-Calero MA
Rowland JH, *see* Ganz PA
Rowland KM, *see* Galanis E
Rowley PT, *see* Frank TS
Roy M, *see* Hoskins P
Roy SK, *see* Dolan ME
Rozman C, *see* Terol M-J
Rubagotti A, *see* Santini G
Rübe C, *see* Paulussen M
Rubens R, *see* Cook GJ
Rubens RD, *see* Body JJ
Rubenstein EB, *see* Cantor SB
Rubin J, *see* Galanis E
— *see* O'Connell MJ
— *see* Wadler S
Rubin SC, *see* Markman M
Rubinstein L, *see* Smith M
Rubnitz JE, *see* Pui C-H
Rueffer J-U, *see* Diehl V
Ruffié P, *see* Fizazi K
Ruiter D, *see* Koops HS
Ruiters MHJ, *see* Wisman GBA
Rummans TA, *see* Loprinzi CL
Russo D, *see* Frank TS
Russo P, *see* Kavolius JP
Rusthoven J, *see* Latreille J
Rutqvist L, *see* Recht A
Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, Dombernowsky P. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer, 3502

Saarikoski S, *see* Anttila M
Sabattini E, *see* Zinzani PL
Sacchi S, Kantarjian HM, Smith TL, O'Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early Treatment decision with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia, 882
Sack H, *see* Eberhardt W
Sacks N, *see* Ellis P
Saez AI, *see* Sanchez E
Safran H, *see* Choy H
Sagani PC, *see* Herr HW
Sahmoud T, *see* Bleiberg H
— *see* Clahsen PC
— *see* Curran D
— *see* Giaccone G
— *see* Grimaldi C
Saijo N, *see* Furuse K
Saito H, *see* Kinoshita T
Saito K, *see* Asou N
Saito T, *see* Usui N
Sakr WA, *see* Al-Sarraf M
Salako Q, *see* DeNardo GL
Sale M, *see* Wojtowicz-Praga S
Salgia R, Skarin AT. Molecular abnormalities in lung cancer, 1207
Saliba F, Hagipantelli R, Misset J-L, Bastian G, Vassal G, Bonnay M, Herait P, Cote C, Mahjoubi M, Mignard D, Cvitkovic E. Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: A prospective assessment, 2745
Sallan SE, *see* Dalton VMK
— *see* Nysom K
Salloum E, *see* Cooper DL
Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W. Interferon *versus* interferon plus prednisone remission maintenance therapy for multiple myeloma: A Southwest Oncology Group study, 890
— *see* Kraut EH
Salonga D, *see* Gorlick R
— *see* Metzger R
Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Phase I clinical and pharmacological study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors, 3858
Salvagno L, *see* Santini G
Salvatore M, *see* Ciarmiello A
Salze P, *see* Tourani J-M
Sambandam S, *see* Akerley W
Samlowski W, *see* Salmon SE
Samuels B, *see* Khouri IF
— *see* Ueno NT
Samuels BL, *see* Masters GA
Sanchez E, Chacon I, Plaza MM, Muñoz E, Cruz MA, Martinez B, Lopez L, Martinez-Montero JC, Orradre JL, Saez AI, Garcia JF, Piris MA. Clinical outcome in diffuse large b-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins, 1931
Sandbach J, *see* Perez EA
Sandbichler P, *see* Rosen HR
Sanders JE, *see* Syrjala KL
Sandlund JT, *see* Pui C-H
Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, Patronas N, Heiss J, Jaffe E, deSmet M, Kohler D, Simon R, Wittes R. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma, 3000
Sands S, *see* Mason WP
Sangelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study, 3392
San Miguel JF, *see* Ciudad J
Santillana S, *see* Gómez H
Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR, Rubagotti A, Congiu AM, Centurioni R, Olivieri A, Tedeschi L, Vespignani M, Nati S, Soracco M, Porcellini A, Contu A, Guarnaccia C, Pescosta N, Majolino I, Spriano M, Vimercati R, Rossi E, Zambaldi G, Mangoni L, Endrizzi L, Sileni VC, Miggiano MC, Marino G, Damasio E, Rizzoli V. VACOP-B *versus* VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group, 2796
Sarin R, *see* Bhattacharyya M
Saris S, *see* Glantz MJ
Sartori S, *see* Tassinari D
Sartor O, *see* Bennett CL
Sasako M, *see* Degiuli M
Sass G, *see* Christodoulou CV
Sastre-Garau X, *see* Lombard I

Sather HN, *see* Heerema NA
— *see* Nachman J
— *see* Uckun FM
Sausville EA, *see* Senderowicz AM
Savarese D, Boucher J, Corey B. Glutamine treatment of paclitaxel-induced myalgias and arthralgias (letter), 3918
Saven A, *see* Tetreault S
Saville MW, *see* Welles L
Savino L, *see* Susini T
Sawaguchi H, *see* Masuda N
Sawka C, *see* Shepherd F
Sawyer WT, *see* Lindley C
Saxman SB, Finch D, Gonin R, Einhorn LH. Long-term follow-up of a phase III study of three *versus* four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience, 702
Saylors RL III, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, Vietti TJ. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group study, 945
Scadden DT, *see* Tulpule A
— *see* Wu CJ
Scagliotti G, Gregor A, Giaccone G. Radiotherapy with/without cisplatin following chemotherapy in limited small-cell lung cancer (letter), 3479
— *see* Giaccone G
Scanlan JM, *see* Syrjala KL
Scardino PT, *see* Leibman BD
Schaaf LJ, *see* Saltz LB
Schaefer PL, *see* Galanis E
— *see* Taylor BV
Schechter NR, Portlock CS, Yahalom J, Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone, 1916
Scheidel-Petrovic A, *see* Laczika K
Scheinbenbogen C, *see* Keilholz U
Scheithauer BW, *see* Galanis E
Schellens J, *see* Mackean M
Scher HI, *see* Bajorin DF
— *see* Herr HW
— *see* Shipp MA
Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sörensen N, Kühl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome, 2478
Schildkraut J, *see* Audrain J
Schilman S, *see* Jaeckle KA
Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L,Lucas VS, Khor SP, Diasia R, Von Hoff DD, Burris HA III. Phase I clinical and pharmacologic study of enuluracil plus fluorouracil in patients with advanced cancer, 1450
— *see* Dolan ME
— *see* Glick JH
— *see* Lilenbaum RC
— *see* Venook AP
Schimmer AD, Quatermain M, Imrie K, Ali V, McCrae J, Stewart AK, Crump M, Derzko C, Keating A. Ovarian function after autologous bone marrow transplantation, 2359
Schlaeppi J-M, *see* Eppenberger U
Schlimok G, *see* Riethmüller G
Schlossman R, *see* Freedman AS
Schmeller N, *see* Steyerberg EW
Schmidt M, *see* Thiede C
Schmiegel W, *see* Riethmüller G
Schmitt M, *see* Eppenberger U
Schmitz PI, *see* Levendag PC
Schmitz S-FH, *see* Betticher DC
Schmoll H-J, *see* Köhne C-H
— *see* Kollmannsberger C
Schnipper L, *see* Ayash LJ
Schnitt S, *see* Chabner E
— *see* Gage I
Schöffski P, *see* Köhne C-H
— *see* Kollmannsberger C
Schold SC, *see* Jaeckle KA
Schold SC Jr, *see* Chang SM
— *see* Friedman HS
Scholten C, *see* Laczika K
Schomberg P, *see* Taylor BV
Schott G, *see* Köhne C-H
Schottstaedt MW, *see* Valero V
Schraut W, *see* Funke I
Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, Oliveira J, Lewensohn R, Schüller J, Riviere A, Arvay C, Langecker P, Jacob H, Cvitkovic E, Vokes E. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer, 1054
Schroeder G, *see* O'Connell MJ
Schubert U, *see* Köhne C-H
Schuller DE, *see* Al-Sarraf M
Schüller J, *see* Schrijvers D
Schultz D, *see* D'Amico AV
Schulze K, *see* Paszat LF
Schwaab G, *see* De Crevoisier R
Schwabe GC, *see* Scheurlen WG
Schwartz B, *see* Basser RL
Schwartz G, *see* Ayash LJ
— *see* Saltz LB
Schwarzinger I, *see* Laczika K
Schwenn M, *see* Laver J
Sciuto R, *see* Lopez M
Scott WR, *see* Morris M
Sculier J-P, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, Efremidis A, Lafitte JJ, Berchier MC, Alexopoulos CG, Zacharias C, Mommen P, Ninane V, Klastersky J. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer, 1388
Seagren S, *see* Choi NC
Seaman J, *see* Berenson JR
— *see* Hortobagyi GN
Sebban C, *see* Cole BF
— *see* Guglielmi C
Seday MA, *see* Bennett CL
Seeber S, *see* Eberhardt W
Seeger RC, *see* Matthay K
— *see* Ozkaynak MF
Seen-Hiber R, *see* Pantel K
Seibel N, *see* Nicholson HS
— *see* Smith M
Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodoulou M, Gollub M, Baselga J, Norton L,

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer, 3353
— *see* Bruno R
Seitz J-F, *see* Bécouarn Y
Seman AJ, *see* Friedman HS
Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who recieve docetaxel treatment, 3426
Semple D, *see* Saltz LB
Senan S, *see* Levendag PC
Sender LS, *see* Dunkel IJ
Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms, 2986
Sensel MG, *see* Heerema NA
— *see* Nachman J
— *see* Uckun FM
Sensenbrenner L, *see* Egorin MJ
Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: A double-blind placebo-controlled clinical trial, 1574
—, Klein JL, Wolff BG, Baum R, Chetanneau A, Pecking A, Fischman AJ, Hoover HC Jr, Wynant GE, Subramanian R, Goroff DK, Hanna MG Jr. Radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer with technetium 99m-labeled totally human monoclonal antibody 88BV59: Results of pivotal phase III multicenter studies, 1777
Serrano J, *see* Gibril F
Serretta R, *see* Mercadante S
Sertoli MR, *see* Santini G
Sextro M, *see* Diehl V
— *see* Loeffler M
Seymour JF. Long-term pamidronate in multiple myeloma (letter), 2572
Seymour MT, *see* Eisen T
Shad AT, *see* Haddy TB
Shah A, *see* Hudson MM
— *see* Murray N
— *see* Westeel V
Shah BD, *see* Gambhir SS
Shapiro C, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, Hayes DF, Harris J, Henderson IC. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients, 3493
— *see* Ayash LJ
— *see* Guadagnoli E
Shapiro F, *see* Aghajanian C
Shapiro JD, *see* Toner GC
Shatila AH, *see* Mansour EG
Shattuck-Eidens D, *see* Frank TS
Sheehan CE, *see* Kallakury BV
Sheehan F, *see* Westeel V
Sheehan TMT, *see* Christodoulou CV
Sheiner LB, *see* Bruno R
Sheldon JM, *see* Merchant TE
Shen D, *see* McLaughlin P
Shen S, *see* DeNardo GL
Shepherd F, Beaulieu R, Gelmon K, Thuot CA, Sawka C, Read S, Singer J. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network Study, 1736
— *see* Goodwin PJ
— *see* Latreille J
Shepherd J, *see* Gore M
Shepherd JE, *see* Gambhir SS
Shepherd L, *see* Levine M
— *see* O'Connell MJ
Sheridan WP, *see* Basser RL
Shiach CR, *see* Evans PAS
Shieh D-B, *see* Kwiatkowski DJ
Shimada H, *see* Matthay K
Shimanuki Y, *see* Yamamoto K
Shimizu Y, Akiyama F, Umezawa S, Ishiya T, Utsugi K, Hasumi K. Combination of consecutive low-dose cisplatin with bleomycin, vincristine, and mitomycin for recurrent cervical carcinoma, 1869
Shin DM, Glisson BS, Khuri FR, Ginsberg L, Papadimitrakopoulou V, Lee JJ, Lawhorn K, Gillenwater AM, Ang K-K, Clayman GL, Callender DL, Hong WK, Lippman SM. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma, 1325
Shiomoto G, *see* Mullai N
Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, Donnelly BJ, Venner PM, Perez CA, Murray KJ, Doggett RS, True LD. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of radiation therapy oncology group 89-03, 3576
Shipp MA, Scher HI, Harrington DP, Mayer RJ. In reply (letter), 3478
Shiraishi T, *see* Mori M
Shochat SJ, *see* Green DM
— *see* Harris MB
Short MA, *see* Evans PAS
Shpall EJ, *see* Cagnoni PJ
Shpilsky A, *see* Silber JH
Shriver SL, *see* Dezube BJ
Shulman LN, *see* Gage I
Shuster JJ, Gieser PW. In reply (letter), 393
—, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DH Jr, Lauer S, Look AT, Borowitz MJ, Carroll AJ, Camitta B. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study, 2854
— *see* Harris MB
— *see* Laver J
— *see* Mahoney DH Jr
Sidlofsky S, *see* Andrulis IL
Sidransky D, *see* Liggett WH Jr
Sieber M, *see* Diehl V
Siegel D, *see* Desikan KR
Siegelmann-Daniel N, Hanlon A, Ridge JA, Padmore R, Fein DA, Langer CJ. Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients, 745
Siegler M, *see* Daugherty CK
Sierra S, *see* Goss PE
Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W, Feig SA. Feasibility, toxicity, and biologic response of interleu-

kin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group, 914
Silberfarb PM, *see* Ahles TA
Silber JH, Fridman M, DiPaola RS, Erder MH, Pauly MV, Fox KR, First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy, 2392
—, Fridman M, Shpilsky A, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV, Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer, 2435
Silberman H, *see* Metzger R
Sileni VC, *see* Santini G
Silva JM, *see* Garcia-Patiño E
Silver B, *see* Chabner E
— *see* Gage I
Silverstein MJ, Lagios MD, Martino S, Lewinsky BS, Craig PH, Beron PJ, Gamagami P, Waisman JR, Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast, 1367
Silvestro P, *see* Ciarmiello A
Simeone JF, *see* Berenson JR
— *see* Hortobagyi GN
Simmonds M, *see* Christie JM
Simone JV, Lyons J, The Evolution of cancer care for children and adults (editorial), 2904
Simon K, *see* Berlin J
Simon R, *see* Sandor V
— *see* Smith M
Sindelar WF, *see* Yang JC
Singer J, *see* Shepherd F
Singer S, *see* Amatruda JF
Singhal S, *see* Desikan KR
Sinoff C, *see* Hortobagyi GN
Sipkema D, *see* Levendag PC
Sire M, *see* Gamelin É
Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ, Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks, 1122
—, Czaykowski PM, Tannock IF, Phase I/II study of the CAPABLE regimen for patients with poorly differentiated carcinoma of the nasopharynx, 2514
Sjögren S, Ingonäs M, Lindgren A, Holmberg L, Bergh J, Prognostic and predictive value of c-*erb*B-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers, 462
Skapek SX, Hawk BJ, Hoffer FA, Dahl GV, Granowetter L, Gebhardt MC, Ferguson WS, Grier HE, Combination chemotherapy using vinblastine and methotrexate for the treatment of preogressive desmoid tumor in children, 3021
Skarin A, *see* Salgia R
— *see* Wu C
Sklenar I, *see* Hofstra LS
Skolnick MH, *see* Frank TS
Skovlund E, *see* Zeimet AG
Skovsgaard T, *see* Ryberg M
Slamon DJ, *see* Pegram MD
Sleiffer DT, *see* Steyerberg EW
Slevin M, *see* Gore M
Sloan JA, Loprinzi CL, Kuross SA, Miser AW, O'Fallon JR, Mahoney MR, Heid IM, Bretscher ME, Vaught NL, Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer, 3662
— *see* Barton DL
— *see* Loprinzi CL
Sluiter WJ, *see* Hofstra LS
Small TN, *see* Boulad F
Smetzer L, *see* Schilsky RL
Smink DS, *see* Silber JH
Smith DC, Dunn RL, Strawderman MS, Pienta KJ, Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer, 1835
— *see* Redman BG
Smith EI, *see* Katzenstein HM
Smith I, *see* Dombernowsky P
— *see* Ellis P
Smith IE, *see* Eisen T
Smith JW III, *see* Margolin KA
Smith L, *see* Rowinsky E
Smith M, Ungerleider RS, Korn EL, Rubinstein L, Simon R, In reply (letter), 391
—, Bernstein M, Bleyer WA, Borsi JD, Ho P, Lewis IJ, Pearson A, Pein F, Pratt C, Reaman G, Riccardi R, Seibel N, Trueworthy R, Ungerleider R, Vassal G, Vietti T, Conduct of phase I trials in children with cancer, 966
Smith T, *see* Rodriguez J
— *see* Sacchi S
Smith TJ, *see* Bloomfield DJ
— *see* Fetting JH
— *see* Hillner BE
Snyder C, *see* Lerman C
Sobol H, *see* Eisinger E
Sobrino P, *see* Arranz R
Société Française d'Oncologie Pédiatrique, *see* Fagnou C
Soiffer RJ, *see* Freedman AS
Solal-Céligny P, Lepage E, Brousse N, Tendler CL, Brice P, Haïoun C, Gabarre J, Pignon B, Tertian G, Bouabdallah R, Rossi J-F, Doyen C, Coiffier B, Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the Groups d'Etude des Lymphomes Folliculaires 86 Trial, 2332
— *see* Cole BF
Solbu G, *see* Löwenberg B
Soldati T, *see* Degiuli M
Soler G, *see* Grau JJ
Solin L, *see* Hoffman JP
— *see* Recht A
Somers R, *see* Guglielmi C
— *see* Hagenbeek A
— *see* Tirelli U
Somers VA, Pietersen AM, Theunissen PH, Thunnissen FB, Detection of K-*ras* point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT, 3061
Sommadossi J-P, *see* Dezube BJ
Sondak V, *see* Macfarlane DJ
— *see* Margolin KA
Sondel PM, *see* Sievers EL
Sonderegger T, *see* Betticher DC
Sonneveld P, *see* Guglielmi C
— *see* Löwenberg B

Soracco M, *see* Santini G
Sorbe B, *see* Hofstra LS
Sorensen JM, *see* Cheson BD
Sörensen N, *see* Scheurlen WG
Sorensen PHB, *see* de Alava E
— *see* Lawlor ER
Sosman JA, *see* Margolin KA
Soubeyran P, *see* Ravaud A
Souhami R, *see* Craft A
Soumerai SB, *see* Guadagnoli E
Soyer HP, *see* Pehamberger H
Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients, 830
Spence AM, *see* Chang SM
Spicer J, *see* Bajorin DF
Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies, 3866
— *see* Wozniak AJ
Spirtos NM, *see* Markman M
Spittle M, *see* Stewart S
Splinter TAW, *see* Giaccone G
— *see* Tjan-Heijnen VCG
Spooner D, *see* Craft A
Spriano M, *see* Santini G
Spriggs D, Makhija S. Ovarian cancer staging: Time for a closer look? (editorial), 2577
— *see* Aghajanian C
— *see* Saltz LB
Sridhara R, *see* Egorin MJ
Stachowiak J, *see* Fouillard L
Stadler WM, Kuzel T, Dumas M, Vogelzang NJ. Multicenter phase II trial of interleukin-2, interferon-a, and 13-*cis*-retinoic acid in patients with metastitic renal-cell carcinoma, 1820
— *see* Daugherty CK
Stahel R, *see* Lundin J
Stahl M, *see* Eberhardt W
Stamatis G, *see* Eberhardt W
Stappert-Jahn U, *see* Diehl V
Stark JJ, *see* Miller DR
Stark-Vancs V, *see* Sandor V
Stavrakis A, *see* Ripamonti C
Stearns V, Gelmann EP. Does tamoxifen cause cancer in humans?, 779
Steen V, *see* Wojtowicz-Praga S
Stefanek M, *see* Audrain J
Steger C, *see* Saltz LB
Steinberg M, *see* Hoctin-Boes G
Steinberg SM, *see* Senderowicz AM
— *see* Welles L
— *see* Wilson WH
— *see* Yang JC
Steiner A, *see* Pehamberger H
Stein H, *see* Hiddemann W
Steinherz PG, *see* Heerema NA
— *see* Uckun FM
Stella PJ, *see* Barton DL
Stenning S, *see* Fossâ SD
— *see* Kaye SB
Stenson K, *see* Brockstein B
Stephan JL, *see* Pein F
Stephenson J Jr, *see* Rowinsky E
Stephens RJ, *see* Bailey AJ
Steuber CP, *see* Mahoney DH
— *see* Mahoney DH Jr
Steward CG, *see* Marks DI
Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, Clancy L, Verweij J, de Wit R, Pfeifer W, Fennelly J, von Eiff M, Frisch J. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients, 642
Stewart AK, *see* Schimmer AD
Stewart CF, *see* Saylors RL III
Stewart D, *see* Latreille J
Stewart E, *see* Friedman HS
Stewart JA, *see* Berlin J
Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ. Randomized comparative trial of pegylated liposomal doxorubicin *versus* bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma, 683
Steyerberg EW, Gerl A, Fossâ SD, Sleiffer DT, de Wit R, Kirkels WJ, Schmeller N, Clemm C, Habbema JDF, Keizer HJ. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer, 269
Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens-A Southwest Oncology Group trial, 48
Stine KC, *see* Saylors RL III
Stinson SF, *see* Senderowicz AM
Stoik G, *see* Andrulis IL
Stolte M, *see* Thiede C
Stoppa-Lyonett D, *see* Eisinger E
Storer B, *see* Berlin J
Stosiek P, *see* Pantel K
Stram DO, *see* Matthay K
Straus DJ, Huang J, Testa MA, Levine AM, Kaplan LD for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142-Low-dose *versus* standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor, 3601
Strauss GM, *see* Kwiatkowski DJ
Strawderman MS, *see* Smith DC
Strobel T, *see* Tai Y-T
Strobl S, *see* Curti BD
Strongitharm D, *see* Andrulis IL
Strong LC, *see* Frank TS
Stroobants SG, *see* Vansteenkiste JF
Strupp J, *see* Gralla RJ
Stryckmans P, *see* Löwenberg B
Stuart G, *see* Hoskins P
Stupp R, *see* Brockstein B
Sturgeon J, *see* Warde P
Stuschke M, *see* Eberhardt W

Stutzer CA, *see* Fernandez CV
Subramanian R, *see* Serafini AN
Suciu S, *see* Koops HS
— *see* Löwenberg B
Suckow CW, *see* Dezube BJ
Sugano D, *see* Cole BF
— *see* Zee B
Sugarbaker DJ, *see* Kwiatkowski DJ
Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL. Preclinical and clinical studies of bone marrow uptake of fluorine-18-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy, 173
Sugimachi K, *see* Mori M
Sulkes A, Benner SE, Canetta RM. Uracil-ftorafur: An oral fluoropyrimidine active in colorectal cancer, 3461
Sullivan AM, *see* Watts MJ
Sulzen L, *see* Brockstein B
Sundin A, *see* Örlefors H
Suonio E, *see* Joensuu H
Surtees R, Clelland J, Hann I. Demyelination and single-carbon transfer pathway metabolites during the treatment of acute lymphoblastic leukemia: CSF studies, 1505
Susini T, Baldi F, Howard CM, Baldi A, Taddiei G, Massi D, Rapi S, Savino L, Massi G, Giordano A. Expression of the retinoblastoma-related gene Rb2/p130 correlates with clinical outcome in endometrial cancer, 1085
Sutcliff VE, *see* Gibril F
Sutherland D, *see* Andrulis IL
Sutton L, *see* Leblond V
Suzushima H, *see* Asou N
Svensson B, *see* Glimelius B
Svensson JH, *see* Glimelius B
Swan DK, *see* Barton DL
Swanson PE, *see* Ogunbiyi OA
Swerdlow SH, *see* Chen J
Swift P, *see* Matthay K
Sylvester R, *see* Kaye SB
Syrjala KL, Roth-Roemer SL, Abrams JR, Scanlan JM, Chapko MK, Visser S, Sanders JE. Prevalence and predictors of sexual dysfunction in long-term survivors of marrow transplantation, 3148
Syrjänen K, *see* Anttila M
Szer J, *see* Basser RL
Sznol M, *see* Curti BD
Szpirglas H, *see* Schrijvers D

Tabah I, *see* Ravaud A
Tada T, *see* Masuda N
Taddiei G, *see* Susini T
Tadrist Z, *see* Tourani J-M
Tai Y-T, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer, 2583
Tajima N, *see* Usui N
Takada Y, *see* Kudoh S
Takahashi M, *see* Asou N
Takashima S, *see* Yamamoto N
Takeda N, *see* Masuda N
Takei Y, *see* Usui N
Takeyama K, *see* Asou N
Takifuji N, *see* Masuda N
Taki T, *see* Adachi M
Takiuchi H, Ajani JA. Uracil-tegafur in gastric carcinoma: A comprehensive review, 2877
Taksin A-L, *see* Leblond V
Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: Results of a prospective cohort study, 275
Tallini G, Ghossein RA, Emanuel J, Gill J, Kinder B, Dimich AB, Costa J, Robbins R, Burrow GN, Rosai J. Detection of thyroglobulin, thyroid peroxidase, and *RET*/PTC1 mRNA transcripts in the peripheral blood of patients with thyroid disease, 1158
Tallman M, Hakimian D, Peterson LA. Massive splenomegaly in hairy cell leukemia, 1232
— *see* Cheson BD
Talpaz M, *see* Cortes J
— *see* Gandhi V
— *see* Kurzrock R
— *see* Rodriguez J
— *see* Sacchi S
Tamimura M, *see* Yamamoto K
Tamura J, *see* Asou N
Tamura T, *see* Furuse K
Tannehill SP, *see* Mehta MP
Tannock IF, *see* Bloomfield DJ
— *see* Phillips K-A
— *see* Siu LL
Tarbell NJ, *see* Dalton VMK
Tassinari D, Desiderio F, Ravaioli A, Sartori S. Patient-physician relationship and unproven therapies (letter), 3203
Tate DJ, *see* Wolden SL
Tattersall M. In reply (letter), 2283
Tavelin B, *see* Linderholm B
Taylor BV, Buckner JC, Cascino TL, O'Fallon JR, Schaefer PL, Dinapoli RP, Schomberg P. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma, 2195
Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, Robert NJ, Budd GT, Paradelo JC, Natale RB, Bearden JD, Mailliard JA, Osborne CK. Multicenter randomized clinical trial of goserelin *versus* surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: An intergroup study, 994
Taylor GA, *see* Rafi I
Taylor SA, *see* Kraut EH
— *see* Salmon SE
— *see* Wozniak AJ
Tedeschi L, *see* Santini G
Tedesco M, *see* Benevolo M
Temeck B, *see* Herscher LL
ten Bokkel Huinnink WW, *see* Bruno R
Tendler C, *see* Cole BF
— *see* Solal-Céligny P
Ten Haken RK, *see* McGinn CJ
ten Velde GPM, *see* Peters FPJ
Teodorovic I, *see* Tirelli U
Tepler I, *see* Seidman AD
Terenziani M, *see* Bonadonna G
Terés J, *see* Grau JJ
Terhardt-Kasten E, *see* Hiddemann W

Terol M-J, López-Guillermo A, Bosch F, Villamor N, Cid M-C, Rozman C, Campo E, Montserrat E. Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: Relationship with tumor dissemination and prognostic importance, 35
ter Schegget J, *see* Wisman GBA
Tertian G, *see* Decuadin D
— *see* Solal-Céligny P
Tesch H, *see* Diehl V
Testa MA, *see* Straus DJ
Testa NG, *see* Weaver A
Tester WR, *see* Shipley WU
Tetreault S, Abler SL, Robbins B, Saven A. Peripheral T-cell lymphoma after anti-CD20 antibody therapy (letter), 1635
Thalhammer-Scherrer R, *see* Laczika K
Thames HD, *see* Baumann M
Thatcher N, *see* Keilholz U
— *see* Steward WP
Theobald DE, *see* Passik SD
Théodore C, *see* Fizazi K
Theodoulou M, *see* Seidman AD
Therasse P, *see* Curran D
Theriault RL, *see* Hortobagyi GN
Thetter O, *see* Pantel K
Theunissen PH, *see* Somers VA
Thiede C, Alpen B, Morgner A, Schmidt M, Ritter M, Ehninger G, Stolte M, Bayerdörffer E, Neubauer A. Ongoing somatic mutations and clonal expansions after cure of *Heliobacter pylori* infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma, 3822
Thiel H-J, *see* Wendt TG
Thiessen JJ, *see* Siu LL
Thiriaux J, *see* Sculier J-P
Thomas A, *see* Frank TS
Thomas CR Jr, Williams TE, Turrisi AT III. Don't be mis-guided when the data are silent and the editorial misses the mark (letter), 1631
Thomas FD, *see* Serafini AN
Thomas J, *see* Hagenbeek A
— *see* Lundin J
— *see* Tirelli U
Thomas M, *see* Hainsworth JD
Thomas PJ, *see* Langevin A-M
Thomas PR, *see* Green DM
— *see* Mulhern RK
Thomas R, *see* Ciarmiello A
Thommes JA, *see* Northfelt DW
Thompson E, *see* Loeffler M
Thompson EI, *see* Hudson MM
Thompson JF, *see* Koops HS
Thorner PS, *see* Katzenstein HM
Thorstad WL, *see* Bigner DD
Thunnissen FB, *see* Peters FPJ
— *see* Somers VA
Thuot CA, *see* Shepherd F
Thyss A, *see* Blay J-Y
— *see* Löwenberg B
— *see* Pein F
Tiemann M, *see* Hiddemann W
Tienghi A, *see* Bacci G
Tilgner J, *see* Reichardt P
Timmons TM, *see* Clayman GL
Tinazzi A, *see* Fossati R
Tindle S, *see* Desikan KR
Tirelli U, Errante D, Van Glabbeke M, Teodorovic I, Kluin-Nelemans JC, Thomas J, Bron D, Rosti G, Somers R, Zagonel V, Noordijk EM. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgin's lymphoma: Results of a randomized study of the European Organization for research and treatment of cancer lymphoma cooperative study group, 27
Tishler RB, *see* Colevas AD
Tjabbes T, *see* Dombernowsky P
Tjan-Heijnen VCG, Biesma B, Festen J, Splinter TAW, Cox A, Wagener DJT, Postmus PE. Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma, 2708
Tjong-A-Hung SP, *see* Wisman GBA
Tokue Y, *see* Yamamoto N
To LB, *see* Basser RL
Tomaszewski JE, *see* D'Amico AV
Tomlinson GE, *see* Oeffinger KC
Tompkins A, *see* Senderowicz AM
Toner G, *see* Zalcberg J
Toner GC, Shapiro JD, Laidlaw CR, Rischin D, Millward MJ, Wolf M, Januszewicz H, Mitchell SV, Curran AC, Matthews JP, Bishop JF. Low- *versus* standard-dose lenograstim prophylaxis after chemotherapy: A randomized, crossover comparison, 3874
Tong W, *see* Seidman AD
Topalian SL, *see* Yang JC
Toppmeyer D, *see* Villalona-Calero MA
Tormey DC, *see* Mansour EG
Torri J, *see* Wojtowicz-Praga S
Torri V, *see* Fossati R
Tourani J-M, Pfister C, Berdah J-F, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch J-M, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu J-M, Chastang C. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study, 2505
Tournade MF, *see* Pein F
Townsend JJ, *see* Jaeckle KA
Tran K, *see* Amatruda JF
Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriguez R, Drobins P, Miller W Jr, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J, Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study, 3524
Tricot G, *see* Desikan KR
Trigg ME, *see* Heerema NA
— *see* Hutchinson RJ
— *see* Nachman J
Tripathy D, *see* Pegram MD
Trippoli S, *see* Messori A
Trope CG, *see* Hofstra LS
Trotta P, *see* Wadler S
True LD, *see* Shipley WU
Trueworthy R, *see* Smith M
Trümper L, *see* Hiddemann W

Trunet PF, Bhatnagar A, Chaudri HA. In reply (letter), 2892
— *see* Dombernowsky P
Tsang V, *see* Westeel V
Tseng C-h, *see* Gershenwald JE
Tsubaki K, *see* Asou N
Tsui CC, *see* Yu AL
Tsuji K, *see* Mori M
Tsuji T, *see* Adachi M
Tuck D, *see* Welles L
Tu D, *see* Levine M
Tulpule A, Yung RC, Wernz J, Espina BM, Myers A, Scadden DT, Cabriales S, Ilaw M, Boswell W, Gill PS. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma, 3369
Tura S, *see* Zinzani PL
Turrisi AT, *see* Thomas CR Jr
Tursz T, *see* Fizazi K
Tutsch KD, *see* Berlin J
Twaddell T, *see* Pegram MD
Twelves C, *see* Mackean M

Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, Steinherz PG, Kraft P, Hutchinson R, Nachman JB, Reaman GH, Heerema NA. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group, 527
— *see* Heerema NA
Ueno NT, Rondón G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Körbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagyi GN, Champlin RE. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer, 986
— *see* Khouri IF
Ueo H, *see* Mori M
Ulbright TM, *see* Leibovitch I
Umezawa S, *see* Shimizu Y
Unger JM, *see* Margolin KA
Ungerleider R, *see* Smith M
Untereiner M, *see* Tourani J-M
Unterhalt M, *see* Hiddemann W
Uppenkamp M, *see* Lundin J
Urban C, *see* Benesch M
Ushijima S, *see* Masuda N
Usui N, Dobashi N, Kobayashi T, Yano S, Maki N, Asai O, Saito T, Yamaguchi Y, Watanabe H, Kato A, Ogihara A, Katori M, Nagamine M, Takei Y, Yamazaki H, Funakoshi S, Tajima N, Ogawa M, Kuraishi Y. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia, 2086
Utsugi K, *see* Shimizu Y
Uttenreuther-Fischer MM, *see* Yu AL

Vaglini M, *see* Koops HS
Vahdat L, *see* Hesdorffer C
Valagussa P, *see* Bonadonna G
Valdez I, *see* Haddy TB
Valdivia S, *see* Gómez H
Valentine AD, *see* Meyers CA
Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA III. A phase II study of docataxel in patients with pactitaxel-resistant metastatic breast cancer, 3362
— *see* Bruno R
Validire P, *see* Lombard I
Valk P, *see* Lowe VJ
Valk PE, *see* Gambhir SS
Vallejos C, *see* Gómez H
Valteau-Couanet D, *see* Pein F
Valverde B, *see* Ciudad J
van Besien K, *see* Popat U
— *see* Ueno NT
Van Custem E, *see* Cocconi G
Van den Abbeele A, *see* Wu C
Vandenberg T, *see* Levine M
Van den Bogaert W, *see* Weltens C
van den Broek L, *see* Clahsen PC
Van Der Lelie H, *see* Guglielmi C
van der Lelie J, *see* Löwenberg B
Van der Putte SCJ, *see* Geelen FAMJ
van der Zee AGJ, *see* Wisman GBA
van de Velde CJH, *see* Clahsen PC
van de Vijver MJ, *see* Clahsen PC
Van Glabbeke M, *see* Tirelli U
van Glabbeke M, *see* Hagenbeek A
van Groeningen C, *see* Fosså SD
— *see* Kaye SB
van Halteren HK, Peters H, Gerlag PGG. Large bowel mucosal metastases from breast cancer, 3711
van Hazel G, *see* Cocconi G
van Hoesel Q, *see* Giaccone G
van Hoof A, *see* Hagenbeek A
van Meerbeeck J, *see* Curran D
— *see* Giaccone G
Vannier JP, *see* Pein F
van Oosterom AT, *see* Bruno R
Van Poznak C, *see* Gulati SC
van Putten WLJ, *see* Berns EMJJ
— *see* Foekens JA
Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, Deneffe GJ, Nackaerts KL, Verschakelen JA, Lerut TE, Mortelmans LA, Demedts MG. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: A prospective study on 690 lymph node stations from 68 patients, 2142
van Zandwijk N, *see* Giaccone G
Varterasian ML, Mohammad RM, Eilender DS, Hulburd K, Rodriguez DH, Pemberton PA, Pluda JM, Dan MD, Pettit GR, Chen BDM, Al-Katib AM. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 56
Vasa S, *see* Lindley C
Vasconcelles M, *see* Wu C
Vassal G, *see* Saliba F
— *see* Smith M
Vasselli S, *see* Benevolo M
Vaughan WP, *see* Edwards MJ
Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, Armstead B, Fox K, Wein A. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regimen, 255

Vaught NL, *see* Barton DL
— *see* Sloan JA
Veeder MH, *see* Barton DL
Velagapudi R, *see* Villalona-Calero MA
Veltri E, *see* Gridelli C
Vena D, *see* Cheson BD
Venkatraman E, *see* Aghajanian C
Venner PM, *see* Shipley WU
Venne V, *see* Frank TS
Vennin P, *see* Eisinger E
Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264, 1811
Venuat A-M, *see* Decuadin D
Venzon DJ, *see* Gibril F
Vermeer MH, *see* Geelen FAMJ
Veronesi U, *see* Zucali R
Verschakelen JA, *see* Vansteenkiste JF
Verweij J, *see* Bruno R
— *see* Mackean M
— *see* Steward WP
Vesole DH, *see* Desikan KR
Vespignani M, *see* Santini G
Vezina LG, *see* Nicholson HS
Viallet J, *see* Treat J
Vici P, *see* Lopez M
Vick NA, *see* Bigner DD
Vidriales B, *see* Ciudad J
Vietti T, *see* Langevin A-M
— *see* Saylors RL III
— *see* Smith M
Villablanca JG, *see* Ozkaynak MF
Villalba L, *see* Senderowicz AM
Villalona-Calero MA, Baker SD, Hammond L, Aylesworth C, Eckhardt SG, Kraynak M, Fram R, Fischkoff S, Velagapudi R, Toppmeyer D, Razvillas B, Jakimowicz K, Von Hoff DD, Rowinsky E. Phase I and pharmacokinetic study of the water-soluble dolastatin 15 analog LU103793 in patients with advanced solid malignancies, 2770
Villalona M, *see* Rowinsky E
Villamor N, *see* Terol M-J
Vimercati R, *see* Santini G
Vincent-Salomon A, *see* Lombard I
Vindevoghel A, *see* Hofstra LS
Visa J, *see* Grau JJ
Visani G, *see* Löwenberg B
Visch LL, *see* Levendag PC
Visser AG, *see* Levendag PC
Visser S, *see* Syrjala KL
Vivier N, *see* Bruno R
Vivino LL, *see* Haddy TB
Vlamis V, *see* Bajorin DF
Vogel V, *see* Audrain J
Vogelzang NJ, *see* Daugherty CK
— *see* Nichols CR
— *see* Stadler WM
Vogt J, *see* Pantel K
Vokes E, *see* Brockstein B
— *see* Fleming GF
— *see* Kies MS
— *see* Masters GA
— *see* Mauer AM
— *see* Schrijvers D
— *see* Wadler S
von Eiff M, *see* Steward WP
Von Hoff DD, *see* Rowinsky E
— *see* Schilsky RL
— *see* Valero V
— *see* Villalona-Calero MA
von Kalle K, *see* Diehl V
von Pawel J, *see* Steward WP
von Roemeling R, *see* Treat J
Von Roenn JH, *see* Dezube BJ
von Rohr A, *see* Betticher DC
von Wolff B, *see* Khouri IF
Vose JM, Bierman PJ, Lynch JC, Weisenburger DD, Kessinger A, Chan WC, Greiner TC, Armitage JO. Effect of follicularity on autologous transplantation for large-cell non-Hodgkin's lymphoma, 844
Vredenburgh JJ, *see* Laughlin MJ
Vriesendorp HM. The next (third) dimension to dosing of anticancer agents, 3715
Vukov AM, *see* Galanis E
— *see* O'Connell MJ
Vuong T, *see* Al-Sarraf M

Wacker P, *see* Shuster JJ
Wade J, *see* Demetri G
— *see* Kraut EH
Wadler S, Benson AB III, Engelking C, Catalano R, Field M, Kornblau SM, MItchell E, Rubin J, Trotta P, Vokes E. Recommended guidelines for the treatment fo chemotherapy-induced diarrhea, 3169
Wagener DJT, *see* Tjan-Heijnen VCG
Wagner H, *see* Mehta MP
Wagner J-P, *see* Blay J-Y
Wahl RL, *see* Macfarlane DJ
— *see* Sugawara Y
Wainman N, *see* Siu LL
Waisman JR, *see* Silverstein MJ
Walde D, *see* Latreille J
Walker MJ, *see* Margolin KA
Walker S, *see* McGinn CJ
Wallace K, *see* Spiridonidis CH
Wall DA, *see* Saylors RL III
Walsh G, *see* Eisen T
— *see* Ellis P
Walter AW, Hancock ML, Pui C-H, Hudson MM, Ochs JS, Rivera GK, Pratt CB, Boyett JM, Kun LE. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital, 3761
Walzman R, *see* Aghajanian C
Wang H-J, *see* Hoon DSB
Wang S, *see* McGinn CJ
Wang Y-M, *see* Rowinsky E
Wanke LA, *see* Payne R
Wannenmacher M, *see* Pirzkall A
Ward BE, *see* Frank TS
Warde P, Gospodarowicz M, Panzarella T, Catton C, Sturgeon J, Moore M, Jewett M. Management of stage II seminoma, 290
— *see* Bloomfield DJ
Ward M, *see* Hesdorffer C

Warr D, *see* Latreille J
— *see* Levine M
Warren D, *see* Ayash LJ
Watanabe H, *see* Usui N
Watanabe K, *see* Furuse K
Watanabe T, *see* Yamamoto N
Watson P, *see* Lynch HT
Watson SM, *see* Mauer AM
Watts MJ, Sullivan AM, Leverett D, Beniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization, 1554
Weathers T, *see* Loehrer PJ Sr
Weaver A, Chang J, Wrigley E, de Wynter E, Woll PJ, Lind M, Jenkins B, Gill C, Wilkinson PM, Pettengell R, Radford JA, Collins CD, Dexter TM, Testa NG, Crowther D. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer, 2601
Weber B, *see* Blackwood MA
— *see* Frank TS
— *see* Pegram MD
Weber M. Sharing information with patients (letter), 2283
Webster K, *see* Markman M
Weeks JC, *see* Guadagnoli E
— *see* Hayman JA
— *see* Talcott JA
Weese JL, *see* Hoffman JP
Weichselbaum RR, *see* Brockstein B
— *see* Kies MS
Wei-Ling X, *see* Anttila M
Wein A, *see* D'Amico AV
— *see* Vaughn DJ
Weinberger M, *see* Bennett CL
Weinberg VK, *see* Matthay K
Weiner MA, *see* Marcus RB
Weinhous M, *see* Macklis R
Weisenburger DD, *see* Armitage JO
— *see* Vose JM
Weisman C, *see* Tai Y-T
Weiss GR, *see* Margolin KA
— *see* Wozniak AJ
Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia, 1885
— *see* Byrd JC
Weitman ST, *see* Langevin A-M
Weitzner MA, *see* Meyers CA
Weizel H, *see* Andrulis IL
Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I, Figg WD, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW, Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma, 1112
Wells RJ. Secrecy for data monitoring committees: Inferior ethics, bad policy (letter), 390
Weltens C, Van den Bogaert W. Radiotherapy error analysis older than yesterday (letter), 2288
Wendt TG, Grabenbauer GG, Rödel CM, Thiel H-J, Aydin H, Rohloff R, Wustrow TPU, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy *versus* radiotherapy alone in advanced head and neck cancer: A randomized multicenter study, 1318
Wenig B, *see* Kies MS
Wernz J, *see* Tulpule A
Westeel V, Murray N, Gelmon K, Shah A, Sheehan F, McKenzie M, Wong F, Morris J, Grafton C, Tsang V, Goddard K, Murphy K, Parsons C, Amy R, Page R. New combination of the old drugs for elderly patients with small-cell lung cancer: A phase II study of the PAVE regimen, 1940
Westerhausen M, *see* Köhne C-H
Wey K, *see* McLaughlin P
Whalen T, *see* Hutchinson RJ
Whang W, *see* Grann VR
Wharam M, *see* Grossman SA
Wheeler C, *see* Ayash LJ
Wheeler H, *see* Hortobagyi GN
Whitcup SM, *see* Sandor V
White CA, *see* McLaughlin P
White P Jr, *see* Groeger JS
Whitmore JB, *see* Meropol NJ
Whittington R, *see* D'Amico AV
Wibault P, *see* De Crevoisier R
Wickerham DL, *see* Fisher B
— *see* Fisher B
Widschwendter M, *see* Zeimet AG
Wieand HS, *see* O'Connell MJ
Wiernik P, *see* Loeffler M
Wikstrand CJ, *see* Bigner DD
Wilcox P, *see* Geller G
Wilding G, *see* Berlin J
Wild LD, *see* Mehta RR
Wilimas JA, *see* Hudson MM
Wilke H, *see* Eberhardt W
— *see* Köhne C-H
Wilkinson PM, *see* Weaver A
Wilkinson R, *see* Andrulis IL
Willan AR, *see* Bloomfield DJ
Willemse PHB, *see* Hofstra LS
Willemze R, *see* Geelen FAMJ
— *see* Lundin J
Willenbacher W, Mumm A, Bartsch H-H. Late pulmonary toxicity of bleomycin (letter), 3205
Willett C, *see* Minsky BD
Williams C, *see* Latreille J
— *see* Levine M
Williams CD, *see* Watts MJ
Williams GM. Differences in toxicity findings for antiestrogens (letter), 1999
Williams ME, *see* McLaughlin P
Williams R, *see* Payne R
Williams RD, *see* Kahn D
Williams T, *see* Choy H
Williams TE, *see* Thomas CR Jr
Willman K, *see* Berns EMJJ
Wilsgaard T, *see* Risberg T
Wils J, *see* Grimaldi C
Wilson J, *see* Ratliff AF
Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD, Humphrey R, Kohler DR, Elwood P. Phase II and dose-escalation with or without granulocyte colony-stimulating factor

study of 9-aminocamptothecin in relapsed and refractory lymphomas, 2345
— *see* Little R
— *see* Welles L
Wiltshaw E, *see* Gore M
Winer EP, *see* Frank TS
— *see* Lindley C
Wingate P, *see* Akerley W
Winick N, *see* Kamen BA
— *see* Mahoney DH Jr
— *see* Ratliff AF
Winkelmann W, *see* Paulussen M
Winnerlein-Trump E, *see* Diehl V
Winquist EW. Radiation therapy for stage II seminoma (letter), 1999
Winter KA, *see* Shipley WU
Wishnow KI, *see* Talcott JA
Wisman GBA, Hollema H, de Jong S, ter Schegget J, Tjong-A-Hung SP, Ruiters MHJ, Krans M, de Vries EGE, van der Zee AGJ. Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear, 2238
Wissing S, *see* Paulussen M
Wist E, *see* Risberg T
Witte J, *see* Riethmüller G
Wittes R, *see* Little R
— *see* Sandor V
Wojtowicz-Praga S, Torri J, Johnson M, Steen V, Marshall J, Ness E, Dickson R, Sale M, Rasmussen HS, Chiodo TA, Hawkins MJ. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer, 2150
Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin's disease, 536
—, Donaldson SS, Lamborn KR. In reply (letter), 2288, 2571
Wolfe T, *see* Zelefsky MJ
Wolff BG, *see* Serafini AN
Wolff K, *see* Pehamberger H
Wolff L, *see* Nachman J
Wolff RA, *see* Pisters PWT
Wolfinger RD, *see* Leibman BD
Wolf M, *see* Toner GC
Wollner N, *see* Kushner BH
Woll P, *see* Steward WP
Woll PJ, *see* Weaver A
Wolmark N, *see* Fisher B
Wöltjen H-H, *see* Hiddemann W
Womer R, *see* de Alava E
Wong F, *see* Westeel V
Wong N, *see* Foulkes WD
Wood DE, *see* Meropol NJ
Wood ME, *see* Frank TS
Work E, Nielsen OS, Bentzen SM, Fode K, Palshof T. In reply (letter), 1634
— *see* Bentzen SM
Wormann B, *see* Wulf G
Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Spiridonidis CH, Baker LH, Albain KS, Kelly K, Taylor SA, Gandara DR, Livingston RB. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study, 2459
Wright FA, *see* Hryniuk W
Wrightson WR, *see* Edwards MJ
Wrigley E, *see* Weaver A
Wu CJ, Scadden DT. Posttransplant Kaposi's sarcoma treated with paclitaxel (letter), 3478
—, Vasconcelles M, DePiro P, Van den Abbeele A, Rakusin A, Bechard K, Skarin A. Primary cardiac angiosarcoma presenting as a malignant pericardial effusion, 3913
Wuest D, *see* Aghajanian C
Wulf G, Reichard U, Wormann B, Hiddemann W. *Pneumocystis carinii* pneumonia with peripheral nodular infiltrated in a patient with T-acute lymphoblastic leukemia, 3476
— *see* Diehl V
Wunder J, *see* de Alava E
Wustrow TPU, *see* Wendt TG
Wyatt GE, *see* Ganz PA
Wynant GE, *see* Serafini AN
Wyvill KM, *see* Welles L

Xu H-J, *see* Kwiatkowski DJ

Yahalom J, *see* Abrey LE
— *see* Schechter NR
Yakoub-Agha I, *see* Leblond V
Yamada O, *see* Asou N
Yamaguchi Y, *see* Usui N
Yamamoto H, *see* Kudoh S
Yamamoto K, Hanada R, Kikuchi A, Ichikawa M, Aihara T, Oguma E, Moritani T, Shimanuki Y, Tanimura M, Hayashi Y. Spontaneous regression of localized neuroblastoma detected by mass screening, 1265
Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Tokue Y, Narabayashi M, Adachi I, Takashima S. Construction and validation of a practical prognostic index for patients with metastatic breast cancer, 2401
Yamazaki H, *see* Usui N
Yana T, *see* Masuda N
Yang C-T, Lee M-H, Lan R-S, Chen J-K. Telomerase activity in pleural effusions: diagnostic significance, 567
Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity, 197
Yano S, *see* Usui N
Yarchoan R, *see* Welles L
Yarnold J, *see* Recht A
Yarosh DB, *see* Jaeckle KA
Yates A, *see* Dunkel IJ
Yates R, *see* Hoctin-Boes G
Ybanez J, *see* Cooper BW
Ychou M, *see* Bécouarn Y
Yee L, *see* Akerley W
Yeh SJ, *see* Cheung N-KV
Yelle L, *see* Latreille J
Yen R-F, *see* Kao C-H
Yen T-C, *see* Kao C-H
Yeo W, Johnson PJ. Bleomycin cutaneous toxicity, 1626
Younes A. Paclitaxel for the treatment of lymphoma (letter), 2289
— *see* Khouri IF
Young A, *see* Christodoulou CV
Young ML, *see* Glick JH

Yu AL, Uttenreuther-Fischer MM, Huang C-S, Tsui CC, Gillies SD, Reisfeld RA, Kung FH. Phase I trial of human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma, 2169
Yu F, *see* Gibril F
Yu H, *see* Levesque MA
Yung RC, *see* Tulpule A

Zacharias C, *see* Sculier J-P
Zacharski LL, *see* Ahles TA
Zacherl J, *see* Rosen HR
Zafrani B, *see* Lombard I
Zagonel V, *see* Tirelli U
Zahasky KM, *see* Loprinzi CL
Zahos K, *see* Pecora AL
Zalcberg J, Milward M, Bishop J, McKeage M, Zimet A, Toner G, Friedlander M, Barter C, Rischin D, Loret C, James R, Bougon N, Berille J. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer, 1948
Zalutsky MR, *see* Bigner DD
Zambaldi G, *see* Santini G
Zambetti M, *see* Bonadonna G
Zamboni WC, *see* Saylors RL III
Zamora P, *see* Arranz R
Zampino G, *see* Colleoni M
Zasadny KR, *see* Sugawara Y
Zea A, *see* Curti BD
Zee B, Cole B, Li T, Browman G, James K, Johnston D, Sugano D, Pater J. Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma, 2834
—, James K, Pater J. In reply (letter), 3718
— *see* Hoskins P
— *see* Latreille J
— *see* Osoba D
Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Müller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C. Ascitic interleukin-12 is an independent prognostic factor in Ovarian cancer, 1861
—, Widschwendter M, Daxenbichler G, Skovlund E, Marth C. In reply (letter), 3208
Zelefsky MJ, Lyass O, Fuks Z, Wolfe T, Burman C, Ling CC, Leibel SA. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy, 3380
Zelenetz AD, *see* Mann GB
Zhao X-G, *see* Bigner DD
Zhukovsky D, *see* Kaplan R
Zimet A, *see* Zalcberg J
Zinzani PL, Pileri S, Bendandi M, Buzzi M, Sabattini E, Ascani S, Gherlinzoni F, Magagnoli M, Albertini P, Tura S. Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: Results from a prospective, multicenter trial with double randomization, 1532
Zippelius A, Riethmüller G, Pantel K. In reply (letter), 806
Zittoun R, *see* Löwenberg B
Zoltick B, *see* Vaughn DJ
Zon RT, Nichols C, Einhorn LH. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels, 1294
Zoubek A, *see* Paulussen M
Zuber M, *see* Eppenberger U
Zucali R, Mariani L, Marubini E, Kenda R, Lozza L, Rilke F, Veronesi U. Early breast cancer: Evaluation of the prognostic role of the site of the primary tumor, 1363
Zucker JM, *see* Fagnou C
— *see* Pein F
Zulian GB, *see* Betticher DC
Zumstein LA, *see* Clayman GL
Zunic P, *see* Fouillard L

SUBJECT INDEX

ABV. *See* Doxorubicin, bleomycin, vincristine regimen
ABVD. *See* Adriamycin, bleomycin, vinblastine, dacarbazine regimen
Access to quality cancer care, AFCOS consensus statement on, 1628-1629, 2001
Acetorphan and loperamide, for irinotecan-induced delayed-onset diarrhea, 2745-2751
Acquired immune deficiency syndrome (AIDS)
  Burkitt-like lymphomas in, 3788-3795
  Kaposi's sarcoma in
    fumagillin analog for, 1444-1449
    interferon alfa with zidovudine for, 1736-1742
    paclitaxel for, 1112-1121
    pegylated liposomal doxorubicin *v* bleomycin and vincristine for, 683-691
    pegylated liposomal doxorubicin *v* doxorubicin, bleomycin, and vincristine for, 2445-2451
    pulmonary, liposomal daunorubicin for, 3369-3374
  non-Hodgkin's lymphoma in
    characterization of, 3788-3795
    prognostic factors for, 3601-3606
Acute lymphoblastic leukemia
  childhood
    anthracycline dose in, and late cardiotoxicity, 545-550
    bone mass after treatment of, 3752-3760
    cytogenetic abnormalities in, 1270-1278
    high-risk, intrathecal chemotherapy with/without cranial radiation for, 920-930
    in vitro cytotoxicity of docetaxel in, 907-913
    lower-risk B-lineage, intensive IV methotrexate/IV mercaptopurine regimen for, 246-254, 2283-2285
    myeloid-associated antigen expression in, 3768-3773
    residual disease in, detection with fluorescent PCR, 3616-3627
    secondary brain tumors after, 3761-3767
    translocation t(1;19) in, 527-535
  minimal residual disease
    immunophenotypic detection of, 3774-3781
    prognostic significance of, 3774-3781
  Philadelphia-positive, unrelated donor bone marrow transplantation for, 931-936

T-lineage
cytogenetic abnormalities in, 1270-1278
GW506U78 in, pharmacokinetics and response to, 3607-3615
Pneumocystis carinii pneumonia and peripheral nodular infiltrates with, 3476-3477
relapsed, *p53* mutations in, prognostic significance of, 3164
treatment, demyelination and single-carbon transfer pathway metabolites during, 1505-1511
Acute lymphocytic leukemia, childhood
antimetabolite-based therapy for, 2840-2847
B-precursor, significance of sex in, 2854-2863
interaction of prognostic factors in, 2854-2863
second malignancies after treatment for, 2848-2853, 3761-3767, 3917-3918
significance of sex in, 2854-2863
Acute lymphoid leukemia, childhood, acute neurotoxicity in, association with IV methotrexate and intrathecal triple therapy, 1712-1722
Acute myelogenous leukemia
adult, nucleolar organizer region counts in, prognostic significance of, 1512-1518
childhood, consolidation chemotherapy for, IL-2 after, 914-919
congenital, with cutaneous involvement, 3199-3200
Acute myeloid leukemia
adult, induction therapy for, daunorubicin in, 2086-2092
childhood, in vitro cytotoxicity of docetaxel in, 907-913
in elderly, 872-881
postremission therapy in, 872-881
remission-induction chemotherapy in, 872-881
with inversion(16), postremission chemotherapy for, competitive RT-PCR for molecular monitoring during, 1519-1525
mitoxantrone and low-dose cytarabine in, 872-881
p53 mutations in, prognostic significance of, 3163-3164
therapy-related
after high-dose etoposide, 3386-3391
inversion of chromosome 16 and *CBFB* and *MYH11* gene rearrangements in, 1890-1896
Acute promyelocytic leukemia. *See* Leukemia(s), acute promyelocytic
Adeno-associated virus, as gene transfer vector, 2548-2556
Adenocarcinoma, hepatic metastases, 2105-2112
Adenoviral vectors, for gene transfer, 2548-2556
Adhesion molecules. *See also* Intercellular adhesion molecule-1
CD44s, downregulation, in prostatic adenocarcinoma, 1302-1309
Adjuvant chemohormonal therapy, for breast cancer, 3486-3492
Adjuvant chemotherapy
for brain tumors, influence of surgical resection on, 389-390
for breast cancer
doctor/patient communication about, 515-521
effect on recurrence and survival, 3486-3492
fatigue after, 1689-1696
patients' knowledge and expectations of, 515-521
response to, p53 accumulation and, 470-479
for colon cancer
with 5-FU, leucovorin, levamisole regimen, 295-300
6-month *v* 12-month course of, 295-300
for gastric cancer, postoperative, with mitomycin-ftorafur *v* mitomycin alone, 1036-1039, 3714
for invasive bladder cancer, 1601-1612
Adjuvant radiotherapy. *See* Radiotherapy, adjuvant
Adjuvant therapy
for breast cancer, quality of life and preferences for treatment after, 1380-1387
with interferon alfa-2a, in resected primary stage II cutaneous melanoma, 1425-1429, 3205-3206
Adolescent(s). *See* Children and adolescents
Adriamycin. *See* Doxorubicin
Adriamycin, bleomycin, vinblastine, dacarbazine regimen
for advanced Hodgkin's disease, 19-26, 2283
plus MOPP, in advanced pediatric Hodgkin's disease, 897-906
plus radiation, in advanced pediatric Hodgkin's disease, 897-906
Adults, cancer care for, evolution of, 2904-2905
Age
of infant with stage D(S) neuroblastoma, prognostic significance of, 2007-2017
and metastatic melanoma, prognostic significance of, 1103-1111
prognostic significance of
in acute promyelocytic leukemia, 78-85
in breast cancer, 2686-2692, 2693-2699
in premenopausal women with node-negative breast cancer, 470-479
and treatment-related death in NHL, 2065-2069
AIDS Clinical Trials Group
findings on fumagillin analog for AIDS-related Kaposi's sarcoma, 1444-1449
Protocol 142 in HIV-associated non-Hodgkin's lymphoma, 3601-3606
Albumin, serum levels in metastatic melanoma, prognostic significance of, 1103-1111
Alcohol, and tongue carcinoma, 745-753
O^6-Alkylguanine-DNA alkyltransferase
activity, O^6-benzylguanine effects on, 1803-1810
in glioma, prognostic significance of, 3851-3857
Alternative medicine. *See also* Nonproven therapies
patients' interest in, management of, 1-2, 3203
use in pediatric oncology patients, 1279-1286
American Federation of Clinical Oncology Societies
consensus statement on access to quality cancer care, 1628-1629, 2001
member institutions, 1630, 2001
mission statement, 1630
American Society of Clinical Oncology
on cancer care during last phase of life, 1986-1996
current status and future challenges for (Presidential Address, 1998), 3191-3198
future of, 380-386
history of, 380-386
plenary session, presentations at, 3478
Presidential Address, 1998, 3191-3198
Presidential Address, May 1996, 380-386
recommendations for use of tumor markers in breast and colorectal cancer (1997 update), 793-795
training resource document for curriculum development in medical oncology, 372-379
Amifostine
clinical trials of, design and interpretation of, 3179-3190
salivary gland protection by, in radioiodine treatment, 3542-3549
9-Aminocamptothecin
colloidal dispersion, dosage and schedule, phase I and pharmacologic study of, 1122-1130
in lymphomas, efficacy and maximum dose-intensity for, with/without G-CSF support, 2345-2351, 2895
in oral chemotherapy, 2563
for solid tumors in children, 2494-2499

Aminopterin, for refractory malignancies, 1458-1464
Anal cancer
  radiochemotherapy in, *v* optimal radiotherapy alone, 802-803
  squamous cell, advanced, gemcitabine and docetaxel regimen for, 3866-3873
Anaphylactoid reaction, to granulocyte colony-stimulating factor, in normal stem-cell donor, 812-813
Anemia, epoetin beta for, in gastrointestinal cancer patients, 434-440
Angiogenesis inhibitor, in treatment of AIDS-related Kaposi's sarcoma, 1444-1449
Angiogenin, in node-negative breast cancer, prognostic significance of, 3129-3136
Angiosarcoma, cardiac, presenting as malignant pericardial effusion, 3913-3915
Anthracyclines
  cardiotoxicity of
    assessment of, radioimmunoscintigraphy for, 86-92
    late, after treatment for childhood cancer, 545-550
    protection against, dexrazoxane for, 86-92
  dose, in treatment of childhood cancer, and late cardiotoxicity, 545-550
Antiandrogen therapy, for unresectable hepatocellular carcinoma, evaluation of, 411-417
Antiemetic(s)
  dexamethasone as, in prevention of cisplatin-induced acute emesis, 2937-2942
  granisetron as
    effectiveness and safety of, 754-760
    institutional guidelines for use of, 771-778
  ondansetron as
    effectiveness and safety of, 754-760
    institutional guidelines for use of, 771-778
  serotonin antagonist. *See also* Granisetron; Ondansetron
    institutional guidelines for use of, 771-778
Antiestrogens, for breast cancer, comparison of, 348-353, 1999-2000
Antisense therapy, for lung cancer, potential molecular targets in, 1207-1217
Apoptosis
  and chemoresponsiveness of ovarian cancer, 2577-2578, 2583-2590, 3211
  failure of, in neoplasia, 2577-2578, 2583-2590, 3211
Arm problems, in breast cancer survivors, 487-494
Aromatase inhibitor, oral, for advanced breast cancer, 453-461, 2892-2893
ASCO. *See* American Society of Clinical Oncology
Askin tumor
  clinical presentation of, 1997-1998
  diagnosis of, 1997-1998
Astrocytoma
  anaplastic, Temodal in, 3851-3857
  high-grade, response to treatment, dimensions used in evaluation of, 1234, 2291-2292
  O^6 methylguanine-DNA methyltransferase levels in, prognostic significance of, 3310-3315
  pediatric, recurrent, temozolomide for, 3037-3043
  surgical resection of, effects on adjuvant therapy and outcome, 389-390
Austrian Working Group for Surgical Oncology, findings on adjuvant intraperitoneal chemotherapy for gastric cancer, 2733-2738
Autologous bone marrow transplantation. *See* Bone marrow transplantation, autologous
Autologous stem-cell support. *See* Stem-cell support, autologous
Axillary node status, as predictive factor in chemotherapy for operable breast cancer, 107-114

BAX protein, expression, and outcome in ovarian cancer, 2577-2578, 2583-2590, 3211
BCL-2 protein family, and regulation of programmed cell death after chemotherapy, 2577-2578, 2583-2590, 3211
BCNU. *See* Carmustine
BCR-ABL transcripts, RT-PCR for, in long-term follow-up of IFN-α treatment for CML, 1526-1531
BCV. *See* Carmustine, cyclophosphamide, etoposide regimen
BEACOPP. *See* Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone regimen
O^6-Benzylguanine
  in humans, metabolic, pharmacokinetic, and pharmacodynamic findings on, 1803-1810
  preoperative administration of, for glioma, 3570-3575
BEP. *See* Bleomycin, etoposide, cisplatin regimen
BEP/EP. *See* Bleomycin, etoposide, cisplatin/etoposide, cisplatin regimen
Biliary cancer, anemia with, epoetin beta for, 434-440
Biricodar. *See* VX-710
Bisphosphonates
  analgesic effects, with metastatic bone pain, 3890-3899
  current use in oncology, 3890-3899
  in multiple myeloma therapy, evidence-based review of, 1218-1225, 3204-3205
  in treatment of bone metastases, 3890-3899
    evidence-based review of, 1218-1225, 3204-3205
Blacks, lung cancer in, 651-657
Bladder cancer
  advanced, gemcitabine and docetaxel regimen for, 3866-3873
  invasive
    adjuvant chemotherapy for, 1601-1612
    neoadjuvant chemotherapy and bladder-sparing surgery for, 1298-1301
  neoadjuvant chemotherapy for, in bladder preservation, 3576-3583
  superficial, extravesical tumor relapse in, 1099-1102
Bladder preservation, with invasive bladder cancer, 1298-1301
Bladder symptoms, after early prostate cancer treatment, 275-283
Bleomycin
  cutaneous toxicity of, 1625-1627
  for nonseminomatous germ cell tumors, cure rate *v* morbidity with, 799-800
  pulmonary toxicity of, late, 3205
Bleomycin, etoposide, cisplatin/etoposide, cisplatin regimen, for poor-prognosis metastatic germ cell tumors
  filgrastim during, 716-724
  intensive induction-sequential chemotherapy, 692-701
Bleomycin, etoposide, cisplatin regimen
  for advanced disseminated germ cell tumors, 1287-1293, 3205
  for favorable-prognosis germ cell tumor, three-cycle *v* four-cycle treatment, 702-706
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone regimen, for advanced Hodgkin's disease, 3810-3821
Bleomycin, vincristine, cisplatin/etoposide, ifosfamide, cisplatin, bleomycin regimen, for poor-prognosis metastatic germ cell tumors
  filgrastim during, 716-724
  intensive induction-sequential chemotherapy, 692-701

Bleomycin, vincristine, mitomycin, consecutive low-dose cisplatin regimen, for recurrent cervical cancer, 18691878
Blood transfusion, costs of, in cancer care, 2364-2370
BMT. *See* Bone marrow transplantation
Body mass index, and inflammatory breast cancer, 3731-3735
Body-surface area, and dosing of anticancer agents, 2297-2298, 2299-2304, 3715-3716
Bone, renal cell carcinoma metastases to, resection of, 2261-2266
Bone marrow
  chemoprotection, with MDR1 retroviral gene transfer, 165-172
  depression during chemotherapy for ovarian cancer, prevention of, rhIL-3 in, 3335-3344
  fluorine-18-fluorodeoxyglucose uptake, G-CSF effect on, 173-180
  lymphomatous, FDG-PET evaluation for, 603-609
  micrometastases
    in Ewing's sarcoma, prognostic significance of, 1707-1711
    meta-analysis of prognostic impact of, 557-566
    RT-PCR analysis for, 806-807, 1707-1711
  rescue, after intensive chemotherapy
    for children with brain tumors, 210-221
    with ^{131}I-MIBG for refractory neuroblastoma, 229-236
Bone marrow transplantation
  in acute myeloid leukemia, molecular monitoring after, competitive RT-PCR for, 1519-1525
  autologous
    for breast cancer
      high-dose chemotherapy plus, 800-802
      occult tumor contamination, and survival, 3509-3517
    in diffuse large B-cell lymphoma, 63-69
    for Hodgkin's disease, recurrence after, vinblastine for, 584-588
    for mantle-cell lymphoma, high-dose chemoradiotherapy plus, 13-18
    for non-Hodgkin's lymphoma
      relapse after, second BMT for, 804-806
      in relapsed or refractory disease, augmented preparative regimens for, 48-55
    ovarian function after, 2359-2363
  predicting day 100 nonrelapse toxic mortality after, 3796-3802
  pregnancy after, 1978-1985
  survivors, sexual dysfunction in, 3148-3157
  unrelated donor, for Philadelphia-positive acute lymphoblastic leukemia, 931-936
  value of pretransplant evaluation in, 3796-3802
Bone mass, after childhood acute lymphoblastic leukemia, 3752-3760
Bone scan, in detection of bone metastases in gastrinoma patients, 1040-1053
BOP/VIP-B. *See* Bleomycin, vincristine, cisplatin/etoposide, ifosfamide, cisplatin, bleomycin regimen
Bowel symptoms, after early prostate cancer treatment, 275-283
Brachytherapy, high-dose-rate, for primary nasopharyngeal carcinoma, 2213-2220
Brain, renal cell carcinoma metastases to, resection of, 2261-2266
Brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
Brain stem tumor, pediatric, recurrent, temozolomide for, 3037-3043
Brain tumors
  adjuvant chemotherapy for, influence of surgical resection on, 389-390
  children with
    chemotherapy and bone marrow rescue for, 210-221
    myeloablative chemotherapy with autologous bone marrow rescue for recurrent tumor, 2486-2493
    retrieval therapy for recurrent tumor, 2486-2493
    temozolomide for recurrent tumor, 3037-3043
  methylphenidate treatment for, neurobehavioral benefits of, 2522-2527
  outcome with, influence of surgical resection on, 389-390
  secondary, after childhood ALL, 3761-3767
  surgical resection of, effects on adjuvant therapy and outcome, 389-390
BRCA1 gene
  and cell-cycle regulation, 1969-1977
  in development, 1969-1977
  germ-line mutations
    breast and ovarian cancer associated with, survival rates for, 395-396, 397-404, 3206-3207
    with sporadic breast cancer, 115-120
  mutations
    breast and ovarian cancer associated with, 1969-1977, 2417-2425
    and lifetime risk of breast cancer, 1969-1977
    prophylactic surgery for carriers of, 979-985, 2573-2575
    surveillance in families that carry, 397-404, 3206-3207
    and survival rates for breast and ovarian cancer, 395-396, 397-404, 3206-3207
  protein, function of, 1969-1977
  sequence analysis, correlation with family history and ovarian cancer risk, 2417-2425
  structure, 1969-1977
  as tumor-suppressor gene, 1969-1977
BRCA2 gene
  mutations
    breast and ovarian cancer associated with, 1969-1977, 2417-2425
    and lifetime risk of breast cancer, 1969-1977
    prophylactic surgery for carriers of, 979-985, 2573-2575
  sequence analysis, correlation with family history and ovarian cancer risk, 2417-2425
  as tumor-suppressor gene, 1969-1977
BRCA genes
  germ-line mutations, breast cancer associated with, prognosis for, 1642-1649, 3206-3208
  mutations
    breast cancer associated with, prognosis for, 1642-1649, 3206-3208
    and risk of ovarian cancer, 2417-2425
    spectrum of, 1969-1977
    testing for. *See* Breast cancer susceptibility testing
Breast cancer. *See also ASCO Annual Meeting Highlights*
  adjuvant chemohormonal therapy for, 3486-3492
  adjuvant therapy for
    doctor/patient communication about, 515-521
    fatigue after, 1689-1696
    patients' knowledge and expectations of, 515-521
    quality of life and preferences for treatment after, 1380-1387
    response to, p53 accumulation and, 470-479
  advanced
    gemcitabine and docetaxel regimen for, 3866-3873
    goserelin *v* surgical ovariectomy for, 994-999
    high-dose multimodality therapy for, 1000-1007
    infusional fluorouracil, epirubicin, and cyclophosphamide *v* infusional fluorouracil, epirubicin, and cisplatin for, 1350-1357
    LU103793 for, 2770-2779
    oral aromatase inhibitor for, 453-461, 2892-2893
    refractory, weekly docetaxel infusion for, 2164-2168

aggressiveness, hormone replacement therapy and, 3115-3120
aging, progression, and phenotype in, 2686-2692
autologous bone marrow or peripheral-blood progenitor cells for, occult tumor contamination, and survival, 3509-3517
bcl-2 expression in, prognostic significance of, 2025-2031
bcl-2 immunocytochemical assays in, 2025-2031
bone metastases
bisphosphonate treatment for, 1218-1225, 3204-3205, 3890-3899
^{18}FDG PET in evaluation of, 3375-3379
osteoblastic *v* osteolytic, ^{18}FDG PET findings in, 3375-3379
brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
BRCA-associated, 1639-1641
clinical implications for, 1969-1977
molecular genetics of, 1969-1977
and risk of ovarian cancer, 2417-2425
susceptibility testing. *See* Breast cancer susceptibility testing
in young women, prognosis for, 1642-1649, 3206-3208
in *BRCA1*- or *BRCA2*-positive women, prophylactic surgery for, 979-985, 2573-2575
breast-conserving therapy for. *See* Breast conservation
in carriers of *BRCA* mutations, 1969-1977
prophylactic surgery for, 979-985, 2573-2575
survival rates for, 395-396, 397-404, 3206-3207
c-*erb*B-2 in, prognostic and predictive value of, 462-469, 2409-2416
chemotherapy for
combination *v* single-agent, 3720-3730
dose-intensity in, single scale for comparing, 3137-3147
first-cycle blood counts in, and risk for neutropenia, dose reduction, or delay in treatment, 2392-2400
summation dose-intensity for, 3137-3147
clinical trials in
large, randomized study design for, 809
participation, issues and solutions in, 354-362
contralateral, in tamoxifen-treated women, 2018-2024
dermatomyositis and, 2890-2891
dormancy, 2690
doxorubicin and radiation therapy for, cardiac effects of, 3493-3501
ductal carcinoma in situ
invasive local recurrence of, outcome after, 1367-1373
lumpectomy plus radiotherapy for, 441-452
early
first-cycle blood counts in, as predictors of need for supportive care, 2392-2400
G-CSF use in, cost-effectiveness analysis for, 2435-2444
radiation therapy after conservative surgery for, 1022-1029, 2045-2051
site of primary tumor in, prognostic significance of, 1363-1366
supportive care during treatment of, 2392-2400
systemic adjuvant therapy for, quality of life after, 1380-1387
epirubicin for
cardioprotective effect of dexrazoxane with, 86-92
cardiotoxicity of, 3502-3508
estrogen receptor status in, prognostic significance of, 470-479
first-cycle blood counts in, as predictors of need for supportive care, 2392-2400
genotype, and phenotype, 2690-2691
graft-*v*-tumor effects in, 986-993
hepatic metastases, 2105-2112
heterogeneity of, 2686-2692
high-dose chemotherapy for
v standard therapy, evaluation of, 810-811
trials of, patient selection for, 1238-1239
high-dose chemotherapy with autologous bone marrow transplant for
clinical trials of, 1237-1238, 1238-1239
secondary myelodysplasia and acute leukemia after, 1008-1012
third-party payers and, 1237-1238
high-dose chemotherapy with stem-cell support for
clinical trials of, 1238-1239
evaluation of, 387-386, 800-802
Registry results and, 387-386
high-risk
high-dose chemotherapy for, evaluation of, 810-811
radiation therapy for, 1655-1660
hormone replacement therapy and, 3115-3120
infiltrating ductal, race as prognostic factor in, 2693-2699
inflammatory
body mass index and, 3731-3735
combined modality therapy for, 1661-1668
high-dose chemotherapy with autologous hematopoietic progenitor-cell support for, 1661-1668
inherited susceptibility to, 1639-1641, 1969-1977. *See also* Breast cancer susceptibility testing
family history suggesting, and breast-conserving therapy in young women, 2045-2051
invasive, vascular enumeration in, prognostic significance of, 1684-1688
Ki-67 positivity in, prognostic significance of, 470-479
left-sided, radiation therapy for, cardiac mortality after, 1374-1379, 2579-2582, 2625-2631, 3918
locally advanced, response to neoadjuvant chemotherapy, tumor clearance of ^{99m}Tc-sestamibi as predictor of, 1677-1683
metastatic
choroidal, 2280-2282
in complete remission, trials of observation *v* maintenance therapy for, 1669-1676
cytotoxic and hormonal treatment for, overview of, 3439-3460
epirubicin in, cardiotoxicity of, 3502-3508
first- and second-line treatment in, 3720-3730
HER2/*neu*-overexpressing, cisplatin plus recombinant humanized anti-p185$^{HER2/neu}$ MAb for, 2659-2671
high-dose chemotherapy for, trials of, 1238-1239
in large bowel mucosa, 3711-3713
paclitaxel-resistant, docetaxel for, 3362-3368
poor-risk, allogeneic peripheral-blood progenitor-cell transplantation for, 986-993
prognostic index for, 2401-2408
receptor-positive, goserelin *v* surgical ovariectomy for, 994-999
RT-PCR markers for detection of, 2632-2640
weekly paclitaxel therapy for, 3353-3361
metastatic phenotype, 2689-2690
metastatic potential of, RT-PCR detection of CEA mRNA in lymph nodes or blood and, 128-132
node-negative
adjuvant chemotherapy for, effect on recurrence and survival, 3486-3492
neu/erbB-2 amplification in, prognostic significance of, 1340-1349
p53 mutations in, prognostic significance of, 3164-3165
in premenopausal patient, prognostic factors for, 470-479
tumor angiogenesis factors in, prognostic significance of, 3129-3136

tumor markers in, prognostic significance of, 3129-3136
tumor proteolysis factors in, prognostic significance of, 3129-3136
vascular endothelial growth factor in, prognostic significance of, 3121-3128, 3129-3136
node-positive
cyclophosphamide, epirubicin, and fluorouracil *v* cyclophosphamide, methotrexate, and fluorouracil for, 2651-2658, 3916-3917
p53 mutations in, prognostic significance of, 3164
receptor-negative, 16-week multidrug regimen *v* cyclophosphamide, doxorubicin, and fluorouracil for, 2382-2391
operable. *See also* Mastectomy
preoperative chemotherapy for, effect on outcome, 2672-2685
primary chemotherapy in
clinical prognostic and predictive factors for, 107-114
Milan Cancer Institute experience, 93-100
paclitaxel-resistant
docetaxel for, 3362-3368
treatment of, 3917
pegylated liposomal doxorubicin for, 811-812
p53 in
prognostic significance of, 2641-2650, 3164-3165
and response to adjuvant therapy, 470-479
and response to tamoxifen therapy for recurrent disease, 121-127
poor-prognosis
adjuvant loco-regional radiation therapy in, 1655-1660
allogeneic peripheral-blood progenitor-cell transplantation for, 986-993
multicycle high-dose chemotherapy for, hematopoietic recovery after, 1899-1908
primary, prognostic significance of cathepsins B and L in, 1013-1021
prognosis for
age and, 2686-2692, 2693-2699
improvement in, from 1965 to 1984, 1030-1033
markers for, 462-469, 470-479
race and, 2693-2699
in women using hormone replacement therapy, 3115-3120
progression
evidence of, 2687-2688
markers of, 2688-2689
prophylactic surgery for, in *BRCA1*- or *BRCA2*-positive women, 979-985, 2573-2575
quality of life after, 487-494
radiation-induced
prevention of, 338-347, 2285-2287
screening and detection of, 338-347, 2285-2287
radiation therapy for, cardiac mortality after, 1374-1379, 2579-2582, 2625-2631, 3502-3508, 3918
recurrence
new/erbB-2 amplification and, 1340-1349
skin, after breast-conserving therapy, 480-486
tamoxifen therapy for, p53 protein as predictive factor in, 121-127
refractory, infusional flavopiridol for, 2986-2999
skeletal complications of, prevention of, with pamidronate, 2038-2044
sporadic
germ-line *BRCA1* mutations and, 115-120
v inherited, 1969-1977
stage I, breast conservation in, 101-106
stage II, breast conservation in, 101-106
stage IIIB, high-dose multimodality therapy for, 1000-1007
stage IV, paclitaxel and topotecan with G-CSF support in, 2032-2037
survival, prognostic factors related to, 462-469
survivors
arm problems in, 487-494
causes of mortality in, 2018-2024
hot flashes in, venlafaxine hydrochloride for, 2377-2381
hot flashes in, vitamin E for, 495-500
long-term quality of life for, 487-494
quality of life for, 501-514
sexual functioning of, 487-494, 501-514
tamoxifen for
with adjuvant cyclophosphamide, methotrexate, and fluorouracil, 1358-1362
survival impact of, 2018-2024
v toremifene, 348-353, 1999-2000
treatment of
c-*erb*B-2 overexpression and, 462-469
clinical trials, patient selection for, 809
tumor markers in, ASCO recommendations for use of, 1997 update, 793-795
tumor size, clinical and prognostic significance of, 2686-2687
Breast cancer susceptibility testing, 133-138
decision making about, 2868-2876
provider and consumer attitudes about, 2868-2876
psychologic effects of, 1650-1654
Breast conservation
with ductal carcinoma in situ, invasive local recurrence after, 1367-1373
primary chemotherapy in operable breast cancer and, 93-100
and radiation therapy
cardiac mortality after, 1374-1379
cost-effectiveness of, 1022-1029
for young women, family history and treatment outcome with, 2045-2051
skin recurrences after, 480-486
in stage I and II breast cancer, 101-106
use rates, interstate comparison of, 101-106
Bryostatin 1, for relapsed NHL and CLL, 56-62
Burkitt-like lymphomas, in HIV-infected (AIDS) patients, 3788-3795
Burkitt's lymphoma
clinical features of, 2794
p53 mutations in, clinical significance of, 3164

Caelyx. *See* Doxorubicin, pegylated liposomal
CAF. *See* Cyclophosphamide, doxorubicin, fluorouracil regimen
Camptothecins, in oral chemotherapy, 2563
Cancer and Leukemia Group B findings
on small-cell lung cancer treatment, 1954-1960, 2466-2467
on treatment of advanced cancer, 3302-3309
on treatment of advanced chest malignancies, 2157-2163
Cancer antigen 15-3 (CA 15-3), as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Cancer antigen 27.29 (CA 27.29), as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Cancer antigen 19-9 (CA 19-9), as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
Cancer care
evolution of, 2904-2905
during last phase of life, 1986-1996
Cancer cells, in lymph nodes or blood of GI or breast cancer patients, molecular detection of, clinical significance of, 128-132

Cancer pain. *See* Pain management
CAPABLE. *See* Cyclophosphamide, doxorubicin, cisplatin, methotrexate, bleomycin regimen
Capecitabine
  oral, toxicologic and pharmacologic studies of, 1795-1802, 2977-2985
  in oral chemotherapy, 1795-1802, 2561-2562, 2977-2985
Capillary protein leak syndrome, and fluid retention in docetaxel therapy for non-small-cell lung cancer, 3426-3432
Carboplatin, etoposide, bleomycin regimen, for CNS germinoma, relapse after, radiation therapy for, 204-209
Carboplatin, etoposide regimen, plus radiation therapy, for poor-risk non-small-cell lung cancer, 3078-3081
Carboplatin, for ovarian cancer, dose-intensity of, 2426-2434
Carboplatin, thiotepa, etoposide regimen, high-dose, with autologous stem cell rescue
  for children with brain tumors, 210-221
  for recurrent medulloblastoma, 222-228
Carboplatin, vinorelbine regimen, for extensive small-cell lung cancer, 1414-1419
Carcinoembryonic antigen
  mRNA in lymph nodes or blood of breast cancer patients, clinical significance of, 2632-2640
  mRNA in lymph nodes or blood of GI or breast cancer patients, clinical significance of, 128-132
  as tumor marker in breast cancer
    ASCO recommendations for use of, 1997 update, 793-795
    limitations of, 2632-2640
  as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
Carcinoid syndrome
  clinical presentation of, 796-798
  diagnosis of, 796-798
Carcinoid tumors, positron emission tomography with 5-hydroxytryptophan for, 2534-2541
Cardioprotection, by dexrazoxane, with high-dose epirubicin, 86-92
Cardioprotective agents, clinical trials of, design and interpretation of, 3179-3190
Cardiotoxicity
  of anthracyclines
    assessment of, radioimmunoscintigraphy for, 86-92
    protection against, dexrazoxane for, 86-92
  of doxorubicin, late, in long-term survivors of high-grade NHL, 2070-2079
  of doxorubicin and radiation therapy for breast cancer, 3493-3501
  of epirubicin, in breast cancer, 3502-3508
  paclitaxel and, 3481-3482, 3483-3485
Cardiovascular disease, in tamoxifen-treated women, 2018-2024
Carmustine, cyclophosphamide, etoposide regimen, preparative regimen, for autologous bone marrow transplantation, 48-55
Carmustine, dacarbazine, cisplatin, tamoxifen regimen, for advanced melanoma, 664-669
α-Catenin, expression in epithelial ovarian cancer, clinical and prognostic significance of, 2591-2600
Cathepsin B, prognostic significance in breast cancer, 1013-1021
Cathepsin D, as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Cathepsin L, prognostic significance in breast cancer, 1013-1021
CAV/PE. *See* Cyclophosphamide, doxorubicin, vincristine, cisplatin and etoposide regimen
CBFB gene, in therapy-related acute myeloid leukemia, 1890-1896
CBFB/MYH11 fusion transcripts, in therapy-related acute myeloid leukemia, 1890-1896
CBFβ/MYH11 fusion transcripts, competitive RT-PCR for
  in molecular monitoring after bone marrow transplantation in AML, 1519-1525
  in molecular monitoring during postremission chemotherapy for AML, 1519-1525
CD (cluster of differentiation), CD56, and outcome of nasal/nasopharyngeal lymphomas, 70-77
2-CDA. *See* Cladribine
$CD34^+33^-$ cells, in autologous blood stem-cell transplantation, effects on engraftment kinetics and transfusion requirements, 2093-2104
CDKN2A gene. *See* Tumor suppressor gene(s), *p16*
CEF. *See* Cyclophosphamide, epirubicin, fluorouracil regimen
Cell-cycle regulator proteins, expression in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
Cell-mediated immune response, to polyvalent melanoma cell vaccine, correlation with survival, 2913-2920
Central nervous system tumors. *See* Brain tumors; Germinoma, central nervous system; Lymphoma(s), primary CNS; Medulloblastoma
Cerebrospinal fluid, folate and related metabolites, during treatment for acute lymphoblastic leukemia, 1505-1511
Cervical cancer
  advanced
    LU103793 for, 2770-2779
    response to chemotherapy, factors affecting, 1879-1884
  advanced and recurrent, vinorelbine for, phase II study of, 1094-1098
  advanced refractory, weekly docetaxel infusion for, 2164-2168
  chemotherapy for, response to, factors affecting, 1879-1884
  clinical trials in, design of, 1879-1884
  course of, HPV genotype and, 2613-2619
  HPV-associated carcinogenesis in, molecular mechanisms and potential therapies for, 330-337
  p53 in, 3163
  prognosis for, HPV genotype and, 2613-2619
  recurrent
    bleomycin, vincristine, mitomycin and consecutive low-dose cisplatin for, 18691878
    response to chemotherapy, factors affecting, 1879-1884
Cervical intraepithelial neoplasia, telomerase activity in, 2238-2245
Cervix, (pre)neoplastic lesions of, telomerase activity as biomarker for, 2238-2245
Charlson comorbidity scale, results in older cancer patients, 1582-1587
CHART. *See* Continuous hyperfractionated accelerated radiotherapy
Chemoradiation
  for pancreatic adenocarcinoma, preoperative, 3843-3850
  for small-cell lung cancer, radiation dose schedule in, 3528-3536
Chemoradiotherapy. *See also* Radiochemotherapy
  for advanced chest malignancies, 2157-2163
  in anal cancer, *v* optimal radiotherapy alone, 802-803
  docetaxel with concomitant thoracic radiation, 159-164
  for Ewing's sarcoma, high-dose, plus autologous BMT as consolidation therapy, 1697-1706
  for head and neck cancer, 2715-2721
    with G-CSF support, phase I study of, 735-744
  hyperfractionated accelerated, in non-small-cell lung cancer, 622-634
  for mantle-cell lymphoma, high-dose, plus autologous bone marrow transplantation, 13-18
  for nasopharyngeal carcinoma, *v* radiotherapy alone, 1310-1317
  for non-small-cell lung cancer, 3078-3081

in pancreatic cancer, adjuvant preoperative, 317-323
for rhabdomyosarcoma, high-dose, plus autologous BMT as consolidation therapy, 1697-1706
for sarcoma, high-dose, plus autologous BMT as consolidation therapy, 1697-1706
in small-cell lung cancer, 2466-2467
early *v* late radiation therapy in, 1235-1237, 1631-1635
Chemotherapy
analgesic effects of, 803-804
for brain tumors in children, intensive, with autologous stem cell rescue, 210-221
in breast cancer
clinical prognostic and predictive factors for, 107-114
Milan Cancer Institute experience, 93-100
cognitive effects in glioma patients, 2195-2201, 3210-3211
in diffuse large B-cell lymphoma, high-dose, 63-69
history of, 2295-2296, 3714-3715
intensive, leukemia risk after, 3016-3020
for lymphoma, with intraocular or primary CNS involvement, 3000-3006
for medulloblastoma, intensive, with autologous stem cell rescue, 222-228
in non-small-cell lung cancer, 622-634
oral
administration of, 2557-2567
agents for, 2557-2567
applications of, 2557-2567
bioavailability limitations in, 2557-2567
compliance issues with, 2557-2567
future developments in, 2557-2567
rationale for, 2557-2567
postremission, molecular monitoring during, competitive RT-PCR for, 1519-1525
prophylactic G-CSF therapy after, 3874-3879
for prostate cancer, in hormone-resistant disease, economics of, 2272-2279
for seminoma, 290-294
Chemotherapy-induced acral erythema, *v* hand-foot syndrome, 808-809
Chest radiotherapy, docetaxel concomitant with, phase I study, 159-164
Childhood cancer, survivors of
adult, programs for, 2864-2867
follow-up of, 2864-2867
Children and adolescents
acute leukemias in, docetaxel as potential treatment in, 907-913
acute lymphoblastic leukemia in. *See* Acute lymphoblastic leukemia, childhood
acute lymphocytic leukemia in. *See* Acute lymphocytic leukemia, childhood
acute lymphoid leukemia in, neurotoxicity in, associated with IV methotrexate and intrathecal triple therapy, 1712-1722
acute myelogenous leukemia in, consolidation chemotherapy for, IL-2 after, 914-919
acute myeloid leukemia in, in vitro cytotoxicity of docetaxel in, 907-913
alternative and complementary therapy use in, 1279-1286
anthracyclines in
dose, and late cardiotoxicity, 545-550
late cardiotoxicity of, 545-550
astrocytoma in, temozolomide for, 3037-3043
brain tumors in
chemotherapy and bone marrow rescue for, 210-221
recurrent, myeloablative chemotherapy for, with autologous bone marrow rescue, 2486-2493
recurrent, retrieval therapy for, 2486-2493
recurrent, temozolomide for, 3037-3043
cancer care for, evolution of, 2904-2905
clinical pharmacology in, 966-978
desmoid tumor in, progressive, combination chemotherapy for, 3021-3027
filgrastim for, 522-526
glioma in, temozolomide for, 3037-3043
HIV-infected, cancer in, 1729-1735
Hodgkin's disease in
advanced, MOPP/ABVD *v* ABVD plus radiation for, 897-906
radiation therapy for, 391-393
risk of second cancers in survivors, 536-544, 2287-2288, 2570-2572
lymphoblastic lymphoma in, filgrastim for, 522-526
medulloblastoma in
craniospinal radiation for, neuropsychologic functioning after, 1723-1728
recurrent, temozolomide for, 3037-3043
neuroblastoma in, *MYCN* gene expression and outcome for, 3286-3294
osteosarcoma in, temozolomide for, 3037-3043
phase I trials in, conduct of, 966-978
primitive neuroectodermal tumors in, molecular markers in, diagnostic and prognostic significance of, 2478-2485
with refractory cancers, pyrazoloacridine for, 181-186
solid tumors in
chemotherapy and stem-cell transplantation for, 937-944
cyclophosphamide and topotecan for, 945-952
temozolomide for, 3037-3043
T-cell leukemia in, filgrastim for, 522-526
T-cell malignancies in, trial of G-CSF for, 522-526
Wilms' tumor in
doxorubicin for, with pulse-intensive dactinomycin, 237-245
p53 mutations in, prognostic significance of, 3164
recurrent, high-dose chemotherapy for, 3295-3301
Children's Cancer Group findings
on biologic staging of stage III neuroblastoma, 1256-1264
on cranial radiation in high-risk pediatric ALL, 920-930
on cytogenetic abnormalities in T-cell acute lymphoblastic leukemia, 1270-1278
on IL-2 after consolidation chemotherapy for acute myelogenous leukemia, 914-919
on MOPP/ABVD chemotherapy *v* ABVD plus radiation, in advanced pediatric Hodgkin's disease, 897-906
on pediatric HIV-related malignancies, 1729-1735
on prognostic significance of translocation t(1;19) in childhood ALL, 527-535
on temozolomide for recurrent solid tumors, 3037-3043
2-Chlorodeoxyadenosine. *See* Cladribine
Chloroma, epidural, of lower spinal canal, 3201-3202
CHOP. *See* Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
Choroid, breast cancer metastasis to, 2280-2282
Chromosomal abnormalities
balanced, in therapy-related leukemia after DNA-topoisomerase II inhibitor therapy, 1897-1898
in therapy-related leukemia after DNA-topoisomerase II inhibitor therapy, 1890-1896

Chromosomal translocation
in acute lymphoblastic leukemia, prognostic significance of, 1270-1278
t(1;19), prognostic significance in acute lymphoblastic leukemia, 527-535
t(11;22), prognostic significance in Ewing's sarcoma, 1241-1242
t(11;22)(p13;q12), tumors associated with, 3028-3036
Chromosome 12, isochromosome of short arm of [i(12p)], in germ cell tumors, 1246
Chromosome 1, *p73* gene, 3163
Chromosome 16 inversion
in acute myeloid leukemia, postremission chemotherapy for, competitive RT-PCR for molecular monitoring during, 1519-1525
in therapy-related acute myeloid leukemia, 1890-1896
Chromosome 17p, loss of heterozygosity in childhood primitive neuroectodermal tumors, prognostic significance of, 2478-2485
Chromosome 9q22, loss of heterozygosity in childhood primitive neuroectodermal tumors, prognostic significance of, 2478-2485
Chromosome *18q* allelic loss, in colon cancer, prognostic significance of, 427-433
Chronic lymphocytic leukemia
allogeneic blood progenitor-cell transplantation for, nonablative preparative regimen in, 2817-2824
B-cell, GW506U78 in, pharmacokinetics and response to, 3607-3615
bryostatin 1 for, 56-62
fludarabine for
hemolytic anemia after, 1885-1889, 3209-3210
tumor lysis syndrome with, 2313-2320
p53 mutations in, prognostic significance of, 3163-3164
Chronic myelogenous leukemia
in accelerated or blast phase, high-dose cladribine for, 1498-1504
allogeneic transplantation in
comparison to IFN-α therapy, 2899-2900
efficacy of, 2899
morbidity and mortality with, 2899
early chronic-phase, treatment decisions in, 882-889, 2897-2903
initial therapy for, 2897-2903
interferon-alfa therapy in, 882-889, 2897-2903
comparison to transplantation, 2899-2900
efficacy of, 2898
morbidity and mortality with, 2898
interferon for, candidates for, 2897
late-phase, prognostic determinants in, 3782-3787
with long-term cytogenetic remissions on IFN-α, and PCR status of patients, 1526-1531, 2897-2903
parenterally infused hydroxyurea in, 2321-2331
Philadelphia-positive, with cytogenetic clonal evolution, IFN-α therapy for, 3279-3285
p53 mutations in, and disease progression, 3164
prognostic index for, 2898
progression from chronic phase to blast crisis, prognostic factors for, 2897-2898
Cisplatin
and continuous infusion topotecan, in advanced cancer, phase I and pharmacologic study of, 3302-3309
emesis induced by
IV dexamethasone for, dose of, 2937-2942
oral granisetron *v* IV ondansetron for, 1568-1573
prevention, IV dexamethasone for, dose of, 2937-2942
high-dose, delayed emesis after, 1174-1178
and irinotecan, clinical synergy between, 3858-3865
irinotecan combined with, for small-cell lung cancer, 1068-1074
plus recombinant humanized anti-p185$^{HER2/neu}$ monoclonal antibody, in HER2/*neu*-overexpressing metastatic breast cancer, 2659-2671
Cisplatin, carboplatin regimen, with/without ifosfamide, for advanced non-small-cell lung cancer, 1388-1396
Cisplatin, doxorubicin, vincristine, etoposide regimen, for small-cell lung cancer in elderly, 1940-1947
Cisplatin, fluorouracil, leucovorin, IFN-α2b regimen, induction chemotherapy in advanced head and neck cancer, followed by surgery and concurrent chemoradiation, 2715-2721
Cisplatin, fluorouracil regimen
for gastric cancer, *ERCC1* gene expression as predictor of response and survival in, 309-316
for recurrent or metastatic head and neck cancer, modulation by interferon alfa-2b, 1054-1059
Cisplatin, irinotecan regimen
clinical synergy between, 3858-3865
in solid tumors, combined weekly schedule for, 3858-3865
Cisplatin, teniposide regimen, *v* paclitaxel-cisplatin, for advanced non-small-cell lung cancer, 2133-2141
Cisplatin, vinblastine, dacarbazine regimen, with IFN α-2a and IL-2, for metastatic melanoma, 1752-1759
Cisplatin, vincristine, doxorubicin, etoposide regimen, plus G-CSF, for extensive small-cell lung cancer, 2126-2132
Cisplatin, vinorelbine regimen
for advanced non-small-cell lung cancer, 2459-2465
plus radiation therapy, for advanced chest malignancies, 2157-2163
Cladribine
high-dose, for chronic myelogenous leukemia in accelerated or blast phase, 1498-1504
for pretreated non-Hodgkin's lymphoma, dosages of, 850-858
CLD-BOMP. *See* Bleomycin, vincristine, mitomycin, consecutive low-dose cisplatin regimen
Clinical trials. *See also* Phase III trial; Phase II trial; Phase I trial
in breast cancer
large, randomized study design for, 809
participation, issues and solutions in, 354-362
patient selection for, 809
in cervical cancer, design of, 1879-1884
Data Monitoring Committees and, 390-391
in prostate cancer, standardized eligibility criteria and end points in, 3398-3405
of protective agents, design and interpretation of, 3179-3190
randomized, ethical considerations with, 365-371, 1637, 2570
scientific misconduct in, 3433-3438
Clodronate
in breast cancer with bone metastases, evidence-based review of, 1218-1225, 3204-3205
current use in oncology, 3890-3899
CMF. *See* Cyclophosphamide, methotrexate, fluorouracil regimen
CMF(P)TH. *See* Cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, halotestin regimen
CODE. *See* Cisplatin, vincristine, doxorubicin, etoposide regimen
Cognitive functioning
in glioma patients
treated with methylphenidate, 2522-2527
treated with radiation and chemotherapy, 2195-2201, 3210-3211
in SCLC patients treated with chemotherapy and radiation therapy with/without warfarin, 1954-1960

Collagen IV, expression in epithelial ovarian cancer, clinical and prognostic significance of, 2591-2600
Colon cancer. *See also* Colorectal cancer
adjuvant chemotherapy for
with 5-FU, leucovorin, levamisole regimen, 295-300
6-month *v* 12-month course of, 295-300
advanced, gemcitabine and docetaxel regimen for, 3866-3873
chromosome *18q* allelic loss in, prognostic significance of, 427-433
metastases, thymidylate synthase gene expression in, and response to 5-fluorouracil therapy, 1465-1469
refractory, infusional flavopiridol for, 2986-2999
Colorectal cancer. *See also* Colon cancer
advanced
first-line palliative management of, 2943-2952
irinotecan-induced delayed-onset diarrhea in, 2745-2751
KRN8602 with/without filgrastim for, 2181-2187
LU103793 for, 2770-2779
quality of life with, 3662-3673
raltitrexed *v* fluorouracil plus high-dose leucovorin for, 2943-2952
anemia with, epoetin beta for, 434-440
brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
development of, p53 mutations and, 3162-3163
Dukes' C, postoperative monoclonal antibody therapy for, 1788-1794
fluorouracil for
administration schedule and prognostic factors for, 3537-3541
IV continuous *v* bolus administration of, 301-308
modulation by leucovorin, 418-426
toxicity of, 3537-3541
hepatic metastases, 2105-2112
intrahepatic and systemic chemotherapy for, 2528-2533
metastatic
first-line therapy for, 2739-2744
fluorouracil and leucovorin for, fluorouracil dosage optimization in, with pharmacokinetic monitoring, 1470-1478
oxaliplatin in, 2739-2744
radioimmunoscintigraphy with ^{99m}Tc-labeled HumaSPECT, 1777-1787, 2575
occult, radioimmunoscintigraphy with ^{99m}Tc-labeled HumaSPECT, 1777-1787, 2575
p53 mutations in, prognostic significance of, 3165
pulmonary metastases, thymidilate synthase gene expression, and response to 5-fluorouracil therapy, 1465-1469
recurrent, radioimmunoscintigraphy with ^{99m}Tc-labeled HumaSPECT, 1777-1787, 2575
tumor markers in, ASCO recommendations for use of, 1997 update, 793-795
uracil-ftorafur in, 3461-3475
Communication, with patients, 2283
Communication skills training, for oncologists, 1961-1968
Complementary therapy, use in pediatric oncology patients, 1279-1286
Computed tomography (CT), [^{18}F]fluorodeoxyglucose, detection of recurrent or persistent nasopharyngeal carcinoma, 3550-3555
Continuous hyperfractionated accelerated radiotherapy, for non-small-cell lung cancer, patient-assessed symptoms with, 3082-3093
COPP/ABVD. *See* Cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine regimen
Cost-effectiveness analysis
of breast cancer treatment, 1022-1029, 2435-2444
of lung cancer treatment, 3900-3912
of non-small-cell lung cancer treatment, 807-808
of second bone marrow transplantation in non-Hodgkin's lymphoma, 804-806
of small-cell lung cancer treatment, 2700-2707
of solitary pulmonary nodule management, 2113-2125
of Wilms' tumor treatment, 3744-3751
CPT-11. *See* Irinotecan
Cumulative Illness Rating Scale-Geriatric, results, 1582-1587
Curriculum development, in medical oncology, ASCO training resource document for, 372-379
CVD. *See* Cisplatin, vinblastine, dacarbazine regimen
CVP. *See* Cyclophosphamide, vincristine, prednisone regimen
Cyclin D2, overexpression in germ cell tumors, 1246
Cyclin D1, overexpression in laryngeal squamous cell carcinoma, clinical significance of, 3069-3077
Cyclin-dependent kinase, p34^{cdc2}, overexpression in prostatic adenocarcinoma, 1302-1309
Cyclophosphamide
high-dose
and autologous BMT, for breast cancer, posttransplant cytogenetics with, 1008-1012
in peripheral-blood stem-cell mobilization with G-CSF, for multiple myeloma treatment, 1547-1553
and in vivo expansion of activated CD4$^+$ T cells, 2752-2760
and topotecan, combination, for pediatric solid tumors, 945-952
Cyclophosphamide, carboplatin, etoposide, melphalan regimen, for solid tumors in children, autologous stem-cell support with, 937-944
Cyclophosphamide, doxorubicin, cisplatin, methotrexate, bleomycin regimen, for nasopharyngeal carcinoma, 2514-2521
Cyclophosphamide, doxorubicin, fluorouracil regimen, for breast cancer, *v* 16-week multidrug regimen, 2382-2391
Cyclophosphamide, doxorubicin, vincristine, cisplatin and etoposide regimen, for small-cell lung cancer, 2126-2132
Cyclophosphamide, doxorubicin, vincristine, prednisone regimen
for mantle-cell lymphoma, 13-18
for non-Hodgkin's lymphoma in elderly, 27-34, 2065-2069, 2352-2358
plus GM-CSF, 2352-2358
Cyclophosphamide, epirubicin, fluorouracil/mitomycin, vinblastine regimen, for breast cancer, 3720-3730
Cyclophosphamide, epirubicin, fluorouracil regimen, for breast cancer, *v* cyclophosphamide, methotrexate, and fluorouracil, 2651-2658, 3916-3917
Cyclophosphamide, methotrexate, fluorouracil, prednisone, tamoxifen, halotestin regimen
for breast cancer in complete remission, 1669-1676
toxicity of, 1669-1676
Cyclophosphamide, methotrexate, fluorouracil regimen, for breast cancer
v cyclophosphamide, epirubicin, and fluorouracil, 2651-2658, 3916-3917
effects of dose and schedule, 1358-1362
Cyclophosphamide, vincristine, prednisone regimen, for non-Hodgkin's lymphoma, IFN α-2b in, 1538-1546
Cyclophosphamide, vincristine, procarbazine, prednisone/doxorubicin, bleomycin, vinblastine, dacarbazine regimen, for advanced Hodgkin's disease, 3810-3821
Cytokeratin-19
mRNA in lymph nodes or blood of breast cancer patients, clinical significance of, 2632-2640
as tumor marker in breast cancer, limitations of, 2632-2640

Cytokeratin-20
mRNA in lymph nodes or blood of breast cancer patients, clinical significance of, 2632-2640
as tumor marker in breast cancer, 2632-2640

Dacarbazine, *v* dacarbazine with IFN α2b *v* dacarbazine with tamoxifen *v* dacarbazine with IFN α-2b and tamoxifen, for metastatic melanoma, 1743-1751
Dactinomycin, pulse-intensive regimen, with doxorubicin, for Wilms' tumor, 237-245
Data Monitoring Committees, ethical and policy considerations with, 390-391
Daunorubicin
in induction therapy for adult AML, 2086-2092
liposomal, for pulmonary AIDS-related Kaposi's sarcoma, 3369-3374
Demyelination, during treatment of acute lymphoblastic leukemia, 1505-1511
Depression, in cancer patients, oncologists' recognition of, 1594-1600
Dermatomyositis, and breast cancer, 2890-2891
Desmoid tumor, progressive, in children, combination chemotherapy for, 3021-3027
Desmoplastic small round-cell tumors
clinical, pathologic, and molecular spectrum of, 3028-3036
intensive chemotherapy for, leukemic risks of, 3016-3020
Dexamethasone
and granisetron, antiemetic efficacy after high-dose cisplatin, 1174-1178
for prevention of acute cisplatin-induced emesis, intravenous dosing, 2937-2942
Dexrazoxane, clinical trials of, design and interpretation of, 3179-3190
Diarrhea
chemotherapy-induced
assessment of, recommended guidelines for, 3169-3178
treatment of, recommended guidelines for, 3169-3178
irinotecan-induced delayed-onset, pathophysiology and treatment of, 2745-2751
Dimethylsulfoxide, plasma concentrations and pharmacokinetics, in peripheral-blood stem-cell transplant recipients, 610-615
DMSO. *See* Dimethylsulfoxide
DNA flow cytometric analysis
as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
DNA index
as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
DNA mismatch repair, in glioma, prognostic significance of, 3851-3857
DNA-topoisomerase II inhibitors, chemotherapy with, therapy-related leukemia and cytogenetic abnormalities after, 1890-1896, 1897-1898
Docetaxel
with concomitant thoracic radiation, phase I study, 159-164
cytotoxicity, in childhood acute leukemias, 907-913
infusion, for advanced refractory cancer, 2164-2168
for non-small-cell lung cancer, fluid retention in, 3426-3432
for paclitaxel-resistant breast cancer, 3362-3368
pharmacokinetic/pharmacodynamic evaluation, 187-196
weekly administration of, toxicity profile and therapeutic efficacy with, 2164-2168
Docetaxel, cisplatin, fluorouracil, leucovorin regimen, induction chemotherapy, for squamous cell carcinoma of head and neck, phase I/II trial of, 1331-1339
Docetaxel, cisplatin regimen
in advanced non-small-cell lung cancer, phase II study of, 1948-1953
for metastatic urothelial carcinoma, 3392-3397
Docetaxel, gemcitabine regimen, in advanced malignancy, 3866-3873
Dolastatin 15 analog. *See* LU103793
Dose-limiting toxicity, definition of, for pediatric trials, 966-978
Doxil. *See* Doxorubicin, pegylated liposomal
Doxorubicin
cardiotoxicity, late, in long-term survivors of high-grade NHL, 2070-2079
for follicular lymphoma, IFN α-2b and, 2332-2338, 2339-2344, 3716-3717
for high-grade NHL, late effects in long-term survivors of, 2070-2079
pegylated liposomal
for AIDS-related Kaposi's sarcoma, 683-691, 2445-2451
for breast cancer, 811-812
and radiation therapy, for breast cancer, cardiac effects of, 3493-3501
for Wilms' tumor, with pulse-intensive dactinomycin, 237-245
Doxorubicin, bleomycin, vincristine regimen, for AIDS-related Kaposi's sarcoma, 2445-2451
Doxorubicin, cyclophosphamide regimen, preoperative, for operable primary breast cancer, effect on outcome, 2672-2685
Doxorubicin, dactinomycin regimen, for Wilms' tumor, pulse-intensive dactinomycin regimen for, 237-245
DSRCT. *See* Desmoplastic small round-cell tumors

Eastern Cooperative Oncology Group
study of adjuvant preoperative chemoradiotherapy in pancreatic cancer, 317-323
study of dacarbazine, interferon α-2b, and tamoxifen in metastatic melanoma, 1743-1751
study of hyperfractionated accelerated radiation therapy in non-small-cell lung cancer, 3518-3523
trial EST 1684, Q-TWiST analysis of, 388-389
trials of observation *v* maintenance therapy for metastatic breast cancer in complete remission, 1669-1676
ECisF. *See* Fluorouracil, epirubicin, cisplatin regimen
ECycloF. *See* Fluorouracil, epirubicin, cyclophosphamide regimen
Elderly
acute myeloid leukemia in, remission-induction and postremission therapy in, 872-881
cancer patients, comorbidity and functional status in, 1582-1587
limited-stage small-cell lung cancer in, abbreviated treatment for, 3323-3328
with non-Hodgkin's lymphoma
CHOP regimen for, 27-34, 2065-2069, 2352-2358
risk factors for treatment-related death in, 2065-2069
small-cell lung cancer in, PAVE regimen for, phase II study of, 1940-1947
Emesis
delayed, after high-dose cisplatin, 1174-1178
granisetron for, 754-760
ondansetron for, 754-760
End-of-life care, 1986-1996

Endometrial cancer
outcome, correlation with pRb2/p130 expression, 1085-1093
in tamoxifen-treated women, 779-792, 2018-2024, 2573
Eniluracil (776C85)
and 5-fluorouracil, for advanced cancer, clinical and pharmacologic study of, 1450-1457
in oral chemotherapy, 2562
Enzyme-linked immunosorbent assay, p53 overexpression detected by, prognostic significance of, in breast cancer, 2641-2650
EORTC. *See* European Organization for Research and Treatment of Cancer
Epirubicin
for breast cancer, cardioprotective effect of dexrazoxane with, 86-92
in breast cancer, cardiotoxicity of, 3502-3508
dose calculation, 2299-2304, 3715-3716
pharmacokinetics and toxicity of, factors affecting, 2299-2304, 3715-3716
for soft tissue sarcoma, cardioprotective effect of dexrazoxane with, 86-92
Epirubicin, mitomycin regimen, for breast cancer, 3720-3730
Epithelial malignancy, associated with human papillomaviruses, 330-337
Epoetin alfa, for chemotherapy patients, quality of life with, 3412-3425
Epoetin beta, for anemia, in gastrointestinal cancer patients, 434-440
Epstein-Barr virus (EBV), posttransplant lymphoproliferative disorders not associated with, 2052-2059
ERCC1 gene expression, as predictor of response and survival in gastric cancer treated with combination cisplatin and fluorouracil, 309-316
Errata, 2001, 2293, 2575, 2895, 3211
Errors, in clinical radiotherapy, study of, 551-556, 2288-2289
Erythropoietin. *See also* Epoetin beta
clinical trials of, design and interpretation of, 3179-3190
Esophageal adenocarcinoma, advanced, gemcitabine and docetaxel regimen for, 3866-3873
Esophageal cancer
advanced, paclitaxel, fluorouracil, and cisplatin in, 1826-1834
hepatic metastases, 2105-2112
Estramustine phosphate
pharmacologic study of, 2959-2963
and short infusion of paclitaxel, for paclitaxel-pretreated solid tumors in women, 2959-2963
Estrogen receptor status
in breast cancer, prognostic significance of, 470-479
as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Ethics
of off-label drug use, 1637
of phase I trials, 2305-2312
of randomized clinical trials, 365-371, 1637, 2570
and secrecy for Data Monitoring Committees, 390-391
5-Ethynyluracil, in oral chemotherapy, 2562
Etoposide
high-dose, secondary leukemia after, 3386-3391
oral, for platinum-treated ovarian cancer, 405-410
Etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, *v* VACOP-B plus autologous BMT, for diffuse NHL, 2796-2802
Etoposide, ifosfamide, cisplatin regimen, for advanced disseminated germ cell tumors, 1287-1293, 3205
Etoposide, mitoxantrone, prednimustine regimen, for non-Hodgkin's lymphoma, in elderly (≥70 years) patients, 27-34
European Bone Marrow Transplantation Solid Tumor Registry, findings on outcome predictors in stage 4 neuroblastoma, 953-965
European Organization for Research and Treatment of Cancer
Core Quality-of-Life Questionnaire, in assessment of general Norwegian population, 1188-1196
findings on antiandrogen therapy for unresectable hepatocellular carcinoma, 411-417
Lymphoma Cooperative Study Group, findings on CHOP regimen for non-Hodgkin's lymphoma, 27-34
phase II trials with pleural mesothelioma, 145-152
Ewing's family of tumors, in adults
natural history and prognosis of, 3736-3743
treatment of, 3736-3743
Ewing's sarcoma
bone marrow micrometastases, prognostic significance of, 1707-1711
cyclophosphamide, carboplatin, etoposide, melphalan regimen with autologous stem-cell support for, 937-944
EWS/FLI1 fusion gene in, 1241-1242
transcript type, prognostic significance of, 1248-1255, 2895
extraosseous, high-dose induction chemoradiotherapy for, with intensive chemotherapy and autologous BMT as consolidation therapy, 1697-1706
ifosfamide for, 3628-3633
molecular genetic abnormalities in, 1241-1242
with primary lung metastases
prognostic factors for, 3044-3052
survival analysis of, 3044-3052
translocation t(11;22) in, 1241-1242
EWS/ETS fusion gene expression, in primitive neuroectodermal tumors of adults, 1150-1157
EWS/FLI1 fusion gene expression, in Ewing's sarcoma, 1241-1242
prognostic significance of transcript type in, 1248-1255, 2895
Excision repair cross-complementing gene. *See ERCC1* gene
External-beam radiation therapy
adjuvant, for soft tissue sarcoma of extremity, 197-203
for prostate cancer
in early disease, complications of, 275-283
in localized disease, poor prognosis after, identification of, 3094-3100

FAC. *See* 5-Fluorouracil, doxorubicin, cyclophosphamide regimen
Fallopian tube, microscopic residual carcinoma in, intraperitoneal paclitaxel for, 2620-2624
Familial cancer syndrome, *p53* germ-line mutations in, 3163
Fatigue, after adjuvant chemotherapy for breast cancer, 1689-1696
Febrile neutropenia, treatment of, GM-CSF in, 2930-2936
Females
lung cancer in, 651-657
metastatic melanoma in, prognosis for, 1103-1111
Fentanyl, transdermal, *v* oral morphine, for pain management, patient satisfaction and side effects with, 1588-1593
Fentanyl citrate, oral transmucosal, for breakthrough cancer pain, 3238-3245
Fertility
after autologous bone marrow transplantation, 2359-2363
after bone marrow transplantation, 1978-1985
in germ cell tumor patients, treatment effects on, 1245-1246
in testicular cancer patients
with stage I disease on surveillance, 733-734
treatment effects on, 733-734, 1245-1246

Fibroblast growth factor (FGF), basic, in node-negative breast cancer, prognostic significance of, 3129-3136
Filgrastim
after chemotherapy, *v* stem-cell factor plus filgrastim after chemotherapy, in progenitor-cell mobilization for ovarian cancer, 2601-2612
for childhood T-cell leukemia and lymphoblastic lymphoma, 522-526
during combination chemotherapy for metastatic poor-prognosis germ cell tumors, 716-724
and multicycle high-dose chemotherapy for poor-prognosis breast cancer, 1899-1908
Flavopiridol, infusional
for refractory neoplasms, 2986-2999
toxicologic and pharmacologic studies of, 2986-2999
Fludarabine
for chronic lymphocytic leukemia
hemolytic anemia after, 1885-1889, 3209-3210
tumor lysis syndrome with, 2313-2320
preparative regimen using, for allogeneic blood progenitor-cell transplantation in lymphoid malignancy, 2817-2824
in Waldenström's macroglobulinemia, 2060-2064
Fludarabine monophosphate, for mantle-cell lymphoma, 579-583
Fluorine-18-fluorodeoxyglucose, bone marrow uptake of, G-CSF effect on, 173-180
Fluorodeoxyuridine, intrahepatic, and systemic fluorouracil plus leucovorin, for hepatic metastases of colorectal cancer, 2528-2533
Fluoropyrimidine carbamate, novel oral. *See* Capecitabine
Fluoropyrimidines, diarrhea induced by, recommended guidelines for treatment and assessment of, 3169-3178
5-Fluorouracil
for advanced colorectal cancer
high-dose infusion, modulation by leucovorin, 418-426
IV continuous infusion *v* bolus administration of, 301-308
for colorectal cancer
administration schedule and prognostic factors for, 3537-3541
toxicity of, 3537-3541
diarrhea induced by, recommended guidelines for treatment and assessment of, 3169-3178
with IL-2 and IFN-α, for metastatic renal cell carcinoma, 2728-2732
with IL-2 and IFN-α, for outpatient treatment of metastatic renal cell carcinoma, 2505-2513
individual dose adjustment with pharmacokinetic monitoring, and response in metastatic colorectal cancer, 1470-1478
IV continuous infusion, complications of, 301-308
plus Eniluracil (776C85), for advanced cancer, clinical and pharmacologic study of, 1450-1457
5-Fluorouracil, doxorubicin, cyclophosphamide regimen, for breast cancer, response to, p53 accumulation and, 470-479
Fluorouracil, epirubicin, cisplatin regimen, infusional, *v* infusional fluorouracil, epirubicin, and cyclophosphamide, for advanced breast cancer, 1350-1357
Fluorouracil, epirubicin, cyclophosphamide regimen, infusional, *v* infusional fluorouracil, epirubicin, and cisplatin, for advanced breast cancer, 1350-1357
5-Fluorouracil, leucovorin, levamisole regimen, for high-risk colon cancer
6-month *v* 12-month course of, 295-300
as postoperative adjuvant therapy, 295-300
Fluorouracil, leucovorin regimen, for metastatic colorectal cancer, fluorouracil dosage optimization in, with pharmacokinetic monitoring, 1470-1478
Folinic acid. *See* Leucovorin
French Society of Pediatric Oncology, study of high-dose chemotherapy in recurrent Wilms' tumor, 3295-3301
FU. *See* Fluorouracil
Functional improvement, in glioma patients treated with methylphenidate, 2522-2527
Functional Living Index—Cancer, 3662-3673

GA733.2. *See* Gastrointestinal tumor-associated antigen 733.2
Gastrectomy
extended (D2), for gastric cancer, morbidity and mortality after, 1490-1493
with pancreas preservation, for gastric cancer, morbidity and mortality after, 1490-1493
Gastric cancer
adjuvant chemotherapy in, 1036-1039, 3714
adjuvant intraperitoneal chemotherapy with mitomycin for, 2733-2738
anemia with, epoetin beta for, 434-440
combination cisplatin and fluorouracil regimen for, *ERCC1* gene expression as predictor of response and survival in, 309-316
extended (D2) gastrectomy for, morbidity and mortality after, 1490-1493
hepatic metastases, 2105-2112
peritoneal immunocytology in, diagnostic and prognostic value of, 3406-3411
uracil-tegafur for, 2877-2885
Gastrinoma, bone metastases, detection, frequency, location, and management of, 1040-1053
Gastrointestinal cancer
advanced refractory, weekly docetaxel infusion for, 2164-2168
metastatic potential of, RT-PCR detection of CEA mRNA in lymph nodes or blood and, 128-132
Gastrointestinal tumor-associated antigen 733.2
mRNA in lymph nodes or blood of breast cancer patients, clinical significance of, 2632-2640
as tumor marker in breast cancer, limitations of, 2632-2640
G-CSF. *See* Granulocyte colony-stimulating factor
Gemcitabine
pain control and, 803-804
for pancreatic cancer, 803-804
Gemcitabine, docetaxel regimen, in advanced malignancy, 3866-3873
Gene therapy
adenovirus-mediated p53, in advanced recurrent squamous cell carcinoma of head and neck, 2221-2232
bone marrow, with MDR1 gene, 165-172
as cancer therapy, 2548-2556
clinical trials of, 2548-2556
as cytotoxic therapy, 2548-2556
gene transfer systems for, 2548-2556
as immunotherapy, 2548-2556
for lung cancer, potential molecular targets in, 1207-1217
preclinical experiments in, 2548-2556
strategies for, research on, 2548-2556
Genetic counseling, for breast-ovarian cancer susceptibility, 133-138
Genetic testing, for breast-ovarian cancer susceptibility, 133-138
Germ cell tumors
advanced
bleomycin, etoposide, cisplatin for, 1287-1293, 3205
high-dose etoposide for, secondary leukemia after, 3386-3391
biologic markers for, 1246

chromosome i(12p) in, 1246
favorable-prognosis
bleomycin, etoposide, cisplatin for, three-cycle *v* four-cycle regimen, 702-706
management of, 1244-1245
phase III study in, follow-up of, 702-706
good-risk, management of, 1244-1245
metastatic poor-prognosis
and allocation of patients to clinical trials, criteria for, 707-715
BEP *v* VIP for, 1287-1293, 3205
combination chemotherapy for, G-CSF during, 716-724
intensive chemotherapy for, 692-701
management of, 1245
response to chemotherapy, modeling for, 707-715
nonseminomatous. *See* Nonseminomatous germ cell tumors
p53 in, 1246, 3163
poor-risk, management of, 1245, 1287-1293, 3205
prognostic factors for, 702-706, 707-715, 1246
recurrent, vinblastine, ifosfamide, and cisplatin for, 2500-2504
staging of, 1244
treatment of
effects on fertility, 1245-1246
toxicity of, 1245
with very high hCG levels, management strategies and outcomes for, 1294-1297
Germinoma, central nervous system
primary chemotherapy for, relapse after, 204-209
recurrent, radiation therapy for, 204-209
Glioma
O^6-alkylguanine-DNA alkyltransferase in, prognostic significance of, 3851-3857
DNA mismatch repair in, prognostic significance of, 3851-3857
high-grade, radiation and chemotherapy for, effects on cognitive function, 2195-2201, 3210-3211
high-grade advanced, KRN8602 with/without filgrastim for, 2181-2187
methylphenidate treatment for, neurobehavioral benefits of, 2522-2527
pediatric, recurrent, temozolomide for, 3037-3043
preoperative O^6-benzylguanine for, 3570-3575
recurrent, nitrogen mustard, vincristine, and procarbazine for, 2953-2958
recurrent malignant
^{131}I-labeled monoclonal antibody 81C6 for, 2202-2212
paclitaxel for, phase I study of, 2188-2194
response to Temodal, 3851-3857
Glutamine, for paclitaxel-associated myalgias and arthralgias, 3918-3919
GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
Goserelin, *v* surgical ovariectomy, for receptor-positive metastatic breast cancer, 994-999
Graft-*v*-host disease, with allogeneic peripheral-blood progenitor-cell transplantation, 986-993
Graft-*v*-lymphoma/leukemia, with allogeneic blood progenitor-cell transplantation, nonablative preparative regimen in, 2817-2824
Graft-*v*-tumor effects
with allogeneic blood progenitor-cell transplantation, nonablative preparative regimen in, 2817-2824
in breast cancer, 986-993
Granisetron
and delayed emesis after high-dose cisplatin, 1174-1178
and dexamethasone, antiemetic efficacy after high-dose cisplatin, 1174-1178
institutional guidelines for use of, 771-778
oral, antiemetic efficacy in cisplatin-based chemotherapy, 1568-1573
single-dose oral, antiemetic effectiveness and safety of, 754-760
Granulocyte colony-stimulating factor. *See also* Filgrastim
with 9-aminocamptothecin in lymphomas, effects on efficacy and maximum dose-intensity, 2345-2351, 2895
anaphylactoid reaction to, in normal stem-cell donor, 812-813
and bone marrow uptake of fluorine-18-fluorodeoxyglucose during chemotherapy, 173-180
for childhood T-cell leukemia and lymphoblastic lymphoma, 522-526
clinical trials of, design and interpretation of, 3179-3190
during combination chemotherapy for metastatic poor-prognosis germ cell tumors, 716-724
in dose-intensive ifosfamide and epirubicin regimen for soft tissue sarcoma, phase II study of, 1438-1443
in early-stage breast cancer, cost-effectiveness analysis for, 2435-2444
peripheral-blood stem-cell mobilization
enhancement by recombinant human stem-cell factor, 1899-1908
with/without cyclophosphamide, for multiple myeloma treatment, 1547-1553
prophylactic, after chemotherapy, 3874-3879
in small-cell lung cancer
cost-effectiveness analysis for, 2700-2707
priming with, myelotoxicity after, 2708-2714
Granulocyte-macrophage colony-stimulating factor
in CHOP regimen for aggressive non-Hodgkin's lymphoma in elderly, 2352-2358
clinical trials of, design and interpretation of, 3179-3190
and dose-intensity of chemotherapy for small-cell lung cancer, 642-650
as surgical infection prophylaxis, 1167-1173
in treatment of neutropenic fever, 2930-2936
Granulocyte-monocyte colony-forming cells, measurement in back-up bone marrow failure with poor stem-cell mobilization, predictive value of, 1554-1560
Groupe d'Etude des Lymphomes Folliculaires 86 Trial
of interferon for advanced follicular lymphoma, survival and toxicity in, 2332-2338
of interferon for follicular lymphoma, quality-of-life-adjusted survival analysis for, 2339-2344, 3716-3717
Guidelines. *See* Practice guideline(s)
GW506U78, in hematologic malignancy, pharmacokinetics and response to, 3607-3615
Gynecologic Oncology Group
phase II trial of intraperitoneal paclitaxel in residual carcinoma of ovary, fallopian tube, or peritoneum, 2620-2624
study of oral etoposide for platinum-treated ovarian cancer, 405-410

Hairy cell leukemia
cladribine for, 3007-3015
massive splenomegaly in, 1232-1233
Hand-foot syndrome
after IV continuous infusion of 5-fluorouracil, 301-308
in sickle cell disease, 808-809
HD. *See* Hodgkin's disease
Head and neck cancer
advanced
induction chemotherapy, surgery, and concurrent chemoradiation for, 2715-2721

p53 gene therapy in, 2221-2232
simultaneous radiochemotherapy *v* radiotherapy alone in, 1318-1324
metastatic, cisplatin/fluorouracil chemotherapy for, modulation by IFN alfa-2b, 1054-1059
poor-prognosis, concomitant radiotherapy with paclitaxel, fluorouracil, and hydroxyurea and G-CSF support for, 735-744
recurrent
cisplatin/fluorouracil chemotherapy for, modulation by IFN alfa-2b, 1054-1059
paclitaxel, ifosfamide, and cisplatin for, 1325-1330
p53 gene therapy in, 2221-2232
squamous cell carcinoma
docetaxel, cisplatin, fluorouracil, and leucovorin induction chemotherapy for, 1331-1339
paclitaxel, ifosfamide, and cisplatin for, 1325-1330
p53 gene therapy in, 2221-2232
unresectable, reirradiation for, 3556-3562
Helicobacter pylori, eradication, and ongoing mutations and clonal expansion in gastric MALT lymphoma, 3822-3831
Hematologic malignancy. *See also* Leukemia(s); Lymphoma(s); Myelodysplastic syndrome
GW506U78 in, pharmacokinetics and response to, 3607-3615
monoclonal antibody-based therapies for, 3691-3719
p53 mutations in, prognostic significance of, 3163-3164
Hematopoietic growth factors, clinical trials of, design and interpretation of, 3179-3190
Hemoglobin level, epoetin beta and, in gastrointestinal cancer patients, 434-440
Hemolytic anemia, after fludarabine for chronic lymphocytic leukemia, 1885-1889, 3209-3210
Hepatocellular carcinoma
tamoxifen and, in rats *v* humans, 779-792
unresectable, antiandrogen therapy for, evaluation of, 411-417
Hereditary cancer, survival differences in, 395-396
Histology, in stage D(S) neuroblastoma, prognostic significance of, 2007-2017
HIV (human immunodeficiency virus) infection
Burkitt-like lymphomas in, 3788-3795
Kaposi's sarcoma in
fumagillin analog for, 1444-1449
interferon alfa with zidovudine for, 1736-1742
paclitaxel for, 1112-1121
pegylated liposomal doxorubicin *v* bleomycin and vincristine for, 683-691
pegylated liposomal doxorubicin *v* doxorubicin, bleomycin, and vincristine for, 2445-2451
pulmonary involvement, liposomal daunorubicin for, 3369-3374
non-Hodgkin's lymphoma in
characterization of, 3788-3795
prognostic factors for, 3601-3606
pediatric, malignancies in, 1729-1735
HLA. *See* Human leukocyte antigen(s)
Hodgkin's disease
advanced
adjuvant radiation therapy in, 815-817, 818-829, 2893-2894
BEACOPP regimen in, 3810-3821
in children, ABVD chemotherapy for, with MOPP or radiation, 897-906
MOPP/ABV chemotherapy for, 19-26, 2283
MOPP-ABVD regimen in, 897-905, 1235
chemotherapy *v* combined modality therapy for, meta-analysis of, 815-817, 818-829, 2893-2894
early-stage, adjuvant chemotherapy in, 830-843
pediatric
MOPP-ABVD regimen for, 897-906, 1235
radiation therapy for, 391-393
survivors, second cancers in, 536-544, 2287-2288, 2570-2572
radiation therapy for
and adjuvant chemotherapy, meta-analysis of, 830-843
breast cancer linked to, 338-347, 2285-2287
in childhood, 391-393
recurrence
after autologous bone marrow transplant, vinblastine for, 584-588
prevention of, with radiation therapy and adjuvant chemotherapy, 830-843
radiation therapy and adjuvant chemotherapy for, 830-843
survivors
mortality in, 3592-3600
second cancers in, 536-544, 2287-2288, 2570-2572
Homocysteine, in CSF, methotrexate-induced changes in, and seizures, 393-394
Hormone replacement therapy, and aggressiveness of breast cancer, 3115-3120
Hospice, in end-of-life care, 1986-1996
Hot flashes
in breast cancer survivors, vitamin E for, 495-500
in cancer survivors, venlafaxine hydrochloride for, 2377-2381
Human chorionic gonadotropin, serum level, with germ cell tumors, effects on management strategies and outcomes, 1294-1297
Human immunodeficiency virus. *See* HIV (human immunodeficiency virus) infection
Human leukocyte antigen(s), and response to melanoma vaccine, 1430-1437, 2293
Human papillomavirus (HPV)
E6 and E7 oncogenes, in carcinogenesis, 330-337
genotype, prognostic significance in cervical cancer, 2613-2619
malignancies associated with
molecular basis of, 330-337
potential targeted molecular therapy for, 330-337
malignancy-associated subtypes, 330-337
and telomerase activity in (pre)neoplastic cervical lesions, 2238-2245
HumaSPECT-Tc, in radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer, 1777-1787, 2575
Humoral immune response, to polyvalent melanoma cell vaccine, correlation with survival, 2913-2920
Hydroxyurea
effects on deoxynucleotides, 2321-2331
parenterally infused
cellular pharmacodynamics and plasma pharmacokinetics of, 2321-2331
in chronic myelogenous leukemia, 2321-2331

ICAM-1. *See* Intercellular adhesion molecule-1
ICRF-187. *See* Dexrazoxane
IDEC-C2B8
in NHL, 1635-1637
peripheral T-cell lymphoma after, 1635-1637, 3916
for relapsed indolent lymphoma, 2825-2833
Ifosfamide
addition to cisplatin and carboplatin regimen for advanced non-small-cell lung cancer, 1388-1396

for Ewing's sarcoma, 3628-3633
for lung cancer, IV-oral *v* IV-mesna regimen in, 616-621
Ifosfamide, carboplatin, etoposide, vincristine regimen, for small-cell lung cancer, dose-intensity in, 642-650
Ifosfamide, epirubicin regimen, dose-intensive, with filgrastim support, for soft tissue sarcoma, phase II study of, 1438-1443
Ifosfamide, paclitaxel, cisplatin regimen, for transitional cell carcinoma of urothelial tract, 2722-2727
Immune response, to polyvalent melanoma cell vaccine, correlation with survival, 2913-2920
Immunocytology, peritoneal, in gastric cancer, diagnostic and prognostic value of, 3406-3411
Immunotoxins, in treatment of hematologic malignancy, 3697-3699
Indium-111 capromab pendetide scan, for prediction of prostate cancer response to salvage radiotherapy, 284-289
Infection(s)
in neutropenic patients, quinolone prophylaxis for, meta-analysis of, 1179-1187
in surgical oncology, trial of prophylactic GM-CSF for, 1167-1173
Infirm patient, limited-stage small-cell lung cancer in, abbreviated treatment for, 3323-3328
INK4a gene. *See* Tumor suppressor gene(s), *p16*
Integrin α3, expression in non-small-cell lung cancer, prognostic significance of, 1060-1067
Intensive care unit
cancer patients admitted to, multicenter outcome study of, 761-770
probability of mortality in, disease-specific multivariable logistic regression model for, 761-770
Intent-to-treat analysis, of radiation therapy for pediatric Hodgkin's disease, 391-393
Intercellular adhesion molecule-1, expression in non-Hodgkin's lymphoma, 35-40
Interferon
IFN-α
for early chronic-phase chronic myelogenous leukemia, 882-889
with IL-2 and fluorouracil, for outpatient treatment of metastatic renal cell carcinoma, 2505-2513
with IL-2 and 13-*cis*-retinoic acid, in metastatic renal cell carcinoma, 1820-1825
long-term cytogenetic remissions in chronic myelogenous leukemia due to, and PCR status of patients, 1526-1531
for Philadelphia-positive chronic myelogenous leukemia with cytogenetic clonal evolution, 3279-3285
with zidovudine, for HIV-associated Kaposi's sarcoma, 1736-1742
IFN α-2a
adjuvant therapy in resected primary stage II cutaneous melanoma, 1425-1429, 3205-3206
maintenance therapy, in non-Hodgkin's lymphoma, 41-47
IFN α-2b
and cisplatin/fluorouracil chemotherapy for recurrent or metastatic head and neck cancer, 1054-1059
with dacarbazine with/without tamoxifen, for metastatic melanoma, 1743-1751
for follicular lymphoma, 2332-2338, 2339-2344
Q-TWiST analysis of, 2339-2344, 3716-3717
and high-dose fluorouracil infusion for advanced colorectal cancer, 418-426
in induction and maintenance treatment of low-grade NHL, 1538-1546
in multiple myeloma, Q-TWiST analysis of, 2834-2839, 3716-3718
in remission maintenance therapy for multiple myeloma, 890-896
toxicity of, retrospective evaluation of, 3716
Interferon, prednisone regimen, in remission maintenance therapy for multiple myeloma, 890-896
Intergroup trial, of cyclophosphamide, doxorubicin, and fluorouracil *v* 16-week multidrug regimen for node-positive receptor-negative breast cancer, 2382-2391
Interleukin
IL-2
in adoptive transfer of activated CD4$^+$ T cells, 2752-2760
after consolidation chemotherapy for acute myelogenous leukemia, 914-919
with IFN-α and fluorouracil, for metastatic renal cell carcinoma, 2728-2732
with IFN-α and fluorouracil, for outpatient treatment of metastatic renal cell carcinoma, 2505-2513
with IFN-α and 13-*cis*-retinoic acid, in metastatic renal cell carcinoma, 1820-1825
in treatment of advanced melanoma, 2921-2929
IL-12, ascitic-fluid levels in ovarian cancer, prognostic significance of, 1861-1868, 3208-3209
IL-11, recombinant, clinical trials of, design and interpretation of, 3179-3190
IL-3, recombinant human, hematopoietic effects in chemotherapy for ovarian cancer, 3335-3344
Intraperitoneal chemotherapy
with mitomycin, in gastric cancer, 2733-2738
with paclitaxel, in residual carcinoma of ovary, fallopian tube, or peritoneum, 2620-2624
Intrathecal triple therapy, in childhood acute lymphoid leukemia, acute neurotoxicity associated with, 1712-1722
Irinotecan
and cisplatin, clinical synergy between, 3858-3865
diarrhea induced by
delayed-onset, pathophysiology and treatment of, 2745-2751
guidelines for treatment and assessment of, 3169-3178
in oral chemotherapy, 2563
Irinotecan, cisplatin regimen, for small-cell lung cancer, 1068-1074
Irinotecan, etoposide regimen, for small-cell lung cancer, 3329-3334
Isolated hepatic perfusion, with TNF and melphalan, for unresectable liver cancer, 1479-1489
Isolated limb perfusion, prophylactic, for high-risk melanoma, 2906-2912
Italian Gastric Cancer study Group findings, on D2 gastrectomy for gastric cancer, 1490-1493

Jejunal cancer, advanced, LU103793 for, 2770-2779
JM-216, in oral chemotherapy, 2562
Journal of Clinical Oncology, new publisher for, 3719

Kaposi's sarcoma (KS)
AIDS-related
fumagillin analog for, 1444-1449
interferon alfa with zidovudine for, 1736-1742
paclitaxel for, 1112-1121
pegylated liposomal doxorubicin *v* bleomycin and vincristine for, 683-691
pegylated liposomal doxorubicin *v* doxorubicin, bleomycin, and vincristine for, 2445-2451
pulmonary, liposomal daunorubicin for, 3369-3374
posttransplant, paclitaxel for, 3478-3479

Ki-67 expression
in breast cancer, prognostic significance of, 470-479
in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
in epithelial ovarian cancer, clinical and prognostic significance of, 2591-2600
KRN8602, with/without filgrastim, for advanced cancer, phase I and pharmacokinetic study of, 2181-2187

Lactate dehydrogenase, serum levels, in metastatic melanoma, prognostic significance of, 1103-1111
Laparoscopy, in diagnosis of lymphoma, 1909-1915
Laryngeal cancer, squamous cell, overexpression of cyclin D1, clinical significance of, 3069-3077
Leiomyosarcoma, in HIV-infected children, 1729-1735
Lenograstim. *See* Granulocyte colony-stimulating factor
Letrozole, for advanced breast cancer, and megestrol acetate, comparison of, 453-461, 2892-2893
Leucovorin
and aminopterin for refractory malignancies, 1458-1464
and high-dose fluorouracil infusion for advanced colorectal cancer, 418-426
Leukemia(s)
acute
in childhood, docetaxel as potential treatment in, 907-913
complications of, 3199-3202
after high-dose chemotherapy and autologous BMT for breast cancer, 1008-1012
acute lymphoblastic. *See* Acute lymphoblastic leukemia
acute lymphocytic. *See* Acute lymphocytic leukemia
acute lymphoid, childhood, acute neurotoxicity in, association with IV methotrexate and intrathecal triple therapy, 1712-1722
acute myelogenous
adult, nucleolar organizer region counts in, prognostic significance of, 1512-1518
childhood, consolidation chemotherapy for, IL-2 after, 914-919
acute myeloid
adult, induction therapy for, daunorubicin in, 2086-2092
in elderly, remission-induction and postremission therapy in, 872-881
with inversion(16), postremission chemotherapy for, competitive RT-PCR for molecular monitoring during, 1519-1525
in vitro cytotoxicity of docetaxel in, 907-913
mitoxantrone and low-dose cytarabine in, 872-881
p53 mutations in, prognostic significance of, 3163-3164
therapy-related
after high-dose etoposide, 3386-3391
inversion of chromosome 16 and *CBFB* and *MYH11* gene rearrangements in, 1890-1896
acute promyelocytic, prognostic factors in, 78-85
chronic lymphocytic. *See* Chronic lymphocytic leukemia
chronic myelogenous. *See* Chronic myelogenous leukemia
hairy cell, massive splenomegaly in, 1232-1233
nonseminomatous germ cell tumor-associated, 725-732
refractory to conventional therapy, aminopterin for, 1458-1464
risk for, after intensive chemotherapy for solid tumors, 3016-3020
secondary, after high-dose etoposide, 3386-3391
T-cell, childhood, trial of G-CSF for, 522-526
treatment-related, neuroblastoma and, 3880-3889
Leukocyte count, as prognostic factor, in acute promyelocytic leukemia, 78-85
Leukoencephalopathy, in childhood acute lymphoid leukemia, association with IV methotrexate and intrathecal triple therapy, 1712-1722
Li-Fraumeni syndrome, *p53* germ-line mutations in, 3163
Lipid-associated sialic acid, as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
Liver
colorectal metastases to, intrahepatic and systemic chemotherapy for, 2528-2533
dysfunction, paclitaxel in, phase I and pharmacokinetic trial of, 1811-1819
unknown primary tumors metastatic to
clinical features of, 2105-2112
prognostic significance of, 2105-2112
Liver cancer
radiation therapy for, with doses based on normal tissue complication probability model, 2246-2252
unresectable, isolated hepatic perfusion with TNF and melphalan for, 1479-1489
Loperamide, for chemotherapy-induced diarrhea, recommended guidelines for use of, 3175
Loperamide and acetorphan, for irinotecan-induced delayed-onset diarrhea, 2745-2751
Loss of heterozygosity, chromosome *18q*, prognostic significance in colon cancer, 427-433
LU103793
for advanced solid tumors, 2770-2779
pharmacokinetics of, 2770-2779
Lumpectomy, and radiotherapy, for ductal breast cancer, 441-452
Lung, renal cell carcinoma metastases to, resection of, 2261-2266
Lung cancer. *See also* Mesothelioma, pleural
adenocarcinoma
integrin α3 expression in, prognostic significance of, 1060-1067
K-*ras* point mutations in, detection in sputum, 3061-3068
molecular abnormalities in, 1207-1217
advanced, weekly paclitaxel for, 153-158
antisense therapy for, potential molecular targets in, 1207-1217
bone metastases, bisphosphonate treatment for, 1218-1225, 3204-3205, 3890-3899
cavitating squamous cell carcinoma, 363-364
diagnosis of, potential molecular targets in, 1207-1217
economic issues in, 3900-3912
gene therapy for, potential molecular targets in, 1207-1217
hepatic metastases, 2105-2112
ifosfamide for, IV-oral *v* IV-mesna regimen in, 616-621
molecular abnormalities in, 1207-1217
non-small-cell. *See* Non-small-cell lung cancer
small-cell. *See* Small-cell lung cancer
squamous cell, development of, p53 mutations and, 3162
in younger patients
epidemiology of, 651-657
management of, 651-657
surveillance for, 651-657
Lymph nodes, renal cell carcinoma metastases to, resection of, 2261-2266
Lymphoma(s)
allogeneic blood progenitor-cell transplantation for, nonablative preparative regimen in, 2817-2824
anaplastic large T-/null-cell
adult, soluble CD30 serum levels in, clinical significance of, 1532-1537
clinical features of, 2789

B-cell
aggressive, *p53* mutations in, prognostic significance of, 3164
high-grade, *p53* mutations in, prognostic significance of, 3164
low-grade, *p53* mutations in, prognostic significance of, 3164
bone marrow involvement in, FDG-PET evaluation for, 603-609
Burkitt-like, clinical features of, 2791
Burkitt's
clinical features of, 2794
p53 mutations in, clinical significance of, 3164
centroblastic/centrocytic, 1922-1930
centrocytic, 1922-1930
diagnosis of, laparoscopy in, 1909-1915
diffuse large B-cell
bcl2 expression, prognostic significance of, 1931-1939
clinical features of, 2782
clinical features of, cell-cycle regulator protein expression and, 1931-1939
Ki67 expression, prognostic significance of, 1931-1939
MDM2 expression, prognostic significance of, 1931-1939
mediastinal localization, and treatment outcome, 63-69
outcome in, factors affecting, 63-69, 1931-1939
p53 expression, prognostic significance of, 1931-1939
prognosis for, 1931-1939
p21/WAF1 expression, prognostic significance of, 1931-1939
Rb expression, prognostic significance of, 1931-1939
relapsed and refractory, prognostic factors in, 63-69
follicular
clinical characteristics of, 1922-1930, 2783
doxorubicin-containing regimen for, IFN α-2b and, 2332-2338, 2339-2344, 3716-3717
IFN α-2b and, 2332-2338, 2339-2344, 3716-3717
interferon maintenance therapy in, 41-47
v mantle-cell lymphoma, 1922-1930
prognosis for, 1922-1930
response to chemotherapy, 1922-1930
hepatic metastases, 2105-2112
Hodgkin's. *See* Hodgkin's disease
International Prognostic Index for, 2781
intraocular, chemotherapy for, 3000-3006
lymphoblastic
childhood, trial of G-CSF for, 522-526
clinical features of, 2790
lymphoplasmacytic, clinical features of, 2793
mantle-cell. *See* Mantle-cell lymphoma
marginal zone B-cell, MALT type, clinical characteristics of, 2786
marginal zone B-cell, nodal type, clinical features of, 2792
mucosa-associated lymphoid tissue
clinical features of, 2787
of stomach, radiation therapy alone for, 1916-1921
nasal, clinical features, immunophenotype, and treatment outcome for, 70-77
nasopharyngeal, clinical features, immunophenotype, and treatment outcome for, 70-77
non-Hodgkin's. *See* Non-Hodgkin's lymphoma (NHL)
peripheral T-cell
clinical characteristics of, 2786
after Rituximab treatment for NHL, 1635-1637, 3916
primary CNS
chemotherapy for, 3000-3006
combined modality therapy for, 859-863, 864-871
high-dose methotrexate for, 859-863, 864-871
long-term survival in, 859-863
primary cutaneous large B-cell, site-related bcl-2 protein expression in, 2080-2085
primary mediastinal large B-cell, clinical features of, 2788
refractory
advanced, weekly docetaxel infusion for, 2164-2168
9-aminocamptothecin in, efficacy and maximum dose-intensity of, with/without G-CSF support, 2345-2351, 2895
relapsed
9-aminocamptothecin in, efficacy and maximum dose-intensity of, with/without G-CSF support, 2345-2351, 2895
indolent, Rituximab therapy for, 2825-2833
small lymphocytic, clinical characteristics of, 2784
T-cell, GW506U78 in, pharmacokinetics and response to, 3607-3615

Magnetic resonance imaging (MRI), in detection of bone metastases in gastrinoma patients, 1040-1053
Malignant lymphoma. *See* Lymphoma(s)
Mammography, screening, in women 40-49, risk-based recommendations for, 3105-3114
Mantle-cell lymphoma
aggressive, Hyper-CVAD/MTX-Ara-C and stem cell transplantation for, 3803-3809
CHOP regimen for, 13-18
clinical presentation of, 1922-1930, 2568-2569, 2785
diagnosis of, 2568-2569
fludarabine monophosphate for, 579-583
v follicle-center lymphoma, 1922-1930
immunohistology of, 2568-2569
prognosis for, 1922-1930
response to chemotherapy, 1922-1930
treatment of, 3-5
high-dose chemoradiotherapy and autologous bone marrow transplantation in, 13-18
Marimastat, oral, for advanced lung cancer, 2150-2156
Markov model, of small-cell lung cancer treatment with G-CSF, 2700-2707
Mastectomy
bilateral, prophylactic, for *BRCA1*- or *BRCA2*-positive patients, 979-985, 2573-2575
radiation therapy after, issues related to, 2886-2889, 3211, 3918
Maximum tolerated dose, definition of, for pediatric trials, 966-978
MCV. *See* Methotrexate, cisplatin, vinblastine regimen
MDR. *See* Multidrug resistance
MDR-associated protein, overexpression, reversal of multidrug resistance caused by, VX-710 and paclitaxel for, 2964-2976
MDR1 gene
overexpression, reversal of multidrug resistance caused by, VX-710 and paclitaxel for, 2964-2976
retroviral-mediated transfer of, bone marrow chemoprotection with, 165-172
Mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin, bleomycin, vinblastine, dacarbazine regimen
for advanced childhood Hodgkin's disease, 897-906, 1235
sequential, in advanced Hodgkin's disease, 19-26, 2283
Mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin, bleomycin, vinblastine regimen, hybrid, for advanced Hodgkin's disease, 19-26, 2283
Mechlorethamine, vincristine, procarbazine regimen, for recurrent glioma, 2953-2958

Medical oncology, curriculum development in, ASCO training resource document for, 372-379
Medical Research Council, Ewing's tumor study, 3628-3633
Medical Research Council/European Organization for Research and Treatment of Cancer, findings on intensive induction-sequential chemotherapy for poor-prognosis metastatic germ cell tumor, 692-701
Medulloblastoma
  childhood
    craniospinal radiation for, neuropsychologic functioning after, 1723-1728
    recurrent, temozolomide for, 3037-3043
  desmoplastic, molecular markers in, diagnostic and prognostic significance of, 2478-2485
  molecular markers in, diagnostic and prognostic significance of, 2478-2485
  recurrent, high-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for, 222-228
Megakaryocyte growth and development factor, clinical trials of, design and interpretation of, 3179-3190
Megestrol acetate, for advanced breast cancer, and letrozole, comparison of, 453-461, 2892-2893
Melanoma
  advanced
    IL-2-based treatment for, 2921-2929
    KRN8602 with/without filgrastim for, 2181-2187
    LU103793 for, 2770-2779
    response to in vivo expansion of activated $CD4^+$ T cells, 2752-2760
    risk stratification in, 2921-2929
  brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
  combination chemotherapy for, 664-669
  cutaneous
    regional node status in, FDG-PET in prediction of, 1770-1776
    resected primary stage II, adjuvant interferon alfa-2a for, 1425-1429, 3205-3206
    transcription factor AP-2 in, prognostic significance of, 3584-3591
  disseminated, prognostic factors in, 1103-1111
  familial cutaneous, molecular genetics of, 670-682
  hepatic metastases, 2105-2112
  HLA phenotype, and response to polyvalent melanoma cell vaccine, 1430-1437, 2293
  metastatic
    biochemotherapy for, 1752-1759
    cisplatin, vinblastine, and dacarbazine with IFN α-2a and IL-2 for, 1752-1759
    dacarbazine, interferon α-2b, and tamoxifen for, 1743-1751
  PCR detection of circulating melanoma cells in, relation to stage, surgical treatment, and recurrence, 1760-1769
  prophylactic isolated limb perfusion for, 2906-2912
  recurrence, after negative sentinel lymph node biopsy, 2253-2260
  regional nodal failure, after negative sentinel lymph node biopsy, 2253-2260
  soft-tissue metastases, prognostic factors in, 1103-1111
  survival, response to polyvalent melanoma cell vaccine and, 1430-1437, 2293
  survival benefit in, 388-389
  visceral metastases, prognostic factors in, 1103-1111
Melanoma cell vaccine, polyvalent, response to
  correlation with survival, 2913-2920
  HLA association, 1430-1437, 2293
Melphalan, etoposide, carboplatin regimen, in Wilms' tumor, high-dose, with autologous stem-cell rescue, 3295-3301
Memorial Sloan-Kettering Cancer Center
  experience with neuroblastoma and treatment-related myelodysplasia/leukemia, 3880-3889
  guidelines for use of serotonin-antagonist antiemetics, 771-778
  T12 protocol for intensification of preoperative chemotherapy for osteosarcoma, 2452-2458
Meningitis, neoplastic
  high-dose IV methotrexate for, 1561-1567
  intrathecal chemotherapy for, 1561-1567
2-Mercaptoethanesulfonate sodium. *See* Mesna
Mesna, in ifosfamide therapy for lung cancer, 616-621
Mesothelioma
  advanced, KRN8602 with/without filgrastim for, 2181-2187
  pleural, prognostic factors in, 145-152
  radiation therapy for, paclitaxel as radiation sensitizer for, 635-641
Messenger RNA (mRNA), tissue- or tumor-specific transcripts in peripheral blood, RT-PCR detection of, in thyroid cancer, 1158-1166
Meta-analysis
  of adjuvant radiation therapy in advanced Hodgkin's disease, 815-817, 818-829, 2893-2894
  of chemotherapy *v* combined modality therapy for Hodgkin's disease, 815-817, 818-829, 2893-2894
  of prognostic impact of bone marrow micrometastases, 557-566
  of quinolone prophylaxis in neutropenic patients, 1179-1187
  of radiation therapy and adjuvant chemotherapy for Hodgkin's disease, 830-843
[^{131}I]Metaiodobenzylguanidine, dose escalation, and bone marrow rescue, for refractory neuroblastoma, 229-236
Metastasis, high risk for, RT-PCR detection of CEA mRNA in lymph nodes or blood and, 128-132
Methadone, in pain management, 3213-3215, 3216-3221, 3656-3661
Methotrexate
  for acute lymphoblastic leukemia, subclinical demyelination and single-carbon transfer pathway abnormalities caused by, 1505-1511
  for acute lymphoblastic leukemia in children
    intrathecal administration of, 920-930
    with IV mercaptopurine, with lower-risk B-lineage ALL, 246-254, 2283-2285
  in acute lymphoid leukemia, in children, intravenous administration, neurotoxicity with, 1712-1722
  for acute lymphoid leukemia in children, with low-dose leucovorin rescue, neurotoxicity with, 1712-1722
  for B-lineage ALL, intravenous *v* oral, 246-254, 2283-2285
  for CNS lymphoma, survival and late neurotoxicity with, 859-863, 864-871
  effects on sulfur-containing compounds in CSF, and seizures, 393-394
  for neoplastic meningitis, high-dose intravenous administration of, 1561-1567
  for osteosarcoma, pharmacokinetics, and prognosis, 658-663, 2290-2291
  seizures with, homocysteine level in CSF and, 393-394
Methotrexate, cisplatin, vinblastine regimen, neoadjuvant therapy in bladder preservation, 3576-3583
Methotrexate, doxorubicin, cisplatin regimen, for osteosarcoma of extremity, histologic response to, 658-663, 2290-2291
Methotrexate, thiotepa, vincristine, dexamethasone/intrathecal cy-

tarabine, methotrexate regimen, for intraocular and primary CNS lymphoma, 3000-3006
Methotrexate, vinblastine, adriamycin, cisplatin regimen, neoadjuvant therapy in bladder preservation, 1298-1301
O^6 Methylguanine-DNA methyltransferase levels, in astrocytoma, prognostic significance of, 3310-3315
Methylphenidate, for brain tumors, neurobehavioral benefits of, 2522-2527
MGDF. *See* Megakaryocyte growth and development factor
Milan Cancer Institute, experience with primary chemotherapy for operable breast cancer, 93-100
Mitomycin
adjuvant intraperitoneal chemotherapy with, for gastric cancer, 2733-2738
adjuvant therapy with, in gastric cancer, 1036-1039, 3714
Mitomycin, ftorafur regimen, adjuvant therapy with, in gastric cancer, 1036-1039, 3714
Mitoxantrone, and low-dose cytarabine
for acute myeloid leukemia in elderly, 872-881
in acute myeloid leukemia in elderly, 872-881
Mitoxantrone, prednisone regimen, for hormone-resistant prostate cancer, economics of, 2272-2279
Monoclonal antibody. *See also ASCO Annual Meeting Highlights:* Rituximab
17-1A, therapeutic effect in resected Dukes' C colorectal cancer, 1788-1794
anti-CD20, ^{131}I-labeled, for non-Hodgkin's lymphoma, 3270-3278
88BV59 (totally human Mab, HumaSPECT), in radioimmunoscintigraphy of recurrent, metastatic, or occult colorectal cancer, 1777-1787, 2575
81C6, ^{131}I-labeled, for recurrent malignant glioma, 2202-2212
CAMPATH-1H, for retreatment of low-grade non-Hodgkin's lymphoma, 3257-3263
ch14.18, for disialoganglioside-positive neuroblastoma and osteosarcoma, 2169-2180
3F8 (anti-G_{D2}), for minimal residual stage 4 neuroblastoma diagnosed at 1 year of age, 3053-3060
Lym-1, ^{131}I-labeled, for non-Hodgkin's lymphoma, 3246-3256
in peritoneal immunocytology, 3406-3411
recombinant humanized anti-p185$^{HER2/neu}$, plus cisplatin, in HER2/*neu*-overexpressing metastatic breast cancer, 2659-2671
in treatment of hematologic malignancy, 3691-3719
Mood. *See also* Depression
in glioma patients treated with methylphenidate, 2522-2527
MOP. *See* Mechlorethamine, vincristine, procarbazine regimen
MOPP/ABV. *See* Mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin, bleomycin, vinblastine regimen
MOPP/ABVD. *See* Mechlorethamine, vincristine, procarbazine, prednisone/Adriamycin, bleomycin, vinblastine, dacarbazine regimen
Morphine
oral, *v* transdermal fentanyl, for pain management, patient satisfaction and side effects with, 1588-1593
in pain management, 3216-3221, 3222-3229, 3656-3661
MTS-1 gene. *See* Tumor suppressor gene(s), *p16*
MTV. *See* Methotrexate, thiotepa, vincristine, dexamethasone/intrathecal cytarabine, methotrexate regimen
Mucin-1
mRNA in lymph nodes or blood of breast cancer patients, clinical significance of, 2632-2640
as tumor marker in breast cancer, limitations of, 2632-2640
Mucosa-associated lymphoid tissue (MALT) lymphoma
clinical characteristics of, 2786
gastric
ongoing mutations and clonal expansion in, 3822-3831
radiation therapy alone for, 1916-1921
Multidrug resistance
caused by *MDR1* and MRP overexpression, reversal, VX-710 and paclitaxel for, 2964-2976
circumvention of, 3679-3683
mechanisms of, clinical significance of, 3674-3690
Multiple myeloma
combination chemotherapy *v* melphalan plus prednisone for, 3832-3842
induction therapy for, overview of, 3832-3842
interferon maintenance in, Q-TWiST analysis of, 2834-2839, 3716-3718
pamidronate for, long-term, in advanced disease, 593-602, 2572-2573, 3204-3205
peripheral-blood stem-cell infusion for, mobilization with G-CSF with/without cyclophosphamide, 1547-1553
peripheral-blood stem-cell mobilization with G-CSF with/without cyclophosphamide in, 1547-1553
remission maintenance therapy, interferon *v* interferon plus prednisone for, 890-896
stage III, skeletal events in, effects of long-term pamidronate therapy on, 593-602, 2572-2573, 3204-3205
topotecan for, in relapsing or refractory disease, 589-592
MVAC. *See* Methotrexate, vinblastine, adriamycin, cisplatin regimen
MX2-hydrochloride. *See* KRN8602
Myelodysplasia
secondary, after high-dose chemotherapy and autologous BMT for breast cancer, 1008-1012
treatment-related, neuroblastoma and, 3880-3889
Myelodysplastic syndrome, *p53* mutations in, prognostic significance of, 3163-3164
Myeloid-associated antigen, expression in childhood ALL, 3768-3773
MYH11 gene, in therapy-related acute myeloid leukemia, 1890-1896

Nasopharyngeal carcinoma
chemoradiotherapy *v* radiotherapy for, 1310-1317
poorly differentiated, CAPABLE regimen for, 2514-2521
poor-prognosis, management of, 2213-2220
primary, fractionated high-dose-rate brachytherapy in, 2213-2220
recurrent or persistent, detection by FDG-PET *v* CT, 3550-3555
Nasopharynx, primary NHL of, clinical features, immunophenotype, and treatment outcome for, 70-77
National Cancer Institute, findings on pediatric HIV-related malignancies, 1729-1735
National Cancer Institute of Canada Clinical Trials Group, phase II study of topotecan for relapsed ovarian cancer, 2233-2237
National Surgical Adjuvant Breast and Bowel Project B-17, findings on lumpectomy and radiotherapy for ductal breast cancer, 441-452
National Wilms' Tumor Study Group, evaluation of pulse-intensive dactinomycin with doxorubicin, for Wilms' tumor, 237-245
Neoadjuvant chemotherapy
for invasive bladder cancer, bladder preservation with, 1298-1301
for locally advanced breast cancer, tumor clearance of ^{99m}Tc-sestamibi as predictor of response to, 1677-1683
Neuroblastoma
advanced, outcome, predictors of, 953-965
detected by screening, spontaneous regression of, 1265-1269
localized, spontaneous regression of, 1265-1269

minimal residual stage 4, diagnosed at 1 year of age, MAb 3F8 treatment for, 3053-3060
MYCN oncogene expression in, prognostic significance of, 3286-3294
p53 in, 3163
refractory
disialoganglioside-positive, monoclonal antibody ch14.18 for, 2169-2180
^{131}I-metaiodobenzylguanidine dose escalation and bone marrow rescue for, 229-236
spontaneous regression of, 1265-1269
stage D(S)
biologic risk factors in, 2003-2006, 2007-2017
prognostic factors in, 2003-2006, 2007-2017
treatment of, 2003-2006, 2007-2017
stage III
biologic staging, prognostic and clinical significance of, 1256-1264
risk stratification, and treatment success, 1256-1264
stage 4, treated with induction chemotherapy and myeloablative megatherapy followed by stem-cell transplantation, risk factors in, 953-965
stage 4S, 2003-2006
and treatment-related myelodysplasia/leukemia, 3880-3889
Neuroendocrine tumors
hepatic metastases, 2105-2112
positron emission tomography with 5-hydroxytryptophan for, 2534-2541
Neuropsychologic functioning. *See also* Cognitive functioning
in SCLC patients treated with chemotherapy and radiation therapy with/without warfarin, 1954-1960
Neurotoxicity, acute, in childhood ALL, associated with IV methotrexate and intrathecal triple therapy, 1712-1722
Neutropenia
in children with T-cell malignancies, effect of G-CSF on, 522-526
in early-stage breast cancer treatment, first-cycle blood counts as predictors of, 2392-2400
febrile, treatment of, GM-CSF in, 2930-2936
infections in, quinolone prophylaxis for, meta-analysis of, 1179-1187
Nitrogen mustard. *See* Mechlorethamine
Nolatrexed hydrochloride, for solid tumors, dosage and schedule, preclinical and phase I clinical studies of, 1131-1141
Noncompliant patient, limited-stage small-cell lung cancer in, abbreviated treatment for, 3323-3328
Non-Hodgkin's lymphoma (NHL). *See also ASCO Annual Meeting Highlights*
advanced
CAMPATH-1H monoclonal antibody in, 3257-3263
response to in vivo expansion of activated CD4$^+$ T cells, 2752-2760
aggressive, time to relapse, prognostic significance of, 3264-3269
autologous bone marrow transplantation for
augmented preparative regimens for, 48-55
relapse after, second BMT for, 804-806
autologous stem-cell transplantation for, marrow purging and post-transplant radiotherapy for, 2803-2816
B-cell, myeloablative therapy with ^{131}I-anti-CD20 antibody, follow-up and late toxicity in, 3270-3278
classification of, 2780-2795
diffuse, VACOP-B *v* VACOP-B plus autologous BMT for, 2796-2802
dissemination, ICAM-1 expression and, 35-40
in elderly
CHOP regimen for, 27-34, 2065-2069, 2352-2358
risk factors for treatment-related death in, 2065-2069
fractionated radiotherapy of, ^{131}I-Lym-1 antibody for, 3246-3256
high-grade
late effects in long-term survivors of, 2070-2079
time to relapse, prognostic significance of, 3264-3269
histologic subtypes, clinical features of, 2780-2795
HIV-associated
characterization of, 3788-3795
prognostic factors in, 3601-3606
in HIV-infected children, 1729-1735
ICAM-1 expression in
and dissemination, 35-40
prognostic significance of, 35-40
intermediate-grade, time to relapse, prognostic significance of, 3264-3269
large cell, diffuse *v* follicular, effect on outcomes of high-dose chemotherapy and autologous stem-cell transplantation, 844-849
low-grade
IFN α-2b in induction and maintenance treatment of, 1538-1546
interferon maintenance therapy in, 41-47
retreatment with CAMPATH-1H monoclonal antibody, 3257-3263
poor-prognosis, high-dose chemotherapy plus autologous BMT for, 2796-2802
pretreated
CAMPATH-1H monoclonal antibody for, 3257-3263
cladribine therapy for, dosages and, 850-858
prognosis for, ICAM-1 expression and, 35-40
refractory, infusional flavopiridol for, 2986-2999
relapsed
bryostatin 1 for, 56-62
IDEC-C2B8 in, 1635-1637, 3916
paclitaxel infusion for, 574-578, 2289-2290
Non-Hodgkin's Lymphoma Classification Project, 2782-2794
Non-Hodgkin's Lymphoma Cooperative Study Group, trial of VA-COP-B *v* VACOP-B plus autologous BMT for diffuse NHL, 2796-2802
Nonproven therapies
patients' interest in, management of, 1-2, 3203
patients' use of, 5-year follow-up study of, 6-12, 3203
and survival, 6-12, 3203
Nonseminomatous germ cell tumors
bleomycin for, cure rate *v* morbidity with, 799-800
extragonadal, prognosis for, 2500-2504
leukemia associated with, 725-732
with low risk for metastasis, identification and management of, 261-268
primary mediastinal
biologic characteristics of, 725-732
cisplatin-based chemotherapy for, results, 725-732
clinical characteristics of, 725-732
residual retroperitoneal mass histology in, validity of predictions of, 269-274
Non-small-cell lung cancer
advanced
cisplatin and carboplatin with/without ifosfamide for, 1388-1396
cisplatin-based chemotherapy in, 2133-2141
cisplatin *v* cisplatin plus vinorelbine for, 2459-2465
docetaxel and cisplatin in, phase II study of, 1948-1953

gemcitabine and docetaxel regimen for, 3866-3873
KRN8602 with/without filgrastim for, 2181-2187
LU103793 for, 2770-2779
refractory, weekly docetaxel infusion for, 2164-2168
brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
combined modality therapy for, 807-808
continuous hyperfractionated accelerated radiotherapy for, patient-assessed symptoms with, 3082-3093
costs of care for, in commercially insured cohort, 1420-1424
docetaxel for, fluid retention in, 3426-3432
economic issues in, 3900-3912
hyperfractionated accelerated radiation therapy in, 3518-3523
integrin α3 expression in, prognostic significance of, 1060-1067
locally advanced
intensive multimodality therapy for, 622-634
paclitaxel, carboplatin and radiation therapy in, 3316-3322
paclitaxel as radiation sensitizer for, 635-641
lymph node staging in, with FDG-PET scan, 2142-2149
ME491/CD63 expression in, prognostic significance of, 1397-1406
molecular abnormalities in, 1207-1217
MRP-1/CD9 and *KAI1/CD82* expression in, prognostic significance of, 1397-1406
plakoglobin expression in, prognostic significance of, 1407-1413
poor-risk, chemoradiotherapy for, 3078-3081
preoperative chemotherapy and chemoradiotherapy in, 622-634
prognostically unfavorable, intensive multimodality therapy for, 622-634
recurrence, *MRP-1/CD9* and *KAI1/CD82* expression and, 1397-1406
stage I
molecular pathologic substaging system in, 2468-2477
prognostic factors in, 2468-2477
stage III
combined modality therapy in, 807-808
unresectable: vinorelbine, cisplatin, and radiation therapy for, 2157-2163
staging, *MRP-1/CD9* and *KAI1/CD82* expression in, 1397-1406
tirapazamine and cisplatin in, 3524-3527
North American Autologous Blood and Marrow Transplant Registry, results on high-dose chemotherapy with stem-cell support for breast cancer, 387-386
North American Brain Tumor Consortium, phase I study of paclitaxel for recurrent malignant glioma, 2188-2194
North Central Cancer Treatment Group, trial of nitrogen mustard, vincristine, and procarbazine for recurrent glioma, 2953-2958
Nose, primary NHL of, clinical features, immunophenotype, and treatment outcome for, 70-77
NSCLC. *See* Non-small-cell lung cancer
Nucleolar organizer region counts, in adult acute myelogenous leukemia, prognostic significance of, 1512-1518

Octreotide, for chemotherapy-induced diarrhea, recommended guidelines for use of, 3169-3178
Off-label drug use, ethics of, 1637
Oncogenes
bcl-2
expression in breast cancer, 2025-2031
expression in primary cutaneous large B-cell lymphoma, 2080-2085
bcl2, expression in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
BCL-2, expression in lung cancer, 1207-1217
c-*erb*B-2 (HER-2/*neu*)
amplification in prostate cancer, 1302-1309
expression in lung cancer, 1207-1217
overexpression in breast cancer, cisplatin plus recombinant humanized anti-p185$^{HER2/neu}$ MAb for, 2659-2671
overexpression in breast cancer, prognostic significance of, 462-469, 470-479
plasma levels in breast cancer, prognostic significance of, 2409-2416
as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
c-*myc*, amplification in childhood primitive neuroectodermal tumors, prognostic significance of, 2478-2485
K-*ras*, point mutations, detection in sputum of patients with adenocarcinoma of lung, 3061-3068
MDM2, expression in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
MYC, expression in lung cancer, 1207-1217
MYCN
amplification in stage D(S) neuroblastoma, prognostic significance of, 2007-2017
expression in childhood neuroblastoma, prognostic significance of, 3286-3294
neu/erbB-2, amplification in breast cancer, prognostic significance of, 1340-1349
ras, as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
RAS, expression in lung cancer, 1207-1217
Oncologists
communication skills training for, 1961-1968
in end-of-life care, 1986-1996
recognition of depression in cancer patients, 1594-1600
Ondansetron
institutional guidelines for use of, 771-778
intravenous
antiemetic effectiveness and safety of, 754-760
antiemetic efficacy in cisplatin-based chemotherapy, 1568-1573
Oophorectomy, prophylactic, for *BRCA1*- or *BRCA2*-positive patients, 979-985, 2573-2575
Organ transplantation, EBV-negative posttransplant lymphoproliferative disorders and, 2052-2059
Osteosarcoma
disialoganglioside-positive, monoclonal antibody ch14.18 for, 2169-2180
histologic response to chemotherapy, predictive factors for, 658-663, 2290-2291
metastatic, treatment at diagnosis, 3641-3648
pediatric, recurrent, temozolomide for, 3037-3043
preoperative chemotherapy for, intensification of, 2452-2458
prognosis for, correlation with chemotherapy-induced necrosis, 658-663, 2290-2291
Ovarian cancer
advanced
gemcitabine and docetaxel regimen for, 3866-3873
high-dose chemotherapy with peripheral-blood progenitor-cell support for, 1852-1860
topotecan for, after cisplatin or carboplatin and paclitaxel chemotherapy, 3345-3352
ascitic-fluid IL-12 levels in, prognostic significance of, 1861-1868, 3208-3209

BRCA-associated
correlation with personal and family history of malignancy, 2417-2425
genetic testing for susceptibility to, psychologic effects of, 1650-1654
in *BRCA1* mutation carriers, survival rates for, 395-396, 397-404, 3206-3207
in *BRCA1*- or *BRCA2*-positive women, prophylactic surgery for, 979-985, 2573-2575
carboplatin for, dose-intensity of, 2426-2434
chemotherapy for, rhIL-3 in, hematopoietic effects of, 3335-3344
epithelial
α-catenin and collagen IV expression in, clinical and prognostic significance of, 2591-2600
cell adhesion and proliferation in, 2591-2600
Ki-67 expression in, clinical and prognostic significance of, 2591-2600
outcome, BAX protein expression and, 2577-2578, 2583-2590, 3211
topotecan for, after cisplatin or carboplatin and paclitaxel chemotherapy, 3345-3352
inherited susceptibility to, genetic testing for, psychologic effects of, 1650-1654
microscopic residual disease, intraperitoneal paclitaxel in, 2620-2624
paclitaxel in, 96-hour infusion regimen for, 1849-1851
paclitaxel-resistant, oral etoposide for, 405-410
platinum-treated
oral etoposide for, 405-410
topotecan for, 3345-3352
progenitor-cell mobilization for, using stem-cell factor and filgrastim after chemotherapy *v* chemotherapy plus filgrastim alone, 2601-2612
prognosis for
ascitic-fluid IL-12 levels and, 1861-1868, 3208-3209
BAX protein expression and, 2577-2578, 2583-2590, 3211
α-catenin and collagen IV expression and, 2591-2600
Ki-67 expression and, 2591-2600
prophylactic surgery for, for *BRCA1*- or *BRCA2*-positive women, 979-985, 2573-2575
recurrent, topotecan for, 2233-2237
second-line paclitaxel and carboplatin for, 1494-1497
susceptibility, genetic counseling and testing for, 133-138
Ovarian function, after autologous bone marrow transplantation, 2359-2363
Ovariectomy, *v* goserelin, for receptor-positive metastatic breast cancer, 994-999
Oxaliplatin, for metastatic colorectal cancer, 2739-2744
Oxycodone
controlled-release, 3222-3229, 3230-3237
immediate-release, 3230-3237
in pain management, 3222-3229, 3230-3237

p16. *See* Tumor suppressor gene(s), *p16*
p53 (gene and p53 protein product)
adenovirus-mediated gene therapy with, in advanced recurrent squamous cell carcinoma of head and neck, 2221-2232
and apoptosis, 3159-3160
in breast cancer
prognostic significance of, 2641-2650
and response to adjuvant chemotherapy, 470-479
and tamoxifen response in recurrent disease, 121-127
as tumor marker, ASCO recommendations for use of, 1997 update, 793-795
and cell-cycle arrest, 3158-3160
in colorectal cancer, as tumor marker, ASCO recommendations for use of, 1997 update, 793-795
expression in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
and genetic instability, 3160
in germ cell tumors, 1246, 3163
loss, in lung cancer, 1207-1217
mutations
and cancer prognosis, 3163
germ-line, and cancer risk, 3163
in hematologic malignancies, prognostic significance of, 3163-3164
in tumor development, 3160-3161
in tumorigenesis, 3158-3168
in tumor suppression, mechanisms of, 3158-3160
Packed red blood cell transfusion, costs of, in cancer care, 2364-2370
Paclitaxel. *See also* VX-710, paclitaxel regimen
in advanced lung cancer, weekly schedule for, 153-158
breast cancer resistant to, docetaxel for, 3362-3368
and cardiotoxicity, 3481-3482, 3483-3485
continuous infusion of, maximum tolerated dose and dose-limiting toxicities of, 635-641
for gynecologic cancer patients with cardiac risk, 3481-3482, 3483-3485
in hepatic dysfunction, phase I and pharmacokinetic trial of, 1811-1819
for HIV-related Kaposi's sarcoma, 1112-1121
intraperitoneal, in residual carcinoma of ovary, fallopian tube, or peritoneum, 2620-2624
for metastatic breast cancer, weekly dose-dense therapy with, 3353-3361
myalgias and arthralgias associated with, glutamine therapy for, 3918-3919
for non-Hodgkin's lymphoma relapse, continuous infusion of, 574-578, 2289-2290
in ovarian cancer, 96-hour infusion regimen for, 1849-1851
ovarian cancer resistant to, oral etoposide for, 405-410
for posttransplant Kaposi's sarcoma, 3478-3479
as radiation sensitizer for mesothelioma and non-small-cell lung cancer, 635-641
for recurrent malignant glioma, phase I study of, 2188-2194
Paclitaxel, carboplatin regimen
with concurrent radiation therapy, in locally advanced non-small-cell lung cancer, 3316-3322
for ovarian or peritoneal cancer, as second-line therapy, 1494-1497
for urothelial carcinoma, 1844-1848
in advanced disease, 1844-1848
outpatient treatment using, 255-260
Paclitaxel, cisplatin regimen, *v* cisplatin-teniposide, for advanced non-small-cell lung cancer, 2133-2141
Paclitaxel, fluorouracil, cisplatin regimen, in advanced esophageal cancer, 1826-1834
Paclitaxel, fluorouracil, hydroxyurea regimen, for poor-prognosis head and neck cancer, and concomitant radiotherapy with G-CSF support, 735-744
Paclitaxel, ifosfamide, cisplatin regimen, for recurrent head and neck squamous cell carcinoma, 1325-1330

Paclitaxel, topotecan regimen, with G-CSF support, for advanced breast cancer, 2032-2037
Pain management
with bone metastases
bisphosphonates in, 1218-1225, 3204-3205, 3890-3899
samarium-153 lexidronam in, 1574-1581
for breakthrough cancer pain, 3238-3245
equianalgesic dose ratio in, 3213-3215, 3216-3221
methadone in, 3213-3215, 3216-3221
morphine in, 3216-3221, 3222-3229
morphine *v* methadone in, 3656-3661
oral transmucosal fentanyl citrate for, 3238-3245
oxycodone in, 3222-3229, 3230-3237
in pancreatic cancer, 803-804
transdermal fentanyl *v* oral morphine for, patient satisfaction and side effects with, 1588-1593
Palliative care, in end-of-life care, 1986-1996
Palmoplantar erythrodysesthesia, *v* hand-foot syndrome, 808-809
Pamidronate
in breast cancer with bone metastases, evidence-based review of, 1218-1225, 3204-3205
current use in oncology, 3890-3899
for multiple myeloma, long-term, in advanced disease, 593-602, 2572-2573, 3204-3205
prevention of skeletal complications of breast cancer, 2038-2044
Pancreatic adenocarcinoma
preoperative chemoradiation for, 3843-3850
resectable, combined modality treatment of, 3843-3850
Pancreatic cancer
adjuvant preoperative chemoradiotherapy in, 317-323
advanced, gemcitabine for, 803-804
anemia with, epoetin beta for, 434-440
hepatic metastases, 2105-2112
pain control in, 803-804
Pancreatic tumors, endocrine, positron emission tomography with 5-hydroxytryptophan for, 2534-2541
Papillomavirus. *See* Human papillomavirus (HPV)
Patient(s)
preferences for information and treatment participation, 2283
sharing information with, 2283
Patterns of Care, 1992-1994 process survey, on radiation therapy for rectosigmoid and rectal cancer, 2542-2547
PAVE. *See* Cisplatin, doxorubicin, vincristine, etoposide regimen
PEB. *See* Carboplatin, etoposide, bleomycin regimen
Pediatric oncology. *See* Children and adolescents
Pediatric Oncology Group findings
on acute neurotoxicity in childhood ALL, 1712-1722
on 9-aminocamptothecin for solid tumors in children, 2494-2499
on antimetabolite-based therapy for childhood ALL, 2840-2847
on G-CSF therapy for childhood T-cell malignancies, 522-526
on intensive IV methotrexate/IV mercaptopurine regimen for ALL, 246-254, 2283-2285
on neuropsychologic functioning in recipients of craniospinal radiation for medulloblastoma, 1723-1728
on prognostic factors in stage D(S) neuroblastoma, 2003-2006, 2007-2017
on significance of sex in childhood ALL, 2854-2863
on topotecan and cyclophosphamide combination for pediatric solid tumors, 945-952
on treatment of metastatic osteosarcoma, 3641-3648
Penclomedine, phase I clinical and pharmacokinetic trial of, with novel two-stage design, 1142-1149
Pericardial effusions, malignant
cardiac angiosarcoma presenting as, 3913-3915
intracavitary chemotherapy for, 2371-2376
Peripheral-blood progenitor-cell transplantation
allogeneic
for breast cancer, 986-993
for lymphoid malignancies, nonablative preparative regimen in, 2817-2824
autologous, for breast cancer, occult tumor contamination, and survival, 3509-3517
Peripheral-blood stem-cell mobilization
with G-CSF
enhancement by recombinant human stem-cell factor, 1899-1908
enhancement by stem-cell factor, 2601-2612
with/without cyclophosphamide, 1547-1553
poor, back-up bone marrow failure with, 1554-1560
Peripheral-blood stem-cell transplantation
autologous, $CD34^+33^-$ cells in, effects on engraftment kinetics and transfusion requirements, 2093-2104
DMSO and metabolites in recipients of, plasma concentrations and pharmacokinetics of, 610-615
for multiple myeloma, stem cell mobilization with G-CSF with/without cyclophosphamide in, 1547-1553
predicting day 100 nonrelapse toxic mortality after, 3796-3802
value of pretransplant evaluation in, 3796-3802
Peritoneal cancer, second-line paclitaxel and carboplatin for, 1494-1497
Peritoneum, microscopic residual carcinoma in, intraperitoneal paclitaxel for, 2620-2624
Phase I trial
advanced cancer patients' participation in, ethical considerations with, 2305-2312
of 9-aminocamptothecin colloidal dispersion dosage and schedule, 1122-1130
of 9-aminocamptothecin for solid tumors in children, 2494-2499
of aminopterin for refractory malignancies, 1458-1464
of bone marrow chemoprotection with MDR1 retroviral gene transfer, 165-172
of bryostatin 1, in relapsed NHL and CLL, 56-62
of cisplatin and continuous infusion topotecan in advanced cancer, 3302-3309
of cisplatin and irinotecan combined weekly schedule, 3858-3865
cohort-specific consent for, 2305-2312
of concomitant radiotherapy and paclitaxel, fluorouracil, hydroxyurea regimen with G-CSF support, for poor-prognosis head and neck cancer, 735-744
in concurrent chemoradiation for small-cell lung cancer, 3528-3536
of docetaxel
with concomitant thoracic radiation, 159-164
infusional, for advanced refractory cancer, 2164-2168
dose escalation in, patient/subject participation in decision making about, 2305-2312
of Eniluracil (776C85) plus fluorouracil for advanced cancer, 1450-1457
of estramustine and short infusion of paclitaxel for paclitaxel-pretreated solid tumors in women, 2959-2963
of fumagillin analog for AIDS-related Kaposi's sarcoma, 1444-1449
of gemcitabine and docetaxel in advanced malignancy, 3866-3873
of hydroxyurea, parenterally infused, in chronic myelogenous leukemia, 2321-2331

of IDEC-C2B8 in NHL, 1635-1637, 3916
of ^{131}I-labeled monoclonal antibody 81C6, for recurrent malignant glioma, 2202-2212
of ^{131}I-MIBG dose escalation, and bone marrow rescue, for refractory neuroblastoma, 229-236
of infusional flavopiridol for refractory neoplasms, 2986-2999
of intermittent capecitabine for advanced and/or metastatic cancer, 2977-2985
of in vivo expansion of activated CD4$^+$ T cells in cancer patients, 2752-2760
of KRN8602 with/without filgrastim for advanced cancer, 2181-2187
of LU103793 in advanced solid tumors, 2770-2779
of monoclonal antibody ch14.18 for refractory neuroblastoma and osteosarcoma, 2169-2180
of nolatrexed hydrochloride for solid tumors, 1131-1141
novel two-stage design for, 1142-1149
of oral marimastat for advanced lung cancer, 2150-2156
of paclitaxel
in advanced lung cancer, 153-158
in hepatic dysfunction, 1811-1819
in recurrent malignant glioma, 2188-2194
and patient/subject participation in decision making, 2305-2312
pediatric
conduct of, 966-978
design of, 966-978
eligibility criteria for, 966-978
selection of agents for, 966-978
of topotecan and cyclophosphamide for solid tumors, 945-952
of penclomedine, for advanced malignancy, 1142-1149
of preoperative O^6-benzylguanine for glioma, 3570-3575
of pyrazoloacridine, in children and young adults with refractory cancers, 181-186
of temozolomide for recurrent solid tumors in childhood, 3037-3043
of titanocene dichloride in advanced cancer, 2761-2769
of vinorelbine, cisplatin, and radiation therapy for advanced chest malignancies, 2157-2163
of VX-710 and paclitaxel for reversal of MDR caused by *MDR1* and MRP overexpression, 2964-2976
Phase I/II trial
of CAPABLE regimen for poorly differentiated nasopharyngeal carcinoma, 2514-2521
of docetaxel, cisplatin, fluorouracil, leucovorin induction regimen for squamous cell carcinoma of head and neck, 1331-1339
of shark cartilage in advanced cancer, 3649-3655
Phase II recommended dosage
of 9-aminocamptothecin for solid tumors in children, 2494-2499
of capecitabine in oral administration, 2977-2985
of docetaxel with concomitant thoracic radiation therapy, 159-164
of LU103793 for advanced solid tumors, 2770-2779
of marimastat for advanced lung cancer, 2150-2156
of pyrazoloacridine, for pediatric patients with refractory cancers, 181-186
of vinorelbine and cisplatin in chemoradiotherapy for advanced chest malignancies, 2157-2163
Phase II trial
of adjuvant preoperative chemoradiotherapy in pancreatic cancer, 317-323
of CAMPATH-1H monoclonal antibody in low-grade NHL, 3257-3263
of chemoradiotherapy for poor-risk non-small-cell lung cancer, 3078-3081
of chemotherapy alone for intraocular and primary CNS lymphoma, 3000-3006
of cladribine for chronic myelogenous leukemia in accelerated or blast phase, 1498-1504
of combination chemotherapy for melanoma, 664-669
of docetaxel
for paclitaxel-resistant metastatic breast cancer, 3362-3368
pharmacokinetic/pharmacodynamic evaluation in, 187-196
of docetaxel and cisplatin
in advanced non-small-cell lung cancer, 1948-1953
for metastatic urothelial carcinoma, 3392-3397
of etoposide for platinum-treated ovarian cancer, 405-410
of fludarabine monophosphate for mantle-cell lymphoma, 579-583
of G-CSF with 9-aminocamptothecin in lymphomas, 2345-2351, 2895
of high-dose chemotherapy with peripheral-blood progenitor-cell support for advanced ovarian cancer, 1852-1860
of hyperfractionated accelerated radiation therapy in non-small-cell lung cancer, 3518-3523
of ifosfamide, paclitaxel, and cisplatin for transitional cell carcinoma of urothelial tract, 2722-2727
of ifosfamide and epirubicin with filgrastim support, for soft tissue sarcoma, 1438-1443
of IL-2, IFN-α, and 13-*cis*-retinoic acid in metastatic renal cell carcinoma, 1820-1825
of IL-2, IFN-α, and fluorouracil, in metastatic renal cell carcinoma, 2505-2513, 2728-2732
of infusional fluorouracil, epirubicin, and cyclophosphamide *v* infusional fluorouracil, epirubicin, and cisplatin for advanced breast cancer, 1350-1357
of intensive multimodality therapy for locally advanced non-small-cell lung cancer, 622-634
of intraperitoneal paclitaxel in residual carcinoma of ovary, fallopian tube, or peritoneum, 2620-2624
of irinotecan combined with cisplatin for small-cell lung cancer, 1068-1074
of liposomal daunorubicin for AIDS-related pulmonary Kaposi's sarcoma, 3369-3374
of nitrogen mustard, vincristine, and procarbazine for recurrent glioma, 2953-2958
of oxaliplatin in metastatic colorectal cancer, 2739-2744
of paclitaxel
for HIV-related Kaposi's sarcoma, 1112-1121
infusional, for relapsed NHL, 574-578, 2289-2290
of paclitaxel, carboplatin and radiation therapy in locally advanced non-small-cell lung cancer, 3316-3322
of paclitaxel, fluorouracil, and cisplatin in advanced esophageal cancer, 1826-1834
of paclitaxel, ifosfamide, and cisplatin for recurrent head and neck squamous cell carcinoma, 1325-1330
of paclitaxel and carboplatin, for advanced urothelial cancer, 1844-1848
of paclitaxel and topotecan with G-CSF support for advanced breast cancer, 2032-2037
of PAVE regimen for small-cell lung cancer in elderly, 1940-1947
with pleural mesothelioma, 145-152
of rhuMAb HER2 plus cisplatin in HER2/*neu*-overexpressing metastatic breast cancer, 2659-2671
of tirapazamine and cisplatin in non-small-cell lung cancer, 3524-3527

of topotecan for ovarian cancer
in advanced disease, 3345-3352
in relapse, 2233-2237
of vinorelbine for cervical cancer, 1094-1098
Phase III trial
of adjuvant intraperitoneal chemotherapy with mitomycin for gastric cancer, 2733-2738
of chemoradiotherapy *v* radiotherapy for nasopharyngeal carcinoma, 1310-1317
of cisplatin/fluorouracil chemotherapy modulation by IFN alfa-2b in head and neck cancer, 1054-1059
of dacarbazine, interferon α-2b, and tamoxifen for metastatic melanoma, 1743-1751
of GM-CSF in treatment of neutropenic fever, 2930-2936
of IV methotrexate/IV mercaptopurine regimen for ALL, 246-254, 2283-2285
of neoadjuvant chemotherapy in bladder cancer, 3576-3583
of pegylated liposomal doxorubicin *v* doxorubicin, bleomycin, and vincristine for AIDS-related Kaposi's sarcoma, 2445-2451
of prophylactic isolated limb perfusion for melanoma, 2906-2912
Philadelphia chromosome
acute lymphoblastic leukemia positive for, unrelated donor bone marrow transplantation for, 931-936
chronic myelogenous leukemia positive for, with cytogenetic clonal evolution, IFN-α therapy for, 3279-3285
Physician-assisted suicide, ASCO position on, 1986-1996
Picture-face scale, 3662-3673
Plakoglobin, expression in non-small-cell lung cancer, prognostic significance of, 1407-1413
Plasminogen activator inhibitor-1, in node-negative breast cancer, prognostic significance of, 3129-3136
Pleural effusions
malignant, diagnosis of, telomerase activity and, 567-573
telomerase activity in, diagnostic significance of, 567-573
Ploidy, tumor cell, in stage D(S) neuroblastoma, prognostic significance of, 2007-2017
Pneumocystis carinii pneumonia (PCP), in T-acute lymphoblastic leukemia, 3476-3477
Point-EXACCT, detection of K-*ras* point mutations in sputum, 3061-3068
Polymerase chain reaction. *See also* Reverse-transcriptase polymerase chain reaction
detection of circulating melanoma cells, relation to stage, surgical treatment, and recurrence, 1760-1769
fluorescent, detection of residual disease in childhood ALL, 3616-3627
Positron emission tomography (PET)
[^{18}F]fluorodeoxyglucose
detection of benign *v* malignant pulmonary nodules, 1075-1084
detection of lymphomatous bone marrow, 603-609
detection of recurrent or persistent nasopharyngeal carcinoma, 3550-3555
in evaluation of bone metastases in breast cancer, 3375-3379
and lymph node staging in non-small-cell lung cancer, 2142-2149
prediction of regional node status in cutaneous melanoma, 1770-1776
5-hydroxytryptophan, in neuroendocrine tumors, 2534-2541
Posttransplant lymphoproliferative disorders, EBV-negative, 2052-2059
Practice guideline(s), development
practitioner feedback in, 1226-1231
using Practice Guidelines Development Cycle, 1226-1231
Pregnancy, after bone marrow transplantation, 1978-1985
Primitive neuroectodermal tumors
of adults, *EWS/ETS* fusion gene expression in, 1150-1157
cerebral, pediatric, recurrent, temozolomide for, 3037-3043
childhood, molecular markers in, diagnostic and prognostic significance of, 2478-2485
cyclophosphamide, carboplatin, etoposide, melphalan regimen with autologous stem-cell support for, 937-944
molecular genetic abnormalities in, 1241-1242
peripheral
in adults, molecular diagnosis of, 1150-1157
intensive chemotherapy for, leukemic risks of, 3016-3020
Process-flow analysis, of costs of blood transfusion, 2364-2370
Progesterone receptor status, as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Prognostic factor(s)
in acute lymphoblastic leukemia, 3774-3781
translocation t(1;19) as, 527-535
in acute lymphocytic leukemia
interaction of, 2854-2863
sex as, 2854-2863
in acute myelogenous leukemia in adulthood, nucleolar organizer region counts as, 1512-1518
in acute promyelocytic leukemia, 78-85
in anaplastic large-cell lymphoma in adulthood, serum levels of soluble CD30 as, 1532-1537
in astrocytoma, O^6 methylguanine-DNA methyltransferase levels as, 3310-3315
bone marrow micrometastases as, meta-analysis of, 557-566
in breast cancer
age as, 2686-2692, 2693-2699
bcl-2 expression as, 2025-2031
cathepsins B and L as, 1013-1021
c-*erb*B-2 overexpression as, 462-469, 470-479
estrogen receptor status as, 470-479
Ki-67 positivity as, 470-479
with metastases, 2401-2408
new/erbB-2 amplification as, 1340-1349
p53 accumulation as, 2641-2650
plasma c-*erb*B-2 levels as, 2409-2416
in premenopausal patient with node-negative disease, 470-479
for primary chemotherapy, 107-114
race as, 2693-2699
site of primary tumor as, 1363-1366
tumor markers as, 3129-3136
vascular endothelial growth factor as, 3121-3128, 3129-3136
vascular enumeration as, in invasive disease, 1684-1688
in chronic myelogenous leukemia, 3782-3787
in colon cancer, chromosome *18q* allelic loss as, 427-433
in diffuse large B-cell lymphoma, mediastinal localization as, 63-69
in endometrial cancer, *Rb2/p130* gene expression as, 1085-1093
in Ewing's sarcoma
EWS/FLI1 fusion transcript type as, 1248-1255, 2895
with primary lung metastases, 3044-3052
translocation t(11;22) as, 1241-1242
in germ cell tumors, 702-706, 707-715, 1246
in HIV-associated non-Hodgkin's lymphoma, 3601-3606
in laryngeal squamous cell carcinoma, cyclin D1 expression as, 3069-3077

in melanoma
with metastases, 1103-1111
transcription factor AP-2 as, 3584-3591
in nasal/nasopharyngeal lymphomas, CD56 expression as, 70-77
in neuroblastoma
with advanced disease, 953-965
at stage D(S), 2003-2006, 2007-2017
at stage III, biologic tumor characteristics as, 1256-1264
in non-Hodgkin's lymphoma
ICAM-1 expression as, 35-40
time to relapse as, 3264-3269
in non-small-cell lung cancer
integrin α3 expression as, 1060-1067
MRP-1/CD9 and *KAI1/CD82* expression as, 1397-1406
plakoglobin expression as, 1407-1413
in stage I disease, 2468-2477
in ovarian cancer
ascitic-fluid IL-12 levels as, 1861-1868, 3208-3209
BAX protein expression as, 2577-2578, 2583-2590, 3211
α-catenin and Ki-67 expression as, 2591-2600
in pleural mesothelioma, 145-152
in prostate cancer, in localized disease treated with neoadjuvant androgen deprivation and 3D-conformal radiotherapy, 3380-3385
in seminoma, at stage II, 290-294
translocation t(1;19) as, in childhood acute lymphoblastic leukemia, 527-535
translocation t(11;22) as, in Ewing's sarcoma, 1241-1242
Prognostic index, for metastatic breast cancer, 2401-2408
Prostate cancer. *See also ASCO Annual Meeting Highlights*
adenocarcinoma, $p34^{cdc2}$ cyclin-dependent kinase, CD44s, and HER-2/*neu* in, 1302-1309
bone metastases, bisphosphonate treatment for, 1218-1225, 3204-3205, 3890-3899
clinical trials in, standardized eligibility criteria and end points in, 3398-3405
diagnosis of
in low-income patients, factors affecting, 3101-3104
low literacy and, 3101-3104
early, primary therapy for, complications of, 275-283
hormone-refractory
chemotherapy for, economics of, 2272-2279
response to cytotoxic therapy, serum PSA as marker of, 1835-1843
localized
neoadjuvant androgen deprivation and 3D-conformal radiotherapy for, prognostic factors in, 3380-3385
with poor prognosis, identification of, 3094-3100
neoadjuvant androgen deprivation and 3D-conformal radiotherapy for, prognostic factors in, 3380-3385
recurrence after radical prostatectomy or radiation therapy, PSA doubling times with, 2267-2271
refractory, infusional flavopiridol for, 2986-2999
response to salvage radiotherapy, prediction using In-111-labeled capromab pendetide, 284-289
stage at presentation, in low-income patients, factors affecting, 3101-3104
volume, prognostic significance of, 3094-3100
Prostatectomy
failed, response to salvage radiotherapy after, prediction using In-111-labeled capromab pendetide, 284-289
for localized prostate cancer, poor prognosis after, identification of, 3094-3100
radical, for early prostate cancer, complications of, 275-283
Prostate-specific antigen
doubling times, in recurrent prostate cancer, 2267-2271
serum level, as marker of response to cytotoxic therapy for hormone-refractory prostate cancer, 1835-1843
Protective agents, clinical trials of, design and interpretation of, 3179-3190
Proto-oncogenes, *RET*/PTC1, tumor-specific mRNA transcripts in peripheral blood, in thyroid cancer, 1158-1166
Psychologic functioning, in SCLC patients treated with chemotherapy and radiation therapy with/without warfarin, 1954-1960
Purpura, as prognostic factor, in acute promyelocytic leukemia, 78-85
Pyrazoloacridine, in children and young adults with refractory cancers, 181-186
pharmacokinetics of, 181-186

Q-TWiST analysis
of Eastern Cooperative Oncology Group trial EST 1684, 388-389
of IFN α-2b for follicular lymphoma, 2339-2344, 3716-3717
of IFN α-2b in multiple myeloma, 2834-2839, 3716-3718
Quality adjusted time without symptoms or toxicity. *See* Q-TWiST
Quality cancer care, access to, AFCOS consensus statement on, 1628-1629, 2001
Quality of life
for breast cancer survivors, 487-494, 501-514
after systemic adjuvant therapy, 1380-1387
and cancer pain, 1588-1593
with epoetin alfa for chemotherapy patients, 3412-3425
with follicular lymphoma, IFN α-2b and, 2339-2344, 3716-3717
health-related
changes in, interpretation of, 139-144
reference data on, 1188-1196
measurement tools, comparison of, 3662-3673
Quality-of-life scores
epoetin beta and, in gastrointestinal cancer patients, 434-440
mean, clinical relevance of, 1188-1196
Quinolone, prophylactic, in neutropenic patients, meta-analysis of, 1179-1187

Radiochemotherapy. *See also* Chemoradiotherapy
v radiotherapy alone, in advanced head and neck cancer, 1318-1324
Radioimmunoconjugates, in treatment of hematologic malignancy, 3700-3704
Radioimmunoscintigraphy
in assessment of anthracycline cardiotoxicity, 86-92
with In-111-labeled capromab pendetide, for prediction of prostate cancer response to salvage radiotherapy, 284-289
of recurrent, metastatic, or occult colorectal cancer, with HumaSPECT-Tc, 1777-1787, 2575
Radioimmunotherapy, for B-cell non-Hodgkin's lymphoma, follow-up and late toxicity in, 3270-3278
Radioiodinated antibody
for B-cell non-Hodgkin's lymphoma, follow-up and late toxicity in, 3270-3278
for fractionated radiotherapy of non-Hodgkin's lymphoma, 3246-3256
Radioiodine treatment, salivary gland protection by amifostine in, 3542-3549
Radiotherapy
adjuvant
in advanced Hodgkin's disease, 815-817, 818-829, 2893-2894
in breast cancer, 1655-1660, 2579-2582, 2625-2631, 3918
for soft tissue sarcoma of extremity, 197-203

in breast cancer, 1655-1660
adjuvant, 2579-2582, 2625-2631, 3918
after breast-conserving therapy, 1022-1029
cardiac mortality after, 1374-1379, 2579-2582, 2625-2631, 3918
postmastectomy, issues related to, 2886-2889, 3211, 3918
breast cancer linked to
prevention of, 338-347, 2285-2287
screening and detection of, 338-347, 2285-2287
chemotherapy plus. *See* Chemoradiotherapy
clinical, error rates in, 551-556, 2288-2289
cognitive effects in glioma patients, 2195-2201, 3210-3211
cranial, in high-risk pediatric ALL, 920-930
craniospinal, for childhood medulloblastoma, neuropsychologic functioning after, 1723-1728
external-beam. *See* External-beam radiation therapy
for gastric MALT lymphoma, 1916-1921
in head and neck cancer
reirradiation for unresectable disease, 3556-3562
v simultaneous radiochemotherapy, 1318-1324
for Hodgkin's disease
and adjuvant chemotherapy, meta-analysis of, 830-843
breast cancer linked to, 338-347, 2285-2287
in children, 391-393
hyperfractionated accelerated, for non-small-cell lung cancer, 3518-3523
patient-assessed symptoms with, 3082-3093
for intrahepatic cancer, with doses based on normal tissue complication probability model, 2246-2252
lumpectomy and, for ductal breast cancer, 441-452
for medulloblastoma, neuropsychologic functioning in recipients of, 1723-1728
for mesothelioma, paclitaxel as radiation sensitizer for, 635-641
for nasopharyngeal carcinoma, *v* chemoradiotherapy, 1310-1317
in non-Hodgkin's lymphoma, late effects of, 2070-2079
for non-small-cell lung cancer, paclitaxel as radiation sensitizer for, 635-641
for primary nasopharyngeal carcinoma, high-dose, 2213-2220
for rectosigmoid and rectal cancer, 2542-2547
for recurrent CNS germinoma, 204-209
salvage, prostate cancer response to, prediction using In-111-labeled capromab pendetide, 284-289
for seminoma, 290-294, 1999
in small-cell lung cancer
timing of, 1235-1237, 1631-1635
with/without cisplatin, 3479-3480
Radium, in cancer treatment, 2295-2296
Raltitrexed, *v* fluorouracil plus high-dose leucovorin, for advanced colorectal cancer, 2943-2952
ras oncogene, as tumor marker in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
Rectal cancer
distant metastases, effects of quality of surgery on, 324-329
radiation therapy for, 2542-2547
surgery for, effects on metachronous distant metastases and survival, 324-329
survival, effects of quality of surgery on, 324-329
Rectosigmoid cancer, radiation therapy for, 2542-2547
Renal cancer
advanced
KRN8602 with/without filgrastim for, 2181-2187
LU103793 for, 2770-2779
advanced refractory, weekly docetaxel infusion for, 2164-2168
brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
refractory, infusional flavopiridol for, 2986-2999
Renal cell carcinoma. *See also ASCO Annual Meeting Highlights*
hepatic metastases, 2105-2112
metastatic
IL-2, IFN-α, and 13-*cis*-retinoic acid in, 1820-1825
IL-2, IFN-α, and fluorouracil for outpatient treatment of, 2505-2513
IL-2, IFN-α2a, and fluorouracil for, 2728-2732
resection of, 2261-2266
Retinoblastoma-related gene *Rb2/p130*, expression, and prognosis for endometrial cancer, 1085-1093
all-*trans* Retinoic acid, chemotherapy regimen, for acute promyelocytic leukemia, prognostic factors for, 78-85
13-*cis*-Retinoic acid, plus IL-2 and IFN-α, in metastatic renal cell carcinoma, 1820-1825
RET/PTC1, mRNA transcripts, peripheral blood levels of, correlation with thyroid cancer, 1158-1166
Retroviral-mediated gene transfer, of MDR1 gene, in bone marrow chemoprotection for autologous stem-cell transplantation, 165-172
Retroviral vectors, for gene transfer, 2548-2556
Reverse-transcriptase polymerase chain reaction
for bone marrow micrometastasis, 806-807, 1707-1711
for breast cancer metastases, markers for, limitations of, 2632-2640
competitive
for *CBFβ/MYH11*, in postremission acute myeloid leukemia, 1519-1525
for molecular monitoring after bone marrow transplantation, 1519-1525
for molecular monitoring during postremission chemotherapy, 1519-1525
detection of CEA mRNA, 806-807
and metastatic potential of GI or breast cancer, 128-132
detection of tissue- or tumor-specific mRNA transcripts in peripheral blood, in thyroid cancer, 1158-1166
in long-term follow-up of IFN-α treatment for CML, 1526-1531
Rhabdomyosarcoma
high-dose induction chemoradiotherapy for, with intensive chemotherapy and autologous BMT as consolidation therapy, 1697-1706
intensive chemotherapy for, leukemic risks of, 3016-3020
recurrent, temozolomide for, 3037-3043
Risk stratification
in advanced melanoma, 2921-2929
in metastatic breast cancer, 2401-2408
in nonseminomatous testicular germ cell cancer, 261-268
in stage III neuroblastoma, and treatment success, 1256-1264
Rituximab
treatment for NHL, peripheral T-cell lymphoma after, 1635-1637, 3916
treatment for relapsed indolent lymphoma, 2825-2833
RT-PCR. *See* Reverse-transcriptase polymerase chain reaction

St Jude Children's Research Hospital, findings on secondary brain tumors after childhood ALL, 3761-3767
Salivary gland protection, by amifostine, in radioiodine treatment, 3542-3549
Samarium-153 lexidronam, for palliation of pain, with metastatic bone cancer, 1574-1581

Sarcoma(s)
advanced refractory, weekly docetaxel infusion for, 2164-2168
chromosomal translocations in, chimeric transcripts resulting from, 1248-1255, 2895
Ewing's. *See* Ewing's sarcoma
osteogenic. *See* Osteosarcoma
soft tissue. *See* Soft tissue sarcoma(s)
undifferentiated, high-dose induction chemoradiotherapy for, with intensive chemotherapy and autologous BMT as consolidation therapy, 1697-1706
Scientific misconduct, in clinical trials, 3433-3438
SCLC. *See* Small-cell lung cancer
Secondary leukemia
after high-dose etoposide, 3386-3391
after neuroblastoma treatment, 3880-3889
Secondary malignancy, risk for
with cladribine for hairy cell leukemia, 3007-3015
after pediatric ALL, 2848-2853, 3761-3767, 3917-3918
after pediatric Hodgkin's disease, 536-544, 2287-2288, 2570-2572
with tamoxifen, 348-353, 779-792, 2573
SEER. *See* Surveillance, Epidemiology, and End Results Cancer Registry
Seizures, with methotrexate therapy, homocysteine level in CSF and, 393-394
Seminoma, stage II, management of, 290-294, 1999
Sentinel lymph node
biopsy, negative, melanoma recurrence after, 2253-2260
Southern blot analysis of, for breast cancer metastases detection, 2253-2260
Serotonin antagonist antiemetic(s). *See also* Granisetron; Ondansetron
institutional guidelines for use of, 771-778
Sex
of child with B-precursor ALL, prognostic significance of, 2854-2863
and metastatic melanoma, prognostic significance of, 1103-1111
Sexual function
in breast cancer survivors, 487-494, 501-514, 1380-1387
in marrow transplantation survivors, 3148-3157
after prostate cancer treatment, 275-283
Shark cartilage, in advanced cancer, 3649-3655
Single-carbon transfer pathway abnormalities, during treatment of ALL, 1505-1511
Skin, squamous cell carcinoma of
advanced, gemcitabine and docetaxel regimen for, 3866-3873
development, p53 mutations and, 3161-3162
Small-cell lung cancer
advanced
gemcitabine and docetaxel regimen for, 3866-3873
KRN8602 with/without filgrastim for, 2181-2187
LU103793 for, 2770-2779
refractory, weekly docetaxel infusion for, 2164-2168
chemotherapy and radiation therapy with/without warfarin in, psychologic and neuropsychologic effects of, 1954-1960
chemotherapy for, dose intensification of, 642-650
combined modality treatment for
radiation therapy with/without cisplatin in, 3479-3480
timing of radiation therapy in, 1235-1237, 1631-1635
concurrent chemoradiation for, radiation dose schedule in, 3528-3536
in elderly, PAVE regimen for, 1940-1947
extensive
carboplatin and vinorelbine regimen for, 1414-1419
intensive chemotherapy with G-CSF support *v* standard chemotherapy in, 2126-2132
G-CSF in
clinical efficacy and cost-effectiveness analysis for, 2700-2707
myelotoxicity after, 2708-2714
irinotecan and cisplatin for, 1068-1074
limited-stage
abbreviated treatment in elderly, infirm, or noncompliant patients, 3323-3328
early *v* late radiation therapy for, 1235-1237, 1631-1635
radiation therapy with/without cisplatin in, 3479-3480
molecular abnormalities in, 1207-1217
refractory, irinotecan and etoposide for, 3329-3334
relapsed, irinotecan and etoposide for, 3329-3334
thoracic radiation and chemotherapy for, 2466-2467
Small round-cell tumors
desmoplastic. *See* Desmoplastic small round-cell tumors
primitive, in bone and soft tissue of adults, molecular diagnosis of, 1150-1157
Smoking
malignancy related to, economic issues in, 3900-3912
and tongue carcinoma, 745-753
Socioeconomic status, effects on stage at presentation in prostate cancer, 3101-3104
Soft tissue sarcoma(s)
dose-intensive chemotherapy for, with ifosfamide, epirubicin, and filgrastim, 1438-1443
epirubicin for, cardioprotective effect of dexrazoxane with, 86-92
of extremity, adjuvant radiotherapy for, 197-203
locally advanced, dose-intensive chemotherapy for, 1438-1443
metastatic, dose-intensive chemotherapy for, 1438-1443
Soft-tissue sarcoma(s), advanced, LU103793 for, 2770-2779
Soft-tissue sarcomas, *p53* in, 3163
Solid tumors
advanced
Eniluracil (776C85) plus fluorouracil for, 1450-1457
LU103793 for, 2770-2779
cisplatin plus irinotecan in, combined weekly schedule for, 3858-3865
intensive chemotherapy for, leukemia risk after, in young patients, 3016-3020
late, in Hodgkin's disease survivors, 536-544, 2287-2288, 2570-2572
nolatrexed hydrochloride for, dosage and schedule, 1131-1141
oral capecitabine for, toxicologic and pharmacologic studies of, 1795-1802, 2977-2985
paclitaxel-pretreated, in women, estramustine and short-infusion paclitaxel for, 2959-2963
pediatric
cyclophosphamide, carboplatin, etoposide, melphalan regimen with autologous stem-cell support for, 937-944
temozolomide for, in recurrence, 937-944
topotecan and cyclophosphamide for, 945-952
p53 mutations in, prognostic significance of, 3164-3165
refractory
aminopterin for, 1458-1464
Eniluracil (776C85) plus fluorouracil for, 1450-1457
Solitary pulmonary nodule(s)
benign *v* malignant, discrimination by FDG-PET, 1075-1084
cost-effective management of, 2113-2125

FDG-PET of, 1075-1084
cost-effectiveness of, 2113-2125
indeterminant, evaluation by FDG-PET, 1075-1084
Soluble CD30, serum levels in adult anaplastic large-cell lymphoma, clinical significance of, 1532-1537
Somatostatin receptor scintigraphy, in detection of bone metastases in gastrinoma patients, 1040-1053
Southwest Oncology Group findings
on astrocytoma prognosis, 3310-3315
on augmented preparative regimens for autologous BMT in NHL, 48-55
on melanoma treatment, 664-669
on multiple myeloma treatment, 890-896
in relapsing or refractory disease, 589-592
on non-Hodgkin's lymphoma treatment, 574-578, 2289-2290
on non-small-cell lung cancer treatment, 2459-2465, 3078-3081
Spinal cord compression, malignant extradural, emergency treatment of, evidence-based guideline for, 1613-1624
Spitzer QOL index, 3662-3673
Spitzer Uniscale, 3662-3673
Splenomegaly, in hairy cell leukemia, 1232-1233
Squamous cell carcinoma
cervical, vinorelbine for, 1094-1098
of head and neck
advanced recurrent, p53 gene therapy in, 2221-2232
induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin, 1331-1339
recurrent, paclitaxel, ifosfamide, and cisplatin for, 1325-1330
hepatic metastases, 2105-2112
laryngeal, cyclin D1 expression, clinical significance of, 3069-3077
of lung
cavitating, 363-364
development of, p53 mutations and, 3162
of oral tongue
demographics, risk factors, and treatment outcome for, 745-753
prognosis for, in patients < 45 years old, 745-753
of skin
advanced, gemcitabine and docetaxel regimen for, 3866-3873
development of, p53 mutations and, 3161-3162
Stem-cell donor, normal, anaphylactoid reaction to G-CSF, 812-813
Stem-cell factor
enhancement of peripheral-blood stem-cell mobilization by G-CSF, 1899-1908
plus filgrastim after chemotherapy, *v* chemotherapy plus filgrastim alone, in progenitor-cell mobilization for ovarian cancer, 2601-2612
Stem-cell rescue. *See* Stem-cell support, autologous
Stem-cell support, autologous. *See also* Peripheral-blood stem-cell transplantation
bone marrow chemoprotection for, with retroviral-mediated transfer of MDR1 gene, 165-172
after cyclophosphamide, carboplatin, etoposide, melphalan chemotherapy, for solid tumors in children, 937-944
with high-dose chemotherapy
for breast cancer, secondary myelodysplasia and acute leukemia after, 1008-1012
for children with brain tumors, 210-221
for diffuse *v* follicular large-cell lymphoma, 844-849
for metastatic breast cancer, 800-802
for NHL, marrow purging and radiotherapy posttransplantation and, 2803-2816
for recurrent medulloblastoma, 222-228
for stage IIIB breast cancer, 1000-1007
Steroid hormone receptor status, as tumor marker in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
Stomach, MALT lymphoma of
ongoing mutations and clonal expansion in, 3822-3831
radiation therapy alone for, 1916-1921
Subcutaneous Administration Propeukin Program, phase II trial of IL-2, IFN-α, and fluorouracil for outpatient treatment of metastatic renal cell carcinoma, 2505-2513
Suicide
among cancer patients, 2292
physician-assisted, ASCO position on, 1986-1996
Summation dose-intensity, for breast cancer chemotherapy, 3137-3147
Surgery
breast-conserving. *See* Breast conservation
in intensive multimodality therapy for locally advanced non-small-cell lung cancer, 622-634
postoperative infection prophylaxis for, trial of GM-CSF in, 1167-1173
Surveillance, Epidemiology, and End Results Cancer Registry, cardiac mortality after radiation therapy for breast cancer in, 2579-2582, 2625-2631, 3918
Surveillance, of *BRCA1* gene mutation carriers, 397-404, 3206-3207
Survival
in hereditary cancer, 395-396
nonproven therapies and, 6-12, 3203

Tamoxifen
for breast cancer
adjuvant cyclophosphamide, methotrexate, and fluorouracil with, effects of dose and schedule, 1358-1362
survival impact on competing causes of mortality in breast cancer survivors, 2018-2024
and toremifene, comparison of, 348-353, 1999-2000
carcinogenic potential of, 348-349, 779-792, 2573
endometrial cancer associated with, 779-792, 2573
for metastatic melanoma, with dacarbazine with/without IFN α-2b, 1743-1751
pharmacology of, 348-349
for recurrent breast cancer, p53 protein as predictive factor in, 121-127
secondary malignancy with, risk for, 348-349, 779-792, 2573
Technetium 99m-sestamibi, tumor clearance of, as predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer, 1677-1683
Telomerase, activity in pleural effusions, diagnostic significance of, 567-573
Telomerase activity, in cervical scrapings and frozen sections, for detection of (pre)neoplastic cervical lesions, 2238-2245
Temodal, in glioma, 3851-3857
Temozolomide, for recurrent solid tumors in childhood, 3037-3043
Testicular cancer
orchiectomy for, fertility after, 733-734
retroperitoneal lymph node dissection for, fertility after, 733-734, 1245-1246
stage I, on surveillance, paternity in men with, 733-734
Thiotepa, intracavitary therapy with, for malignant pericardial effusions, 2371-2376
Thromboembolism, in tamoxifen-treated women, 2018-2024

Thrombopoietic growth factors, clinical trials of, design and interpretation of, 3179-3190
Thymidylate synthase expression, in gastric cancer, as predictor of response and survival with chemotherapy, 309-316
Thymidylate synthase gene expression, in metastatic colon cancer, and response to 5-fluorouracil therapy, 1465-1469
Thymidylate synthase inhibitor. *See* Nolatrexed hydrochloride
Thyroglobulin, mRNA transcripts, peripheral blood levels of, correlation with thyroid cancer, 1158-1166
Thyroid cancer, and detection of thyroglobulin, thyroid peroxidase, and *RET*/PTC1 mRNA transcripts in peripheral blood, 1158-1166
Thyroid peroxidase, mRNA transcripts, peripheral blood levels of, correlation with thyroid cancer, 1158-1166
TIP. *See* Paclitaxel, ifosfamide, cisplatin regimen
Tirapazamine, cisplatin regimen, in non-small-cell lung cancer, 3524-3527
Titanocene dichloride
  for advanced cancer, weekly schedule for, 2761-2769
  pharmacokinetics of, 2761-2769
T lymphocytes (T cells), $CD4^+$, expansion in vivo, in cancer patients, 2752-2760
TNP-470, for AIDS-related Kaposi's sarcoma, 1444-1449
Tobacco, and tongue carcinoma, 745-753
Tongue, oral, squamous cell carcinoma of
  demographics, risk factors, and treatment outcome for, 745-753
  prognosis for, in patients < 45 years old, 745-753
Topoisomerase inhibitors. *See* Etoposide; Irinotecan; Topotecan
Topotecan
  and cisplatin, in advanced cancer, phase I and pharmacologic study of, 3302-3309
  and cyclophosphamide, combination, for pediatric solid tumors, 945-952
  for multiple myeloma, in relapsing or refractory disease, 589-592
  in oral chemotherapy, 2563
  for ovarian cancer
    phase II study in advanced disease, 3345-3352
    in relapse, 2233-2237
Toremifene
  for breast cancer, and tamoxifen, comparison of, 348-353, 1999-2000
  pharmacology of, 348-349
  secondary malignancy with, risk for, 348-349
TPFL5. *See* Docetaxel, cisplatin, fluorouracil, leucovorin regimen
TP53 gene mutations, in germ cell tumors, 1246
Transcription factor AP-2, in cutaneous melanoma, prognostic significance of, 3584-3591
Transitional cell carcinoma, urothelial, ifosfamide, paclitaxel, and cisplatin for, 2722-2727
Transmembrane-4 superfamily, gene expression, prognostic significance in non-small-cell lung cancer, 1397-1406
Tumor lysis syndrome, fludarabine-induced, in chronic lymphocytic leukemia, 2313-2320
Tumor markers
  in breast cancer, ASCO recommendations for use of, 1997 update, 793-795
  in colorectal cancer, ASCO recommendations for use of, 1997 update, 793-795
Tumor response to treatment
  definitions of, 1234, 2291-2292
  dimensions used in evaluation of, 1234, 2291-2292
Tumor suppressor gene(s)
  p16
    in cancer, 1197-1206
    loss, in lung cancer, 1207-1217
    and melanoma risk, 670-682
  p53. *See p53* gene and p53 protein
  Rb, expression in diffuse large B-cell lymphoma, prognostic significance of, 1931-1939
  RB, loss, in lung cancer, 1207-1217

UFT. *See* Uracil-ftorafur
United Kingdom Children's Cancer Study Group, Ewing's tumor study, 3628-3633
Unknown primary tumors
  advanced carcinoma of, KRN8602 with/without filgrastim for, 2181-2187
  brain metastases, radiosurgery with/without whole-brain radiotherapy in, 3563-3569
  hepatic metastases
    clinical features of, 2105-2112
    prognostic significance of, 2105-2112
Unorthodox therapies. *See* Nonproven therapies
Unproven therapies. *See* Nonproven therapies
Uracil-ftorafur, in colorectal cancer, 3461-3475
Uracil-tegafur
  clinical trials of, 2879-2883
  future applications of, 2883
  for gastric cancer, 2877-2885
  in oral chemotherapy, 2561
  pharmacokinetics of, 2879
  preclinical evaluation of, 2877-2879
  safety of, 2882-2883
  tolerability of, 2882-2883
  v tegafur, clinical studies of, 2880-2883
Urinary bladder. *See* Bladder
Urinary incontinence, after early prostate cancer treatment, 275-283
Urokinase-type plasminogen activator, in node-negative breast cancer, prognostic significance of, 3129-3136
Uroprotection, in ifosfamide therapy for lung cancer, 616-621
Urothelial carcinoma
  advanced, paclitaxel and carboplatin for, 1844-1848
  extravesical, in patients with high-risk superficial bladder tumors, 1099-1102
  metastatic, docetaxel and cisplatin for, 3392-3397
  paclitaxel plus carboplatin for, 1844-1848
    outpatient regimen using, 255-260
  transitional cell, ifosfamide, paclitaxel, and cisplatin for, 2722-2727

VACOP-B. *See* Etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen
Vascular endothelial growth factor, in node-negative breast cancer, prognostic significance of, 3121-3128, 3129-3136
Vascular enumeration, in invasive breast cancer, prognostic significance of, 1684-1688
Venlafaxine hydrochloride, for hot flashes in cancer survivors, 2377-2381
VePesid. *See* Etoposide
V-ICE. *See* Ifosfamide, carboplatin, etoposide, vincristine regimen
Vinblastine, for recurrent Hodgkin's disease after autologous bone marrow transplant, 584-588
Vinblastine, ifosfamide, cisplatin regimen, for recurrent germ cell tumors, 2500-2504
Vinblastine, methotrexate regimen, for progressive desmoid tumor in children, 3021-3027

Vinorelbine
for cervical cancer, phase II study of, 1094-1098
in oral chemotherapy, 2562
VIP. *See* Etoposide, ifosfamide, cisplatin regimen
Viruses, as gene transfer vector, 2548-2556
Vitamin E, for hot flashes, in breast cancer survivors, 495-500
VMP. *See* Etoposide, mitoxantrone, prednimustine regimen
VX-710, paclitaxel regimen
for MDR reversal, 2964-2976
pharmacologic study of, 2964-2976
toxicologic study of, 2964-2976

Waldenström's macroglobulinemia
fludarabine in, 2060-2064
resistant to alkylating agents, management of, 2060-2064
Wilms' tumor
constitutional *WT1* mutations and, 3634-3640
doxorubicin for, with pulse-intensive dactinomycin, 237-245
p53 mutations in, prognostic significance of, 3164
recurrent, high-dose chemotherapy in, 3295-3301
treatment of, administration schedule for, effects on outcome and cost, 3744-3751
Women
marrow transplantation survivors, sexual dysfunction in, 3148-3157
paclitaxel-pretreated solid tumors in, estramustine and short infusion of paclitaxel for, 2959-2963
WT1 gene, constitutional mutations, and Wilms' tumor, 3634-3640

Zidovudine, with interferon alfa, for HIV-associated Kaposi's sarcoma, 1736-1742